<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2018 Workiva -->
<title>Document</title>
</head>
<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD0BF676EBABE52B198EFA1AEF38C5DDF" id=
"sD0BF676EBABE52B198EFA1AEF38C5DDF"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="5"></td>
</tr>
<tr>
<td style="width:17%;"></td>
<td style="width:19%;"></td>
<td style="width:19%;"></td>
<td style="width:19%;"></td>
<td style="width:26%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;">
<font style=
"font-family:inherit;font-size:18pt;font-weight:bold;">UNITED
STATES</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;">
<font style=
"font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;">
<font style=
"font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON,
D.C. 20549</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;">
<font style=
"font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div>
<div style=
"line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:18pt;">
<font style=
"font-family:inherit;font-size:18pt;font-weight:bold;">FORM
10-Q</font></div>
<div style=
"line-height:120%;padding-bottom:4px;text-align:center;font-size:6pt;">
<font style=
"font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:30px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:12pt;padding-left:0px;">
<font style="font-family:Wingdings;font-size:10pt;">x</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:12pt;">
<font style=
"font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">For the
quarterly period ended March 31, 2018</font></div>
<div style=
"line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;">
<font style=
"font-family:inherit;font-size:12pt;font-weight:bold;">or</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:30px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:12pt;padding-left:0px;">
<font style="font-family:Wingdings;font-size:10pt;">Â¨</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:12pt;">
<font style=
"font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">For the
transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></div>
<div style=
"line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Commission
File Number: 000-55764</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;">
<font style=
"font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:20pt;">
<font style=
"font-family:inherit;font-size:20pt;font-weight:bold;">EXICURE,
INC.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name
of registrant as specified in its charter)</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;">
<font style=
"font-family:inherit;font-size:6pt;font-weight:bold;">_____________________________________</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="3"></td>
</tr>
<tr>
<td style="width:49%;"></td>
<td style="width:2%;"></td>
<td style="width:49%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">81-5333008</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:inherit;font-size:8pt;font-weight:bold;">(State or
other jurisdiction of</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:inherit;font-size:8pt;font-weight:bold;">incorporation
or organization)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:inherit;font-size:8pt;font-weight:bold;">(IRS
Employer</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:inherit;font-size:8pt;font-weight:bold;">Identification
No.)</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">8045 Lamon
Avenue</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Suite
410</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Skokie, IL
60077</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;">
<font style=
"font-family:inherit;font-size:8pt;font-weight:bold;">(Address of
principal executive offices)</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;">
<font style=
"font-family:inherit;font-size:8pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Registrantâs
telephone number, including area code (847) 673-1700</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;">
<font style=
"font-family:inherit;font-size:8pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">Indicate by check
mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and
(2)&nbsp;has been subject to such filing requirements for the past
90
days.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">Â¨</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">Indicate by check
mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (Â§232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required
to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">Â¨</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of 
âlarge accelerated filer,â âaccelerated filer,â âsmaller reporting
company,â and âemerging growth companyâ in Rule 12b-2 of the
Exchange Act.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="5"></td>
</tr>
<tr>
<td style="width:18%;"></td>
<td style="width:3%;"></td>
<td style="width:55%;"></td>
<td style="width:21%;"></td>
<td style="width:3%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:left;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">Large&nbsp;accelerated&nbsp;filer</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:center;font-size:10pt;">
<font style="font-family:Wingdings;font-size:10pt;">Â¨</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:left;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">Accelerated&nbsp;filer</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:center;font-size:10pt;">
<font style="font-family:Wingdings;font-size:10pt;">Â¨</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">Non-accelerated
filer</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:Wingdings;font-size:10pt;">Â¨</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">(Do not check if a smaller
reporting company)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">Smaller&nbsp;reporting&nbsp;company</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:center;font-size:10pt;">
<font style="font-family:Wingdings;font-size:10pt;">x</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">Emerging growth
company</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="padding-bottom:4px;text-align:center;font-size:10pt;">
<font style="font-family:Wingdings;font-size:10pt;">x</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.</font> <font style=
"font-family:Wingdings;font-size:10pt;">x</font></div>
<div style=
"line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">Indicate by check
mark whether the registrant is a shell company (as defined by Rule
12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">Â¨</font><font style="font-family:inherit;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div>
<div style=
"line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">As of April 30,
2018, there were 39,454,821 shares of the registrantâs common
stock, par value $0.0001 per share, outstanding.</font>
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="5"></td>
</tr>
<tr>
<td style="width:17%;"></td>
<td style="width:19%;"></td>
<td style="width:19%;"></td>
<td style="width:19%;"></td>
<td style="width:26%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
</table>
</div>
</div>
<div><br /></div>
<hr style="page-break-after:always" />
<div><a name="s22A913064D645C239E35747D0F9F1844" id=
"s22A913064D645C239E35747D0F9F1844"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
QUARTERLY REPORT ON FORM 10-Q</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
TABLE OF CONTENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="3"></td>
</tr>
<tr>
<td style="width:88%;"></td>
<td style="width:1%;"></td>
<td style="width:11%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;"
href="#sD6E7498C199B5D14872504B10066E0EC"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">Special
Note Regarding Forward-Looking Statements</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sD6E7498C199B5D14872504B10066E0EC">3</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;"
href="#s5D133804564059A491DA1AE59F61A19C"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART
I - FINANCIAL INFORMATION</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF733A208D9865EEF8F11CA5A91A81458">5</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sE060E7696E9B59B4A4274EDDF7D85A34"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 1. Financial
Statements</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF733A208D9865EEF8F11CA5A91A81458">5</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF733A208D9865EEF8F11CA5A91A81458"><font style=
"font-family:Times New Roman;font-size:10pt;">Unaudited Condensed
Consolidated Balance Sheets</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF733A208D9865EEF8F11CA5A91A81458">5</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF39DE074AF51589DA09EE2C42A7E0090"><font style=
"font-family:Times New Roman;font-size:10pt;">Unaudited Condensed
Consolidated Statements of Operations</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sF39DE074AF51589DA09EE2C42A7E0090">6</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s8A3533318FA75AD991CB62674F058289"><font style=
"font-family:Times New Roman;font-size:10pt;">Unaudited Condensed
Consolidated Changes in Stockholdersâ Equity</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s8A3533318FA75AD991CB62674F058289">7</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sCB69C3081937561792F149658A2F5BE0"><font style=
"font-family:Times New Roman;font-size:10pt;">Unaudited Condensed
Consolidated Statements of Cash Flows</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sCB69C3081937561792F149658A2F5BE0">8</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s1BFB8F19BA485B868E511F31755285AB"><font style=
"font-family:Times New Roman;font-size:10pt;">Notes to Unaudited
Condensed Consolidated Financial Statements</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sE379F8FACFCF5435A5DCEBAFBEE8C53D">9</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sBDB9D6A64AC8549C9A6D51D21BC0CB52"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 2. Management's
Discussion and Analysis and Results of Operations</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sBDB9D6A64AC8549C9A6D51D21BC0CB52">23</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s213B96CD2A81533894D39E7337ED3F63"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 3. Quantitative
and Qualitative Disclosures About Market Risk</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s213B96CD2A81533894D39E7337ED3F63">33</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s97E51EC7E22652158C3791BEBE7744C7"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 4. Controls and
Procedures</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s97E51EC7E22652158C3791BEBE7744C7">33</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;"
href="#s7613DD62978555E8AEC018304441B665"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART
II - OTHER INFORMATION</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s512CA2DAA9CA58EBA11D26873A81E943">35</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s512CA2DAA9CA58EBA11D26873A81E943"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 1. Legal
Proceedings</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s512CA2DAA9CA58EBA11D26873A81E943">35</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sB7688808B3FE51B0A60E302430411435"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 1A. Risk
Factors</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sB7688808B3FE51B0A60E302430411435">35</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s325AD1559EB95ACD84031E94E3A6CF57"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s325AD1559EB95ACD84031E94E3A6CF57">72</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sD587154A20295929A0A619991FE2F340"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 3. Defaults Upon
Senior Securities</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sD587154A20295929A0A619991FE2F340">73</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s4628008496A85BA1B834B077A738D450"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 4. Mine Safety
Disclosures</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s4628008496A85BA1B834B077A738D450">73</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sAEA079C5FB045A439533AB8168552A81"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 5. Other
Information</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#sAEA079C5FB045A439533AB8168552A81">73</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s230230A0E4C75A6F88B7605392AB2F2F"><font style=
"font-family:Times New Roman;font-size:10pt;">Item 6.
Exhibits</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s230230A0E4C75A6F88B7605392AB2F2F">73</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:8px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;"
href="#s0F73A67C62D05262A4B1B60D9014FE5E"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">Signatures</font></a></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><a style=
"font-family:Times New Roman;font-size:10pt;" href=
"#s0F73A67C62D05262A4B1B60D9014FE5E">74</a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">2</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sD6E7498C199B5D14872504B10066E0EC" id=
"sD6E7498C199B5D14872504B10066E0EC"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">This
Quarterly Report on Form&nbsp;10-Q&nbsp;contains express or implied
âforward-looking statementsâ within the meaning of Section 27A of
the Securities Act of 1933, as amended (the âSecurities Actâ) and
Section 21E of the Securities Exchange Act of 1934, as mended (the 
âExchange Actâ) that are based on our managementâs belief and
assumptions and on information currently available to our
management. All statements other than statements of historical fact
contained in this Quarterly Report on Form 10-Q are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as âmay,â âcould,â âwill,â âwould,â 
âshould,â âexpect,â âplan,â, âanticipate,â âbelieve,â âestimate,â 
âintend,â âpredict,â âseek,â âcontemplate,â âproject,â âcontinue,â 
âpotential,â âongoingâ or the negative of these terms or other
comparable terminology. These forward-looking statements include,
but are not limited to, statements about:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
initiation, timing, progress and results of our research and
development programs, preclinical studies, clinical trials and
Investigational New Drug application (âINDâ), Investigational
Medicinal Product Dossier, Clinical Trial Application (âCTAâ), New
Drug Application (âNDAâ), or other regulatory
submissions;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
dependence on current and future collaborators for developing,
obtaining regulatory approval for and commercializing therapeutic
candidates in the collaboration;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
receipt and timing of any milestone payments or royalties under any
current or future research collaboration and license agreements or
arrangements;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability to identify and develop therapeutic candidates for
treatment of additional disease indications;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our or
a current or future collaboratorâs ability to obtain and maintain
regulatory approval of any of our therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
rate and degree of market acceptance of any approved therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
commercialization of any approved therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability to establish and maintain collaborations and retain
commercial rights for our therapeutic candidates in the
collaborations;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
implementation of our business model and strategic plans for our
business, technologies and therapeutic candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
estimates of our expenses, ongoing losses, future revenue and
capital requirements, including our expectations relating to the
use of proceeds from our private placement offering, and our needs
for additional financing;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability to obtain additional funds for our operations;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability to obtain and maintain intellectual property protection for
our technologies and therapeutic candidates and our ability to
operate our business without infringing the intellectual property
rights of others;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
reliance on third parties to conduct our preclinical studies and
clinical trials;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
reliance on third party supply and manufacturing partners to supply
the materials and components for, and manufacture, our research and
development, preclinical and clinical trial supplies;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability to attract and retain qualified key management and
technical personnel;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
expectations regarding the time during which we will be an emerging
growth company under the JOBS Act;</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">3</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
financial performance;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In Part
I., Item 4. Controls and Procedures, the statements regarding
internal controls</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
impact of government regulation and developments relating to our
competitors or our industry; and</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">other
risks and uncertainties, including those listed in Part II, Item 1Aâ
âRisk Factors.â</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">These
statements relate to future events or our future operational or
financial performance, and involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
these forward-looking statements. Factors that may cause actual
results to differ materially from current expectations include,
among other things, those listed in Part II, Item 1AââRisk Factorsâ
and elsewhere in this Quarterly Report on Form 10-Q.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Any
forward-looking statement in this Quarterly Report on Form 10-Q
reflects our current view with respect to future events and is
subject to these and other risks, uncertainties and assumptions
relating to our business, results of operations, industry and
future growth. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. No
forward-looking statement is a guarantee of future performance. You
should read this Quarterly Report on Form 10-Q and the documents
that we reference in this Quarterly Report on Form 10-Q and have
filed with the Securities and Exchange Commission (the âSECâ) as
exhibits hereto completely and with the understanding that our
actual future results may be materially different from any future
results expressed or implied by these forward-looking statements.
Except as required by law, we assume no obligation to update or
revise these forward-looking statements for any reason, even if new
information becomes available in the future.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">This
Quarterly Report on Form 10-Q also contains estimates, projections
and other information concerning our industry, our business and the
markets for certain therapeutics, including data regarding the
estimated size of those markets, their projected growth rates and
the incidence of certain medical conditions. Information that is
based on estimates, forecasts, projections or similar methodologies
is inherently subject to uncertainties and actual events or
circumstances may differ materially from events and circumstances
reflected in this information. Unless otherwise expressly stated,
we obtained these industry, business, market and other data from
reports, research surveys, studies and similar data prepared by
third parties, industry, medical and general publications,
government data and similar sources. In some cases, we do not
expressly refer to the sources from which these data are
derived.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As used
in this Quarterly Report on Form 10-Q, unless otherwise stated or
the context otherwise indicates, references to âExicure,â the 
âCompany,â âwe,â âour,â âus,â or similar terms refer to Exicure,
Inc. and our wholly-owned subsidiary, Exicure Operating Company.
Exicure Operating Company holds all material assets and conducts
all business activities and operations of the Company.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><a name="s5D133804564059A491DA1AE59F61A19C" id=
"s5D133804564059A491DA1AE59F61A19C"></a></div>
<div style=
"line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><a name="sE060E7696E9B59B4A4274EDDF7D85A34" id=
"sE060E7696E9B59B4A4274EDDF7D85A34"></a></div>
<div style=
"line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">4</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sF733A208D9865EEF8F11CA5A91A81458" id=
"sF733A208D9865EEF8F11CA5A91A81458"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">PART I -
FINANCIAL INFORMATION</font></div>
<div style=
"line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.
Financial Statements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
CONDENSED CONSOLIDATED BALANCE SHEETS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:71%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March&nbsp;31,<br />

2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&nbsp;31,<br />

2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">ASSETS</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Current
assets:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash and cash
equivalents</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">21,124</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">25,764</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Unbilled revenue
receivable</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">13</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Receivable from
related party</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">21</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">17</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Prepaid expenses and
other assets</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,897</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,844</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total current
assets</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">23,047</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">27,638</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Property and
equipment, net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,275</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,317</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other noncurrent
assets</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">32</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">32</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:100px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total
assets</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">24,354</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">28,987</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;font-weight:bold;">LIABILITIES
AND STOCKHOLDERSâ EQUITY</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Current
liabilities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Current portion of
long-term debt</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">776</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accounts
payable</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">974</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,049</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accrued expenses and
other current liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,265</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,273</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Current portion of
deferred revenue</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,034</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total current
liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,015</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,356</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Long-term debt,
net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,103</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,855</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Common stock warrant
liability</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">651</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">523</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other noncurrent
liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">277</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">278</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total
liabilities</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">8,046</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">9,012</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:17px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:17px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:17px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:17px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Stockholdersâ
equity:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style=
"text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;">
<font style="font-family:Times New Roman;font-size:10pt;">Common
stock, $0.0001 par value per share; 200,000,000 shares authorized,
39,454,821 issued and outstanding, March 31, 2018; 39,300,823
shares issued and outstanding, December 31, 2017</font></div>
</td>
<td colspan="2" style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Additional paid-in
capital</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">54,394</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">53,586</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accumulated
deficit</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(38,090</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(33,615</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total stockholders'
equity</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">16,308</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">19,975</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style=
"text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;">
<font style="font-family:Times New Roman;font-size:10pt;">Total
liabilities and stockholdersâ equity</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">24,354</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">28,987</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See
Accompanying Notes to Unaudited Condensed Consolidated Financial
Statements.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">5</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sF39DE074AF51589DA09EE2C42A7E0090" id=
"sF39DE074AF51589DA09EE2C42A7E0090"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:71%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended,<br />
March 31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Revenue:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
revenue</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
revenue</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Operating
expenses:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,275</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,488</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General
and administrative expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,045</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,426</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
operating expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5,320</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,914</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Operating
loss</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,284</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,482</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other income
(expense), net:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(161</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(204</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
income (loss), net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(64</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">34</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
other income (loss), net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(225</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(170</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net loss</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,652</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Basic and diluted
loss per common share</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(0.14</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(15.62</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Basic and diluted
weighted-average common shares outstanding</font></div>
</td>
<td colspan="2" style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">39,357,289</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">169,794</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See
Accompanying Notes to Unaudited Condensed Consolidated Financial
Statements.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">6</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s8A3533318FA75AD991CB62674F058289" id=
"s8A3533318FA75AD991CB62674F058289"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN
STOCKHOLDERSâ EQUITY</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except shares)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:96.60493827160494%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="19"></td>
</tr>
<tr>
<td style="width:66%;"></td>
<td style="width:6%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:2%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:5%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:14px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">Common
Stock</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">Additional
Paid-in- Capital</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">Accumulated
Deficit</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:6pt;"><font style=
"font-family:Times New Roman;font-size:6pt;font-weight:bold;">Total
Stockholdersâ Equity</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance
at December 31, 2017</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">(33,615</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">19,975</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">Adoption of new
accounting standard - ASC 606</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">1,034</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">1,034</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance
at January 1, 2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">(32,581</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">21,009</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">Exercise of
options</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">8,532</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">7</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">7</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">Equity-based
compensation</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">365</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">365</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">Issuance of common
stock, net</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">145,466</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">436</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">436</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">Net loss</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance
at March 31, 2018</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,454,821</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">54,394</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">(38,090</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">16,308</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See
Accompanying Notes to Unaudited Condensed Consolidated Financial
Statements.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">7</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sCB69C3081937561792F149658A2F5BE0" id=
"sCB69C3081937561792F149658A2F5BE0"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:71%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended March 31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash flows from
operating activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net loss</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,652</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Adjustments to
reconcile net loss to cash used in operating
activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Depreciation and
amortization</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">86</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">38</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Equity-based
compensation</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">365</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">380</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Amortization of
long-term debt issuance costs and fees</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">24</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">50</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">73</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Change in fair value
of warrant liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">128</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(38</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Changes in operating
assets and liabilities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Unbilled revenue
receivable and accounts receivable</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">8</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(449</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Receivable from
related party</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(4</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Prepaid expenses and
other current assets</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">311</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(556</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Deferred offering
costs</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(241</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other noncurrent
assets</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(19</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accounts
payable</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(120</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">58</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accrued expenses and
other current liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(8</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(1,581</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Deferred
revenue</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(1,982</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other noncurrent
liabilities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(1</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash used in
operating activities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(4,647</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(6,997</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash flows from
investing activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Capital
expenditures</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(245</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash used in
investing activities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(245</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash flows from
financing activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Proceeds from
exercise of common stock options</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash provided by
financing activities</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net increase decrease
in cash and cash equivalents</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(4,640</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(7,199</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash and cash
equivalents - beginning of period</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">25,764</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">19,623</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Cash and cash
equivalents - end of period</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">21,124</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">12,424</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Supplemental
disclosure of cash flow information</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Non-cash financing
activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Issuance of common
stock for professional services</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">436</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Deferred offering
costs (accounts payable and accrued expenses)</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">733</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Non-cash investing
activities:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Capital expenditures
(accounts payable and accrued expenses)</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">45</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">268</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See
Accompanying Notes to Unaudited Condensed Consolidated Financial
Statements.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">8</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s1BFB8F19BA485B868E511F31755285AB" id=
"s1BFB8F19BA485B868E511F31755285AB"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><a name="sE379F8FACFCF5435A5DCEBAFBEE8C53D" id=
"sE379F8FACFCF5435A5DCEBAFBEE8C53D"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
1. Description of Business and Basis of Presentation</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Description of Business</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure,
Inc. (âParentâ) is a</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">clinical-stage</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">biotechnology
company developing gene regulatory and immuno-oncology therapeutics
based on the Companyâs proprietary Spherical Nucleic Acid (âSNAâ)
technology.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
believe the</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">design
of the Companyâs SNAs gives rise to chemical and biological
properties that</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">may
provide advantages over other nucleic acid therapeutics and enable
therapeutic activity outside of the liver.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company intends to build a leading nucleic acid therapeutics
company focused on the discovery and development of therapeutics
based on the Companyâs proprietary SNA technology, either on its
own or in collaboration with pharmaceutical partners.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Throughout
this Quarterly Report on Form 10-Q, the terms âthe Companyâ and 
âExicureâ refer to Parent and its 100% owned subsidiary, Exicure
Operating Company. Exicure Operating Company holds all material
assets, and conducts all business activities and operations, of the
Company.&nbsp;</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">References
to the âMergerâ refer to the September 26, 2017 transaction whereby
Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1
Acquisition Corporation, or Max-1, merged with and into Exicure
Operating Company (f/k/a Exicure, Inc.), a privately-held Delaware
Corporation referred to herein as Exicure OpCo, with Exicure OpCo
remaining as the surviving entity and a wholly-owned operating
subsidiary of Max-1 (which then changed its name to Exicure, Inc.).
References to the âPrivate Placementâ refers to the transactions
following the Merger that occurred in several closings on September
26, 2017, October 27, 2017 and November 2, 2017 in which we sold to
accredited investors approximately</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$31,513</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">worth
of shares of common stock (before deducting placement agent fees
and expenses which are approximately</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">),
or</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">10,504,196</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares,
at a price of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">per
share.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On July
9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense
Therapeutics, Inc., a privately-held Delaware corporation, and on
the same date changed its name to Exicure, Inc., which actions
together are referred to in these notes to unaudited condensed
consolidated financial statements as the corporate conversion. In
connection with the corporate conversion, the accumulated deficit
of AuraSense Therapeutics, LLC of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$18,837</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">was
reclassified to Additional paid in capital.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Basis of Presentation</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
accompanying unaudited condensed consolidated financial statements
as of March 31, 2018 and December 31, 2017, and for the three
months ended March 31, 2018 and 2017, have been presented in
conformity with generally accepted accounting principles in the
United States (âGAAPâ).</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Principles of Consolidation</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
accompanying unaudited condensed consolidated financial statements
include the accounts of Parent and its 100% owned subsidiary,
Exicure Operating Company. All intercompany transactions and
accounts are eliminated in consolidation.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Going Concern</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018, the Company has generated an accumulated deficit
of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$56,927</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">since
inception and expects to incur significant expenses and negative
cash flows for the foreseeable future. Based on the Companyâs
current operating plans, existing working capital at March 31, 2018
is not sufficient to sustain operations beyond March 31, 2019.
Management believes that it will be able to obtain additional
working capital through equity financings, partnerships and
licensing, or other arrangements, to fund operations. However,
there can be no assurance that such additional financing will be
available and, if available, can be obtained on terms acceptable to
the Company. If the Company is unable to obtain such additional
financing, the Company will need to reevaluate</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">9</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">future
operating plans. Accordingly, there is substantial doubt regarding
the Companyâs ability to continue as a going concern.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
accompanying unaudited condensed consolidated interim financial
statements have been prepared as though the Company will continue
as a going concern, which contemplates the realization of assets
and satisfaction of liabilities in the normal course of business.
The financial statements do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or
the amounts and classification of liabilities that might be
necessary should the Company be unable to continue as a going
concern.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Unaudited Interim Financial Information</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
accompanying interim consolidated balance sheet as of March 31,
2018, the interim consolidated statements of operations for the
three months ended March 31, 2018 and 2017, the interim
consolidated statement of changes in stockholdersâ equity for the
three months ended March 31, 2018, and the interim consolidated
statements of cash flows for the three months ended March 31, 2018
and 2017, are unaudited. The interim unaudited condensed
consolidated financial statements have been prepared on the same
basis as the annual audited financial statements; and in the
opinion of management, reflect all adjustments, which include only
normal recurring adjustments necessary for the fair statement of
the Companyâs financial position as of March 31, 2018, the results
of its operations for the three months ended March 31, 2018 and
2017, and the results of its cash flows for the three months ended
March 31, 2018 and 2017. The financial data and other information
disclosed in these notes related to the three months ended March
31, 2018 and 2017 are unaudited. The results for the three months
ended March 31, 2018 are not necessarily indicative of results to
be expected for the year ending December 31, 2018, or any other
interim periods, or any future year or period.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Use of Estimates</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
preparation of the financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during
the reporting period. Management bases its estimates on certain
assumptions which it believes are reasonable in the circumstance
and while actual results could differ from those estimates,
management does not believe that any change in those assumptions in
the near term would have a significant effect on the Companyâs
financial position, results of operations or cash flows. Actual
results in future periods could differ from those
estimates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Revision of Prior Period Financial Statements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
connection with preparing our condensed consolidated interim
financial information for the three months ended March 31, 2018, we
identified errors that affected prior interim and annual periods
related to the timing of recognition of research and development
expense related to a contract for the clinical trial of one of our
therapeutic candidates. We evaluated whether our previously issued
consolidated financial statements were materially misstated and
concluded that the errors individually and in the aggregate were
not material to any of our previously issued financial statements.
We have revised the accompanying comparative financial statements
to correct the immaterial errors.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
correction of the errors increased prepaid expense and other
current assets by</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$933</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
decreased accrued expenses by</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$96</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
and decreased accumulated deficit by</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">at
December 31, 2017.</font></div>
<div><a name="sC5E151ADE940508EB2ED0622425635C8" id=
"sC5E151ADE940508EB2ED0622425635C8"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
2. Significant Accounting Policies</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">There
have been no changes to the significant accounting policies
disclosed in the Companyâs most recent Annual Report on
Form&nbsp;10-K, except as required by recently adopted accounting
pronouncements, as discussed below.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">10</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Revenue Recognition</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Effective
January 1, 2018, the Company adopted the provisions of Accounting
Standards Codification (âASCâ) 606,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Revenue from Contracts with Customers</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">using
the modified retrospective method for all contracts not completed
as of the date of adoption. The reported results for 2018 reflect
the application of ASC 606 guidance, while the reported results for
2017 were prepared under the guidance of ASC
605,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&nbsp;Revenue
Recognition</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;(ASC
605).</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Under
ASC 606, the Company recognizes revenue when its customer obtains
control of promised goods or services, in an amount that reflects
the consideration which the Company expects to receive in exchange
for those goods or services. To determine revenue recognition for
arrangements that are within the scope of ASC 606, the Company
performs the following five steps:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Identify the contract with the customer.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">A
contract with a customer exists when (i) the Company enters into an
enforceable contract with a customer that defines each partyâs
rights regarding the goods or services to be transferred and
identifies the related payment terms, (ii) the contract has
commercial substance, and (iii) the Company determines that
collection of substantially all consideration for goods and
services that are transferred is probable based on the customerâs
intent and ability to pay the promised consideration. The Company
applies judgment in determining the customerâs intent and ability
to pay, which is based on a variety of factors including the
customerâs historical payment experience, or in the case of a new
customer, published credit and financial information pertaining to
the customer.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Identify the performance obligations in the contract.</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Performance
obligations promised in a contract are identified based on the
goods and services that will be transferred to the customer that
are both capable of being distinct, whereby the customer can
benefit from the good or service either on its own or together with
other available resources, and are distinct in the context of the
contract, whereby the transfer of the good or service is separately
identifiable from other promises in the contract. To the extent a
contract includes multiple promised goods and services, the Company
must apply judgment to determine whether promised goods and
services are both capable of being distinct and distinct in the
context of the contract. If these criteria are not met, the
promised goods and services are accounted for as a combined
performance obligation.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Determine the transaction price.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
transaction price is determined based on the consideration to which
the Company will be entitled in exchange for transferring goods and
services to the customer. To the extent the transaction price
includes variable consideration, the Company estimates the amount
of variable consideration that should be included in the
transaction price utilizing either the expected value method or the
most likely amount method, depending on the nature of the variable
consideration. Variable consideration is included in the
transaction price if, in the Companyâs judgment, it is probable
that a significant future reversal of cumulative revenue under the
contract will not occur. Any estimates, including the effect of the
constraint on variable consideration, are evaluated at each
reporting period for any changes. Determining the transaction price
requires significant judgment.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Allocate the transaction price to performance obligations in the
contract.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If the
contract contains a single performance obligation, the entire
transaction price is allocated to the single performance
obligation. However, if a series of distinct services that are
substantially the same qualifies as a single performance obligation
in a contract with variable consideration, the Company must
determine if the variable consideration is attributable to the
entire contract or to a specific part of the contract. Contracts
that contain multiple performance obligations require an allocation
of the transaction price to each performance obligation on a
relative standalone selling price basis unless the transaction
price is variable and meets the criteria to be allocated entirely
to a performance obligation or to a distinct service that forms
part of a single performance obligation. The consideration to be
received is allocated among the separate performance obligations
based on relative standalone selling prices.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:8px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Recognize revenue when or as the Company satisfies a performance
obligation.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company satisfies performance obligations either over time or at a
point in time. Revenue is recognized over time if either
(i)</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">11</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-left:48px;padding-bottom:8px;text-align:left;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
customer simultaneously receives and consumes the benefits provided
by the entityâs performance, (ii) the entityâs performance creates
or enhances an asset that the customer controls as the asset is
created or enhanced, or (iii) the entityâs performance does not
create an asset with an alternative use to the entity and the
entity has an enforceable right to payment for performance
completed to date. If the entity does not satisfy a performance
obligation over time, the related performance obligation is
satisfied at a point in time by transferring the control of a
promised good or service to a customer. Examples of control are
using the asset to produce goods or services, enhance the value of
other assets, or settle liabilities, and holding or selling the
asset.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Licenses of intellectual property</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">:&nbsp;If
the license to the Companyâs intellectual property is determined to
be distinct from the other performance obligations identified in
the arrangement, the Company recognizes revenues from consideration
allocated to the license when the license is transferred to the
customer and the customer is able to use and benefit from the
licenses. For licenses that are combined with other promises, the
Company utilizes judgment to assess the nature of the combined
performance obligation to determine whether the combined
performance obligation is satisfied over time or&nbsp;at a point in
time and, if over time, the appropriate method of measuring
progress for purposes of recognizing revenue. The Company evaluates
the measure of progress each reporting period and, if necessary,
adjusts the measure of performance and related revenue
recognition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone
payments:</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;At
the inception of each arrangement that includes development
milestone payments, the Company evaluates the probability of
reaching the milestones and estimates the amount to be included in
the transaction price using the most likely amount method. If it is
probable that a significant revenue reversal would not occur in the
future, the associated milestone value is included in the
transaction price. Milestone payments that are not within the
control of the Company or the licensee, such as regulatory
approvals, are not considered probable of being achieved until
those approvals are received and therefore revenue recognized is
constrained as management is unable to assert that a reversal of
revenue would not be possible. The transaction price is then
allocated to each performance obligation on a relative standalone
selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied.
At the end of each subsequent reporting period, the Company
re-evaluates the probability of achievement of such development
milestones and any related constraint, and if necessary, adjusts
its estimate of the overall transaction price. Any such adjustments
are recorded on a cumulative catch-up basis, which would affect
collaboration revenues and earnings in the period of
adjustment.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&nbsp;For
arrangements that include sales-based royalties, including
milestone payments based on levels of sales, and the license is
deemed to be the predominant item to which the royalties relate,
the Company recognizes revenue at the later of (i) when the related
sales occur, or (ii) when the performance obligation to which some
or all of the royalty has been allocated has been satisfied (or
partially satisfied). To date, the Company has not recognized any
royalty revenue resulting from any of its collaboration
agreements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018, the Companyâs only revenue recognized is related to
the Purdue Collaboration (see Note 3).</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Recently Adopted Accounting Pronouncements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In May
2014, the Financial Accounting Standards Board (âFASBâ) issued
Accounting Standards Update (âASUâ) 2014-09 (ASC 606),</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Revenue from Contracts with Customers</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">. This
ASU, as amended by ASU 2015-14, affects any entity that either
enters into contracts with customers to transfer goods and services
or enters into contracts for the transfer of nonfinancial assets.
ASU 2014-09 replaces most existing revenue recognition guidance in
GAAP when it becomes effective. The standardâs core principle is
that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the
consideration to which the company expects to be entitled in
exchange for those goods or services. In doing so, companies will
need to use more judgment and make more estimates than under the
currently effective guidance. These may include identifying
performance obligations in the contract, estimating the amount of
variable consideration to include in the transaction price and
allocating the transaction price to each separate performance
obligation. ASU 2014-09 is effective for Exicure in the first
quarter of 2018 and early adoption is permitted beginning in the
first quarter of 2017. The</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">12</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Company
adopted ASC 606 on a modified retrospective basis. See above 
âRevenue Recognitionâ for a discussion of the Companyâs updated
policies related to revenue recognition effective January 1,
2018.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Impact of adoption of ASC 606</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company adopted ASC 606 using the modified retrospective method.
The cumulative effect of applying the new guidance to all contracts
with customers that were not completed as of January 1, 2018 was
recorded as an adjustment to accumulated deficit as of the adoption
date. As a result of applying the modified retrospective method to
adopt the new guidance, the Company recorded reductions to both
accumulated deficit and deferred revenue, current of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">as of
the date of adoption.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As a
result of the adoption of ASC 606: (i) there were no impacts to the
totals of our cash flows from operating activities, cash flows from
investing activities, or cash flows from financing activities in
the accompanying unaudited condensed consolidated statement of cash
flows for the three months ended March 31, 2018; (ii) there were no
impacts to the balances of the accompanying unaudited condensed
consolidated balance sheet as of March 31, 2018, and (iii) total
revenue, operating loss, and net loss were lower by</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">each in
the accompanying unaudited condensed consolidated statement of
operations for the three months ended March 31, 2018.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
August 2016, the FASB issued ASU 2016-15,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Statement of Cash Flows (Topic 230): Classification of Certain Cash
Receipts and Cash Payments</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU
2016-15 addresses the classification of certain specific cash flow
issues including debt prepayment or extinguishment costs,
settlement of certain debt instruments, contingent consideration
payments made after a business combination, proceeds from the
settlement of certain insurance claims and distributions received
from equity method investees. ASU 2016-15 is effective for the
Company in the first quarter of 2018 and early adoption is
permitted. An entity that elects early adoption must adopt all of
the amendments in the same period. The Company adopted this
guidance on January 1, 2018. The adoption of ASU 2016-15 did not
have a material impact to the Companyâs statement of cash
flows.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In May
2017, the FASB issued ASU 2017-09,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Compensation - Stock Compensation (Topic 718): Scope of
Modification Accounting</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU
2017-09 clarifies when changes to the terms or conditions of a
share-based payment award must be accounted for as modifications.
Under the new guidance, modification accounting is required only if
the fair value, the vesting conditions, or the classification of
the award changes as a result of the change in terms or conditions.
ASU 2017-09 will be applied prospectively to awards modified on or
after the adoption date. ASU 2017-09 is effective for the Company
for fiscal years beginning after December 15, 2017, and interim
periods within those fiscal years. Early adoption is permitted. The
Company adopted this guidance on January 1, 2018. The adoption of
ASU 2017-09 did not have a material impact to the Companyâs
financial statements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Recent Accounting Pronouncements Not Yet Adopted</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
February 2016, FASB issued ASU 2016-02,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Leases (Topic 842)</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">, which
requires lessees to recognize right-of-use assets and lease
liabilities on the balance sheet. ASU 2016-02 is to be applied
using a modified retrospective approach at the beginning of the
earliest comparative period in the financial statements. ASU
2016-02 will be effective for the Company beginning in the first
quarter of 2019. Early adoption is permitted. The Company is
currently evaluating the impact of adopting this standard on its
financial statements.</font></div>
<div><a name="sD72103DFC8FE5FAEBC3A95B90D9E4B4B" id=
"sD72103DFC8FE5FAEBC3A95B90D9E4B4B"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
3. Purdue Collaboration</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
December 2, 2016, the Company entered into a research
collaboration, option and license agreement with Purdue Pharma,
L.P. (âPurdueâ) and referred to herein as the âPurdue
Collaboration.â Purdue has the option to obtain from us the full
worldwide development and commercial rights to AST-005 (the Companyâ
s lead therapeutic candidate that targets tumor necrosis factor),
an option to obtain</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">three</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">additional
collaboration targets and a further option to obtain from us the
full worldwide development and commercial rights to any therapeutic
candidates developed targeting the</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">three</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">additional
collaboration targets. Additionally, Purdue has rights of first
offer to some potential collaboration targets. These rights of
first offer are subject to limitations in time and scope. In
connection with the Purdue Collaboration, the Company received a
non-refundable development fee of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
In addition, the</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">13</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Company
is eligible to receive up to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$776,500</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">upon
successful completion of certain research, regulatory and
commercial sales milestones. The research milestones are payable
upon target identification and IND-enabling pre-clinical
development, per program, with an aggregate total of up to</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
The regulatory milestones are payable upon the initiation or
completion of clinical trials, and regulatory approval in the
United States and outside the United States, per program, with an
aggregate total of up to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
The commercial sales milestones are payable upon achievement of
specified aggregate product sales thresholds and total up to</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
In the event a therapeutic candidate subject to the collaboration
results in commercial sales, the Company is eligible to receive
royalties ranging from the low single digits to a maximum of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">on
future net sales of such commercialized therapeutic candidates.
Additionally, Purdue had an obligation to invest in a qualified
equity financing of the Company if such financing was completed
before June 2, 2017. The Company did not complete such qualified
equity financing before June 2, 2017.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See
Note 13,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Subsequent Events</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">, for
recent developments related to the Purdue
Collaboration.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Prior
to the adoption of ASC 606, the upfront payment of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">was
accounted for pursuant to ASC 605 and was recorded as deferred
revenue and recognized on a ratable basis over the estimated
performance period of the relevant research and development
activities. On January 1, 2018, in connection with the adoption of
ASC 606, the Company recorded the unamortized deferred revenue
of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">as an
adjustment to the beginning balance of retained deficit at January
1, 2018. See Note 2,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Significant Accounting Policies</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">, for
more information related to the adoption of ASC 606.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company identified multiple performance obligations as part of the
Purdue Collaboration agreement, including the upfront payment
of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
discussed above, and the research and development services. The
Company determined that the performance obligations should not be
combined, the license should be recognized at the time the license
is granted and the research and development services at the time
the service is performed. The Purdue Collaboration agreement
includes contingent promises related to specified research,
development and regulatory milestones and sale-based milestones.
Each contingent promise related to contingent and milestone payment
is evaluated to determine whether it represents a material right.
The Company recognizes any payment that is contingent upon the
achievement of a substantive milestone entirely in the period in
which it is determined that the revenue is not subject to a
significant reversal. To date, the Company has not recognized any
contingent payments in connection with the Purdue Collaboration
agreement as revenue.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">During
the three months ended March 31, 2018, the Company recognized
collaboration revenue of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
which consisted entirely of research and development activities
that will be reimbursed by Purdue and is presented on a gross basis
in the accompanying statement of operations. During the three
months ended March 31, 2017, the Company recognized collaboration
revenue of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2,432</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
which included</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$363</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">of
research and development activities that was reimbursed by Purdue
and is presented on a gross basis in the accompanying statement of
operations.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">14</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s02E402F6D5175976BD6717749C3912DD" id=
"s02E402F6D5175976BD6717749C3912DD"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
4. Supplemental Balance Sheet Information</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
Property and equipment, net</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:71%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,<br />
2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">December
31,<br />
2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Scientific
equipment</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,906</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,797</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Leasehold
improvements</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">192</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">192</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Furniture and
fixtures</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">31</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">31</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Computers and
software</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">26</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">26</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Construction in
process</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">38</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">120</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Property and
equipment, gross</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,193</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,166</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Less: accumulated
depreciation</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(918</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(849</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Property and
equipment, net</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,275</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,317</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation
and amortization expense was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$86</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$38</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">ended
March 31, 2018 and 2017</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
Accrued expenses and other current liabilities</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:71%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,<br />
2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">December
31,<br />
2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accrued legal
expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">514</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">251</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Accrued
payroll-related expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">329</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">718</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other accrued
expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">422</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">304</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued
expenses and other current liabilities</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,265</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,273</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div><a name="s96CDFC50666A529BACAB11ADB9361602" id=
"s96CDFC50666A529BACAB11ADB9361602"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
5. Debt</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
January 15, 2018, the Company and Hercules Technology Growth
Capital Limited (âHerculesâ) amended its loan agreement so that
amortization payments due for the</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">thirteen</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">(13)
consecutive months commencing on December 1, 2017 through and
including December 1, 2018 were deferred.&nbsp; Commencing on
January 1, 2019, and continuing on the first business day of each
month thereafter, the loan, including the deferred payments, shall
begin amortizing in equal monthly installments of principal and
interest based upon an amortization schedule equal to</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">eighteen</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">(18)
consecutive months. Any remaining obligations under the loan
agreement and other loan documents are due and payable on the
maturity date on September 1, 2019.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">At
March 31, 2018 and December 31, 2017, the carrying value of the
current and non-current portion of long-term debt is</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$4,879</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$4,855</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">15</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">At
March 31, 2018, the principal maturities of the long-term debt were
as follows:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="3"></td>
</tr>
<tr>
<td style="width:86%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31, 2018</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2019</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,999</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Principal balance
outstanding</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,999</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">less: unamortized
discount</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(108</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">less: unamortized
debt issuance costs</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(12</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Long-term
debt</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,879</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Current
portion</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">776</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Noncurrent
portion</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,103</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company paid interest on debt of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$136</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$153</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">during
the three months ended March 31, 2018 and 2017,
respectively.</font></div>
<div><a name="s83A839F082675670857FD8CE05DE2726" id=
"s83A839F082675670857FD8CE05DE2726"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
6. Stockholdersâ Equity</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Common Stock</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018 and December 31, 2017, the Company had
authorized</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">200,000,000</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
of common stock, par value</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
As of March 31, 2018, the Company had</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">39,454,821</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
issued and outstanding. As of December 31, 2017, the Company
had</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">39,300,823</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
issued and outstanding.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
holders of shares of the Companyâs common stock are entitled
to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">one</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">vote
per share on all matters to be voted upon by Exicure stockholders
and there are no cumulative rights. Subject to preferences that may
be applicable to any outstanding preferred stock, the holders of
shares of the Companyâs common stock are entitled to receive
ratably any dividends that may be declared from time to time by
Exicureâs board of directors (the âBoardâ) out of funds legally
available for that purpose. In the event of the Companyâs
liquidation, dissolution or winding up, the holders of shares of
Exicure common stock are entitled to share ratably in all assets
remaining after payment of liabilities, subject to prior
distribution rights of preferred stock then outstanding. Exicure
common stock has no preemptive or conversion rights or other
subscription rights. There are no redemption or sinking fund
provisions applicable to Exicure common stock. The outstanding
shares of Exicure common stock are fully paid
and&nbsp;non-assessable.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Preferred Stock</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018 and December 31, 2017, the Company had</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
of preferred stock, par value</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">authorized
and</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">no</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
issued and outstanding.</font></div>
<div><a name="sCA1567B081D35472A06F402EC34B58E7" id=
"sCA1567B081D35472A06F402EC34B58E7"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
7. Equity-Based Compensation</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018, the aggregate number of common stock options
available for grant under the 2017 Equity Incentive Plan was</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">1,498,264</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">16</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Equity-based
compensation expense is classified in the statements of operations
as follows:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:59%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended<br />
March 31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Research and
development expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">96</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">44</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">General and
administrative expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">269</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">336</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">365</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">380</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Unamortized
equity-based compensation expense at March 31, 2018 was</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2,997</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
which is expected to be amortized over a weighted-average period
of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">2.8
years</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company utilizes the Black-Scholes option-pricing model to
determine the fair value of common stock option grants. The
Black-Scholes option-pricing model was developed for use in
estimating the fair value of traded options that have no vesting
restrictions and are fully transferable. The model also requires
the input of highly subjective assumptions. In addition to an
assumption on the expected term of the option grants as discussed
below, application of the Black-Scholes model requires additional
inputs for which we have assumed the values described in the table
below:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="6"></td>
</tr>
<tr>
<td style="width:59%;"></td>
<td style="width:19%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:19%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="5" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected
term</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5.9 to 6.0
years</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5.3 to 6.5
years</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Risk-free interest
rate</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2.72%</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1.97% to 2.17%;
weighted avg. 2.07%</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected
volatility</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">82.4%</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">80.8% to 83.1%;
weighted avg. 81.0%</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Forfeiture
rate</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected dividend
yield</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
expected term is based upon the âsimplified methodâ as described in
Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does
not have sufficient experience to provide a reasonable estimate of
an expected term of its common stock options. The Company will
continue to use the âsimplified methodâ until there is sufficient
experience to provide a more reasonable estimate in conformance
with ASC 718-10-30-25 through 30-26. The risk-free interest rate
assumptions were based on the U.S. Treasury bond rate appropriate
for the expected term in effect at the time of grant. The expected
volatility is based on calculated enterprise value volatilities for
publicly traded companies in the same industry and general stage of
development. The estimated forfeiture rates were based on
historical experience for similar classes of employees. The
dividend yield was based on expected dividends at the time of
grant.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
fair value of the underlying common stock and the exercise price
for the common stock options granted during the three months ended
March 31, 2018 and 2017 are summarized in the table
below:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="4"></td>
</tr>
<tr>
<td style="width:57%;"></td>
<td style="width:21%;"></td>
<td style="width:1%;"></td>
<td style="width:21%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common
Stock Options Granted During Period Ended:</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair
Value of Underlying Common Stock</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exercise
Price of Common Stock Option</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Three months ended
March 31, 2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$3.00</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$3.00</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Three months ended
March 31, 2017</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$4.21</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$4.21</font></div>
</td>
</tr>
</table>
</div>
</div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">17</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Companyâs common stock has not yet been publicly traded, therefore
the Company estimates the fair value of its common stock underlying
its common stock options. At March 31, 2018, for financial
reporting purposes and principally to aid Exicure in the
revaluation of certain common stock option awards to non-employees
and certain warrant liabilities, Exicure estimated the per share
fair value of its common stock to be</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
which is the per share price paid by outside investors in the
Private Placement.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
weighted-average grant date fair value of common stock options
granted in the three months ended March 31, 2018 and 2017
was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.13</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.92</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">per
common stock option, respectively.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">A
summary of common stock option activity as of the periods indicated
is as follows:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="13"></td>
</tr>
<tr>
<td style="width:41%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:14%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Options</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average
Exercise Price</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average
Remaining Contractual Term (years)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Aggregate
Intrinsic Value (thousands)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Outstanding -
December 31, 2017</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,672,620</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1.79</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7.5</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5,221</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Granted</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">674,279</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3.00</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Exercised</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(8,532</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">0.86</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Forfeited</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,638</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1.03</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Outstanding - March
31, 2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,335,729</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1.98</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7.5</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5,221</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Exercisable - March
31, 2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,597,078</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1.51</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7.0</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,245</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Vested and Expected
to Vest -</font></div>
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">March 31,
2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,916,640</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2.11</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7.5</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5,190</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
aggregate intrinsic value of common stock options exercised during
the three months ended March 31, 2018 and 2017 was</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$18</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$202</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively.</font></div>
<div><a name="s654DF3D9F3B05CF5AF9BC77E14B89E3F" id=
"s654DF3D9F3B05CF5AF9BC77E14B89E3F"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
8. Income Taxes</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company incurred a pretax loss in each of the three months ended
March 31, 2018 and 2017, which consists entirely of loss in the
U.S. and resulted in</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">no</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">provision
for income tax expense during the periods then ended. The effective
tax rate is</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">0%</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in each
of the three months ended March 31, 2018 and 2017 because the
Company has generated tax losses and has provided a full valuation
allowance against its deferred tax assets.</font></div>
<div><a name="sD5AA4D1082A151B0BA1AC52AE34F25DF" id=
"sD5AA4D1082A151B0BA1AC52AE34F25DF"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
9. Loss Per Common Share</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Basic
loss per common share is calculated by dividing net loss by the
weighted-average number of shares of common stock outstanding
during the period. Diluted loss per common share is calculated
using the treasury share method by giving effect to all potentially
dilutive securities that were outstanding. Potentially dilutive
options and warrants to purchase common stock that were outstanding
during the periods presented were excluded from the diluted loss
per share calculation because such shares had an anti-dilutive
effect due to the net loss reported in those periods. Therefore,
basic and diluted loss per common share is the same for each of the
three months ended March 31, 2018 and 2017.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">18</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following is the computation of loss per common share for the three
months ended March 31, 2018 and 2017:</font></div>
<div style=
"line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:59%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net loss</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,652</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Weighted-average
basic and diluted common shares outstanding</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">39,357,289</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">169,794</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Loss per share -
basic and diluted</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(0.14</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(15.62</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
outstanding securities presented below were excluded from the
calculation of net loss per common share, because such securities
would have been anti-dilutive due to the Companyâs net loss per
share during the periods ending on the dates
presented:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="7"></td>
</tr>
<tr>
<td style="width:70%;"></td>
<td style="width:1%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="5" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Options to purchase
common stock</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,335,729</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,683,826</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Warrants to purchase
common stock</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">413,320</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div><a name="s8D7534D66635512C99EE0335A93698B3" id=
"s8D7534D66635512C99EE0335A93698B3"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
10. Fair Value Measurements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">ASC
Topic 820, Fair Value Measurement, establishes a three-tier fair
value hierarchy, which prioritizes the inputs used in measuring
fair value, as follows: Level 1 Inputs - unadjusted quoted prices
in active markets for identical assets or liabilities accessible to
the reporting entity at the measurement date; Level 2 Inputs -
other than quoted prices included in Level 1 inputs that are
observable for the asset or liability, either directly or
indirectly, for substantially the full term of the asset or
liability; and Level 3 Inputs - unobservable inputs for the asset
or liability used to measure fair value to the extent that
observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity for
the asset or liability at measurement date.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company uses the market approach and Level 1 inputs to value its
cash equivalents.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Companyâs long-term debt bore interest at the prevailing market
rates for instruments with similar characteristics and,
accordingly, the carrying value for this instrument also
approximates its fair value and the financial measurement is also
classified within Level&nbsp;2 of the fair value
hierarchy.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Companyâs common stock warrant liability is classified within Level
3 of the fair value hierarchy. The fair value of the common stock
warrant liability was determined using the Black-Scholes
option-pricing model.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following assumptions were used to estimate the fair value of the
common stock warrant liability at March 31, 2018:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="3"></td>
</tr>
<tr>
<td style="width:79%;"></td>
<td style="width:20%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31, 2018</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected
term</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3.0
years</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Risk-free interest
rate</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2.38</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected
volatility</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">78.1</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Expected dividend
yield</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">A</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">change
in the estimate of expected volatility at March 31, 2018 would
increase or decrease the fair value of the common stock warrant
liability in the amount of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$50</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
A</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">change
in the estimate of fair value of the</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">19</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">common
stock at March 31, 2018 would increase or decrease the fair value
of the common stock warrant liability in the amount of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$94</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following is a reconciliation of the Companyâs liabilities measured
at fair value on a recurring basis using unobservable inputs (Level
3) for the three months ended March 31, 2018:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="4"></td>
</tr>
<tr>
<td style="width:79%;"></td>
<td style="width:1%;"></td>
<td style="width:19%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair
Value Measurements Using Significant Unobservable Inputs (Level
3)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common
Stock Warrant Liability</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Balance at January 1,
2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">523</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Loss included in
other income (expense), net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">128</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Balance at March 31,
2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">651</font></div>
</td>
<td style="vertical-align:bottom;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div><a name="s16751C2F6E06568A90B588D858C820D9" id=
"s16751C2F6E06568A90B588D858C820D9"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
11. Commitments and Contingencies</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Leases</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company conducts all operations in a facility under an operating
lease which commenced in March 2012 and was originally scheduled to
end in February 2015. During the first quarter of 2014, the lease
was extended for an additional</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">six
years</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">through
February 2021, and includes a renewal option. During the second
quarter of 2016, the Company amended the lease agreement to include
additional space to be used primarily for administrative functions
effective in May 2016. Lease payments include a fixed payment
amount as well as contingent payments related to a proportionate
share of operating and real estate expenses. At the inception of
the lease, the lessor paid for leasehold improvements
totaling</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$52</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">which
has been capitalized and is being amortized over the lease term.
The fixed payment amounts, including those in connection with the
amended lease agreement in the second quarter of 2016, increase
over the term of the lease but rent expense is recognized on a
straight-line basis resulting in the recognition of deferred rent
liability of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$46</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$48</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">as of
March 31, 2018 and December 31, 2017, respectively, calculated on
the basis of the extended lease agreement.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Rent
expense consisted of the following:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:59%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Straight-line rent
expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">83</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">83</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Contingent rent
expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">89</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">77</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;Total
rent expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">172</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">160</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">20</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Future
minimum lease payments as of March 31, 2018 are as
follows:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="5"></td>
</tr>
<tr>
<td style="width:78%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:19%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years
ending December 31,</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Operating
Leases</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">256</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2019</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">347</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2020</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">353</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2021</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">59</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Thereafter</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;Total</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,015</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Northwestern University license agreements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
December 12, 2011, (1) AuraSense, LLC assigned to the Company all
of its worldwide rights and interests under AuraSense, LLCâs 2009
license agreement with Northwestern University (âNUâ) in the field
of the use of nanoparticles, nanotechnology, microtechnology or
nanomaterial-based constructs as therapeutics or accompanying
therapeutics as a means of delivery, but expressly excluding
diagnostics (the âassigned fieldâ); (2)&nbsp;in accordance with the
terms and conditions of this assignment, the Company assumed all
liabilities and obligations of AuraSense, LLC as set forth in its
license agreement in the assigned field; and (3)&nbsp;in order to
secure this assignment and the patent rights from NU, the Company
agreed (i) to pay NU an annual license fee, which may be credited
against any royalties due to NU in the same year, (ii) to reimburse
NU for expenses associated with the prosecution and maintenance of
the license patent rights, (iii) to pay NU royalties based on any
net revenue generated by the Companyâs sale or transfer of any
licensed product, and (iv) to pay NU, in the event the Company
grants a sublicense under the licensed patent rights, the greater
of a percentage of all sublicensee royalties or a percentage of any
net revenue generated by a sublicenseeâs sale or transfer of any
licensed product. In August 2015, we entered into a restated
license agreement with NU (the ârestated license agreementâ). In
February 2016, we obtained exclusive license as to NUâs rights in
certain SNA technology we jointly own with NU (the âFebruary 2016
license agreementâ). Our license to NUâs rights is limited to the
assigned field, however we have no such limitation as to our own
rights in this jointly owned technology. In June 2016, we entered
into an exclusive license with NU to obtain worldwide rights to
certain inhibitors of glucosylceramide synthase and their use in
wound healing in diabetes (the âJune 2016 license agreementâ). Our
rights and obligations in these 2016 agreements&nbsp;are
substantially the same as in the restated license agreement from
August 2015 (collectively referred to as âthe Northwestern
University License Agreementsâ). As of March 31, 2018, the Company
has paid to NU an aggregate of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3,419</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in
consideration of each of the obligations described
above.</font></div>
<div><a name="sB2664A6C5CF65BCF98C202EAD33D98DC" id=
"sB2664A6C5CF65BCF98C202EAD33D98DC"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
12. Related-Party Transactions</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Since
its inception in 2011, the Company has shared facilities, certain
staff members and certain operating expenses with AuraSense, LLC,
our former parent and largest stockholder. On an infrequent basis,
the Company also pays certain expenses directly on behalf of
AuraSense, LLC which are related to AuraSense, LLCâs grants, and
AuraSense, LLC sometimes pays expenses directly on behalf of the
Company. These costs are summarized and directly billed between the
Company and AuraSense, LLC on a quarterly basis. In addition,
certain expense and administrative activities are shared between
the Company and AuraSense, LLC. Effective January 1, 2016, the
Company and AuraSense, LLC amended its shared services agreement to
simplify the billing arrangement. Under the amended shared services
agreement, the Company bills AuraSense, LLC</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$8</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">per
quarter for indirect costs incurred by the Company plus a specified
rate for hours worked by Company scientists on projects directly
related to AuraSense, LLC. The amended shared services arrangement
continues to require direct non-labor expenses incurred by the
Company to be billed to AuraSense, LLC. Effective January 1, 2017,
the Company and AuraSense, LLC further amended its shared services
agreement so that the quarterly fee related to administrative
activities billed by the Company to AuraSense, LLC be reduced
to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">per
quarter. This decrease is to reflect the current and expected
future reduction in administrative activities to be provided by the
Company to AuraSense, LLC.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">21</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
EXICURE, INC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
(in thousands, except share and per share data)</font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
amounts due from AuraSense, LLC in connection with the above
mentioned activities were</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$21</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$17</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">at
March 31, 2018 and December 31, 2017, respectively.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following is a summary of amounts billed to AuraSense, LLC and
recognized in the accompanying unaudited statement of operations in
connection with the above mentioned activities:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="8"></td>
</tr>
<tr>
<td style="width:59%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:18%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">For
the Three Months Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Quarterly fee for
indirect costs</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Direct costs of
AuraSense LLC paid by the Company</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company received consulting services from, and paid fees to, one of
its co-founders who is not an employee but serves as a member of
the Board. The Company paid</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$25</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in each
of the three months ended March 31, 2018 and 2017 in connection
with these consulting services and these amounts are recognized as
an expense in the accompanying unaudited consolidated statement of
operations.</font></div>
<div><a name="s6CE5EACEEC7A5C4F9D846B41B7ED97D8" id=
"s6CE5EACEEC7A5C4F9D846B41B7ED97D8"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
13. Subsequent Events</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
April 2018, Purdue notified the Company it has declined to exercise
its option to develop AST-005 at this time, but that it also
intends to retain rights relating to the TNF target, and Purdue
reserves its right to continue joint development, with Exicure, of
new anti-TNF drug candidates and to retain its exclusivity and
other rights to AST-005.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Company has evaluated subsequent events which may require
adjustment to or disclosure in the accompanying unaudited condensed
consolidated financial statements and has concluded that, other
than the recent developments related to the Purdue Collaboration
disclosed above, there are no subsequent events or transactions
that occurred subsequent to the balance sheet date that would
require recognition or disclosure in the accompanying unaudited
condensed consolidated financial statements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">22</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sBDB9D6A64AC8549C9A6D51D21BC0CB52" id=
"sBDB9D6A64AC8549C9A6D51D21BC0CB52"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 2. Managementâs Discussion and Analysis of Financial Condition
and Results of Operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
You should read the following discussion and analysis of our
financial condition and results of operations together with our
unaudited condensed consolidated interim financial statements and
the related notes and other financial information included in this
Quarterly Report on Form 10-Q. Managementâs Discussion is designed
to provide an understanding of our operations and financial
performance and should be read in conjunction with our Annual
Report on Form 10-K for the fiscal year ended December 31, 2017.
Some of the information contained in this discussion and analysis
or set forth elsewhere in this Quarterly Report on Form 10-Q,
including information with respect to our plans and strategy for
our business, includes forward-looking statements that involve
risks and uncertainties as described under the heading 
âForward-Looking Statementsâ elsewhere in this Quarterly Report on
Form 10-Q. You should review the disclosure under the heading âRisk
Factorsâ in this Quarterly Report on Form 10-Q for a discussion of
important factors that could cause actual results to differ
materially from the results described in or implied by the
forward-looking statements contained in the following discussion
and analysis.</font></div>
<div><a name="sB3A0CE64C3B15C9F929CAFFD5BFDEA38" id=
"sB3A0CE64C3B15C9F929CAFFD5BFDEA38"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Operating Overview</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
a clinical-stage biotechnology company developing gene regulatory
and immuno-oncology therapeutics based on our proprietary Spherical
Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs
consisting of densely packed synthetic nucleic acid sequences that
are radially arranged in three dimensions. We believe the design of
our SNAs gives rise to distinct chemical and biological properties
that may provide advantages over other nucleic acid therapeutics
and enable therapeutic activity outside of the liver. Since our
SNAs have shown in a Phase 1 clinical trial and in preclinical
studies that they can cross certain biological barriers when
administered locally, we believe that they have the therapeutic
potential to target diseases not typically addressed with other
nucleic acid therapeutics. We have demonstrated the ability to
cross certain biological barriers in a Phase 1 clinical trial of
our therapeutic candidate, AST-005, and in preclinical studies of
our two other therapeutic candidates, XCUR17 and AST-008, both of
which are currently in Phase 1 clinical trials.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
currently have three clinical programs: AST-008, XCUR17, and
AST-005.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
AST-008</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">AST-008
is an SNA consisting of toll-like receptor 9, or TLR9, agonists
designed for immuno-oncology applications. AST-008 has exhibited
anti-tumor activity as both a monotherapy and in combination with
certain checkpoint inhibitors across a range of preclinical models
of solid and hematological cancers. In the third quarter of 2017,
we received an authorization from the MHRA, the competent health
authority of the United Kingdom, to conduct a Phase 1 clinical
trial with&nbsp;AST-008. We began subject dosing in our Phase 1
clinical trial for&nbsp;AST-008&nbsp;in the fourth quarter of 2017.
We expect this trial to be completed in the third quarter of 2018.
Our current plan anticipates preparing and commencing a Phase 1b/2
clinical trial for AST-008 late this year. We ultimately plan to
clinically advance&nbsp;AST-008&nbsp;in combination with checkpoint
inhibitors.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
XCUR17</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17
is an SNA targeted to IL-17RA for the treatment of mild to moderate
psoriasis. We filed a CTA for a Phase 1 clinical trial of XCUR17 in
patients with psoriasis in Germany in the third quarter of 2017.
Our CTA was approved in February 2018 and we began dosing patients
in our Phase 1 clinical trial in April 2018. We expect this
clinical trial to be completed in the third quarter of
2018.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
AST-005</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">AST-005
is&nbsp;an SNA targeting tumor necrosis factor, or TNF, for the
treatment of mild to moderate psoriasis that is intended to be
administered locally in a gel to psoriatic lesions. In a completed
Phase 1 clinical trial,&nbsp;AST-005,&nbsp;when topically
administered to the skin of patients with mild to moderate
psoriasis, resulted in no drug associated adverse events, and
demonstrated a reduction of tumor necrosis factor messenger RNA, or
TNF mRNA.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As part
of Exicureâs collaboration with Purdue, a Phase 1b clinical trial
was conducted in Germany to evaluate the effect of AST-005 gel in
patients with chronic plaque psoriasis. The trial evaluated the
safety, tolerability, and plaque thickness following topical
application of different strengths of AST-005 formulated as
a</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">23</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">topical
gel. The trial demonstrated that AST-005 is safe and tolerable in
patients at higher doses than were previously studied. Seventy-five
areas of skin were treated with AST-005 gel across twenty-five
patients. One mild and one moderate adverse event in a single
patient was reported in a placebo treated area. No serious adverse
events were observed in any patient. As designed, however, the
study did not result in a statistically significant decrease in
echo lucent band thickness, one of the key indicators of efficacy
in patients with psoriasis.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
December&nbsp;2, 2016, we entered into a research collaboration,
option and license agreement with Purdue referred to as the Purdue
Collaboration. Purdue has the option to obtain from us the full
worldwide development and commercial rights
to&nbsp;AST-005,&nbsp;an option to obtain three additional
collaboration targets and a further option to obtain from us the
full worldwide development and commercial rights to any therapeutic
candidates developed targeting the three additional collaboration
targets.&nbsp; Additionally, Purdue has rights of first offer to
some potential collaboration targets. These rights of first offer
are subject to limitations in time and scope.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
April 2018, Purdue has notified the Company it has declined to
exercise its option to develop AST-005 at this time, but that it
also intends to retain rights relating to the TNF target, and
Purdue reserves its right to continue joint development, with
Exicure, of new anti-TNF drug candidates and to retain its
exclusivity and other rights to AST-005.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Since
our inception in 2011, we have devoted substantial resources to the
research and development of SNAs and the protection and enhancement
of our intellectual property. We have no products approved for sale
and all of our</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$15.5
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in
revenue since inception through March 31, 2018 has been earned
through our research collaboration, license, and option agreement
with Purdue or as a primary contractor or as a subcontractor on
government grants. In addition to our revenue, from inception
through March 31, 2018, we have funded our operations through
private placements of preferred stock with gross proceeds totaling
$42.8&nbsp;million, sales of common stock in the Private Placement
with gross proceeds totaling $31.5 million, and debt financing
totaling $6.0&nbsp;million. As of March 31, 2018, our cash and cash
equivalents were</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Since
our inception, we have incurred significant operating losses. Our
net loss was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$5.5
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2018 and 2017, respectively. As of
March 31, 2018, our accumulated deficit was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.
Substantially all of our operating losses resulted from expenses
incurred in connection with our research programs and from general
and administrative costs associated with our
operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect to continue to incur significant and increasing losses in
the foreseeable future. Our net losses may fluctuate significantly
from quarter to quarter and year to year. We anticipate that our
expenses will increase substantially as we:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">conduct
further preclinical studies and clinical trials of AST-008 and
XCUR17;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">increase
research and development for the discovery and development of
additional therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">advance
other therapeutic candidates into preclinical and clinical
development;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">increase
our research and development to enhance our
technology;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">procure
clinical trial materials;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">seek
regulatory approval for our therapeutic candidates that
successfully complete clinical trials;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">maintain,
expand and protect our intellectual property
portfolio;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">add
operational, financial and management information systems and
personnel, including personnel to support our product development
and planned future commercialization efforts; and</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">operate
as a public company.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
not generated any commercial product revenue nor do we expect to
generate substantial revenue from product sales unless and until we
successfully complete development and obtain regulatory approval
for one or more of our therapeutic candidates. Successful
therapeutic development and regulatory approval are subject to
significant</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">24</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">uncertainty
and we expect will take at least five years. If we obtain
regulatory approval for any of our therapeutic candidates, we
expect to incur significant commercialization expenses related to
product sales, marketing, manufacturing and distribution. Other
sources of revenue could include a combination of research and
development payments, license fees and other upfront payments,
milestone payments, and royalties in connection with our current
and any future collaborations and licenses. Until such time, if
ever, that we generate revenue from whatever source, we expect to
finance our cash needs through a combination of public or private
equity offerings, debt financings and research collaboration and
license agreements. We may be unable to raise capital or enter into
such other arrangements when needed or on favorable terms. Our
failure to raise capital or enter into such other arrangements as
and when needed would have a negative impact on our financial
condition and our ability to develop our therapeutic
candidates.</font></div>
<div><a name="s10E02A6835D85F568FDEF282A00337C0" id=
"s10E02A6835D85F568FDEF282A00337C0"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Recent Developments</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Registration Statement</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
filed and caused to become effective a registration statement with
the SEC on February 6, 2018 registering the resale of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">39,714,143</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">shares
of our common stock issued in 2017 in connection with the Private
Placement.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
been informed by our sponsoring market maker that FINRA has cleared
our Form 211. We are now addressing final administrative items in
order to begin trading on the OTCQB tier of the OTC.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Appointment of Chief Operating Officer</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
April 20, 2018, we announced that Matthias G. Schroff, Ph.D, was
appointed to serve as Chief Operating Officer (âCOOâ) of the
Company, effective April 16, 2018. Dr. Schroff is a biotechnology
industry veteran who brings more than 15 years of senior leadership
experience within global biopharmaceutical companies where he
gained deep scientific and clinical experience in immuno-oncology,
TLR9 biology and broad clinical program management. For more
information on the appointment of Dr. Schroff, please see the
Current Report on Form 8-K filed with the SEC on April 20,
2018.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Purdue Collaboration</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As part
of Exicureâs collaboration with Purdue, a Phase 1b clinical trial
was conducted in Germany to evaluate the effect of AST-005 gel in
patients with chronic plaque psoriasis. The trial evaluated the
safety, tolerability, and plaque thickness following topical
application of different strengths of AST-005 formulated as a
topical gel. The trial demonstrated that AST-005 is safe and
tolerable in patients at higher doses than were previously studied.
Seventy-five areas of skin were treated with AST-005 gel across
twenty-five patients. One mild and one moderate adverse event in a
single patient was reported in a placebo treated area. No serious
adverse events were observed in any patient. As designed, however,
the study did not result in a statistically significant decrease in
echo lucent band thickness, one of the key indicators of efficacy
in patients with psoriasis.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
April 2018, Purdue has notified the Company it has declined to
exercise its option to develop AST-005 at this time, but that it
also intends to retain rights relating to the TNF target, and
Purdue reserves its right to continue joint development, with
Exicure, of new anti-TNF drug candidates and to retain its
exclusivity and other rights to AST-005.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Segment Reporting</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We view
our operations and manage our business as one segment, which is the
discovery, research and development of treatments based on our SNA
technology.</font></div>
<div><a name="s32C125B5739E566E9D682DC5E349B4DF" id=
"s32C125B5739E566E9D682DC5E349B4DF"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Critical Accounting Policies and Significant Judgments and
Estimates</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
managementâs discussion and analysis of financial condition and
results of operations is based on our financial statements, which
have been prepared in accordance with GAAP. The preparation of
these financial statements requires us to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities
at the date of the financial statements, as well as the revenue and
expenses incurred during the reported periods. We base our
estimates on historical experience and on various</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">25</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">other
factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the
carrying value of assets and liabilities that are not apparent from
other sources. Changes in estimates are reflected in reported
results for the period in which they become known. Actual results
may differ from these estimates under different assumptions or
conditions.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
critical accounting policies require the most significant judgments
and estimates in the preparation of our consolidated financial
statements. There have been no significant changes to our critical
accounting policies from those which were discussed in our Annual
Report on Form 10-K for the year ended December 31, 2017, with the
exception of our policy relating to revenue
recognition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As
discussed in Note 2 of the accompanying unaudited condensed
consolidated financial statements, we adopted Accounting Standards
Update No.&nbsp;2014-09,&nbsp;</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue
from Contracts with Customers (Topic 606)</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;(
âASU 2014-09â) effective January 1, 2018. Refer to Note 2 of the
accompanying unaudited condensed consolidated financial statements
for a description of policy related to revenue
recognition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Recently adopted accounting pronouncements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Refer
to Note 2 of the accompanying unaudited condensed consolidated
financial statements for a description of recently adopted
accounting pronouncements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Recent accounting pronouncements not yet adopted</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Refer
to Note 2 of the accompanying unaudited condensed consolidated
financial statements for a description of recent accounting
pronouncements not yet adopted.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">26</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="sF8049324C6BE5092B6A0AA6041725C06" id=
"sF8049324C6BE5092B6A0AA6041725C06"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Results of Operations</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Comparison of the Three Months Ended March 31, 2018 and
2017</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following table summarizes the results of our operations for the
three months ended March 31, 2018 and 2017:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="15"></td>
</tr>
<tr>
<td style="width:41%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months&nbsp;Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars
in thousands)</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Revenue:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Collaboration
revenue</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,396</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">n/m</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total
revenue</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,396</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">n/m</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Operating
expenses:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Research and
development expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,275</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,488</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(213</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(6</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">General and
administrative expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,045</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,426</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">619</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total operating
expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">5,320</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">4,914</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">406</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">8</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Operating
loss</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,284</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,482</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,802</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">113</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other income
(expense), net:</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Interest
expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(161</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(204</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(21</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Other income (loss),
net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(64</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">34</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(98</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">n/m</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total other income
(loss), net</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(225</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(170</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(55</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">32</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net loss</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(5,509</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,652</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,857</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">108</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Revenue</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="14"></td>
</tr>
<tr>
<td style="width:41%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:14%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months&nbsp;Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="5" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars
in thousands)</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="5" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Collaboration
revenue</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,396</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">n/m</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total
revenue</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">36</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,432</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(2,396</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">n/m</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Revenue
in both the three months March 31, 2018 and 2017 related to the
Purdue Collaboration. In connection with the Purdue Collaboration,
we received a non-refundable development fee of $10.0&nbsp;million
in December 2016. Prior to the adoption of ASC 606, the upfront
payment of $10.0&nbsp;million was accounted for pursuant to ASC 605
and was recorded as deferred revenue and recognized on a ratable
basis over the estimated performance period of the relevant
research and development activities. On January 1, 2018, in
connection with the adoption of ASC 606, we recorded the
unamortized deferred revenue of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">as an
adjustment to the beginning balance of accumulated deficit at
January 1, 2018.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
collaboration revenue of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$36
thousand</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">during
the three months ended March 31, 2018 related to research and
development activities that is reimbursable by Purdue and is
presented on a gross basis in the accompanying consolidated
statement of operations. We recognized</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">of
collaboration revenue in the three months ended March 31, 2017,
which consisted of three months of amortization of deferred revenue
mentioned above and</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">related
to research and development activities that was reimbursed by
Purdue and is presented on a gross basis in the accompanying
consolidated statement of operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We do
not expect to generate any product revenue for the foreseeable
future. However, future revenue may include amounts attributable to
partnership activities including, a combination of research and
development payments, license fees and other upfront payments,
milestone payments, product sales and royalties, and</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">27</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">reimbursement
of certain research and development expenses, in connection with
the Purdue Collaboration or any future collaboration and
licenses.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Refer
to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Recent Developments</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">above
for more information on the Purdue Collaboration.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Research and development expense</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following table summarizes our research and development expenses
incurred during the periods indicated:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="15"></td>
</tr>
<tr>
<td style="width:41%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&nbsp;in&nbsp;thousands)</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Clinical development
programs expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,276</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,900</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(624</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(33</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Platform and
discovery-related expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">915</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">764</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">151</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">20</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Employee-related
expense</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">831</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">620</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">211</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">34</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Facilities,
depreciation, and other expenses</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">253</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">204</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">49</font></div>
</td>
<td style="vertical-align:bottom;border-bottom:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">24</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Total research and
development expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,275</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">3,488</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(213</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(6</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:18px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Full time
employees</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">17</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">18</font></div>
</td>
<td style="vertical-align:bottom;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(1</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Research
and development expense was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3.3
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2018 and</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$3.5
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March&nbsp;31, 2017, a decrease of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
or</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
The decrease in research and development expense of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">was
primarily due to a net decrease in costs related to our clinical
development programs of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
partially offset by higher employee-related expenses of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and
higher platform and discovery-related expense of</font>
<font style="font-family:Times New Roman;font-size:10pt;color:#000000;">
$0.2 million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The net
decrease in clinical development programs expense was mostly due to
lower costs associated with AST-005 (for which the Phase 1b
clinical trial, subject of the Purdue Collaboration, ended during
the first quarter of 2018) and lower costs for preparation for the
Phase 1 clinical trial of XCUR17, partially offset by increased
costs for Phase 1 clinical trial activities of AST-008. Included in
clinical development expense for the three months ended March 31,
2018 and 2017 was approximately</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$36
thousand</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively, of expense that is reimbursed by Purdue (included in
revenue) related to the Phase 1b trial of AST-005. Higher
employee-related expense of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">was
mostly the result of salary increases and a change in mix of
scientific staff as well as higher non-cash stock-based
compensation expense. The increase in platform and
discovery-related expense of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">is
mostly due to higher costs to maintain our intellectual property
portfolio, partially offset by lower costs related to contract
research organizations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect our research and development expenses to increase in 2018 as
we continue spending on our clinical development programs, further
develop our SNA technology platform and broaden our pipeline of
SNA-based candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
General and administrative expense</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="15"></td>
</tr>
<tr>
<td style="width:41%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three
Months&nbsp;Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&nbsp;in&nbsp;thousands)</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="6" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">General and
administrative expense</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">2,045</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1,426</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">619</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">%</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Full time
employees</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">8</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">1</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">General
and administrative expense was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2018 and</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$1.4
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2017, an increase of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
or</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">43%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.
This increase is due to higher legal costs of $0.2 million
associated with the preparation of Form S-1 to register the shares
of common stock in connection with the Merger and the Private
Placement as well as other activities to obtain regulatory approval
for</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">28</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
trading of our common stock on the over-the-counter market and
higher compensation and related expenses of $0.2 million associated
with salary increases. Also contributing to the increase in general
and administrative expense of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">were
higher costs of $0.2 million associated with being a public
company, including higher expense for director and officer
insurance and investor and public relations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect that general and administrative expenses will increase in
the future as we expand our operating activities and incur
additional costs associated with being a publicly-traded company.
These increases will likely include legal, accounting and filing
fees, directorsâ and officersâ liability insurance premiums and
fees associated with investor relations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Interest expense</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Interest
expense consists of interest expense pursuant to the loan and
security agreement with Hercules that we closed on
February&nbsp;17, 2016 with an initial advance of
$6.0&nbsp;million.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Other income (loss), net</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Other
income (loss), net consists of interest income earned on our cash
and cash equivalents, fair value adjustments of our common stock
warrant liabilities, and gains and losses on foreign currency
transactions.</font></div>
<div><a name="s98BDEF1CD012523BB788E68822EBF56A" id=
"s98BDEF1CD012523BB788E68822EBF56A"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Liquidity and Capital Resources</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Overview</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">To date
we have primarily funded our operations through private placements
of equity securities, the Purdue Collaboration, a debt financing,
and grants from governmental agencies. Since inception and through
March 31, 2018, we have received approximately $95.3 million in
aggregate gross proceeds from these transactions, including $42.8
million in aggregate gross proceeds from private placement
offerings of preferred stock, $31.5 million in gross proceeds from
sales of common stock in the Private Placement with gross proceeds
totaling $31.5 million, an upfront payment of $10.0&nbsp;million in
connection with the Purdue Collaboration, $6.0 million in debt
financing, and an aggregate of $5.0 million from grants awarded by
governmental agencies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Since
our inception, we have not generated any product revenue and have
incurred recurring net losses. Our Company is not profitable, and
we cannot provide any assurance that we will ever be profitable. As
of March 31, 2018, we have an accumulated deficit of</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Based
on our current operating plans, existing working capital at March
31, 2018 is not sufficient to sustain operations beyond March 31,
2019.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Management
believes that it will be able to obtain additional working capital
through equity financings, partnerships and licensing, or other
arrangements, to fund operations. However, there can be no
assurance that such additional financing will be available and, if
available, can be obtained on terms acceptable to us. If we are
unable to obtain such additional financing, we will need to
reevaluate future operating plans. Accordingly, there is
substantial doubt regarding the Companyâs ability to continue as a
going concern.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">See ââ
Funding Requirementsâ below for additional information on our
future capital needs.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">29</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Cash Flows</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
following table shows a summary of our cash flows for the three
months ended March 31, 2018 and 2017:</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="9"></td>
</tr>
<tr>
<td style="width:70%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:1%;"></td>
<td style="width:12%;"></td>
<td style="width:1%;"></td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="7" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></div>
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">March
31,</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-style:italic;">(in&nbsp;thousands)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="3" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:center;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash used in
operating activities</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(4,647</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(6,997</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash used in
investing activities</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">â</font></div>
</td>
<td style="vertical-align:bottom;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(245</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Net cash provided by
financing activities</font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">7</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
<td style=
"vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td colspan="2" style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">43</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;"><br /></font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
increase decrease in cash and cash equivalents</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(4,640</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">$</font></div>
</td>
<td style=
"vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:right;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(7,199</font></div>
</td>
<td style=
"vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">)</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Operating activities</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Net
cash used in operating activities was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$4.6
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$7.0
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2018 and 2017, respectively. The
decrease in cash used in operating activities of</font>
<font style="font-family:Times New Roman;font-size:10pt;color:#000000;">
$2.4 million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">was
primarily due to the absence of the first quarter 2017 payment of
$1.5&nbsp;million in connection with the Northwestern University
license agreements and lower cash used for working
capital.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">
Investing activities</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Net
cash used in investing activities was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">for the
three months ended March 31, 2018 and 2017, respectively. Cash used
in investing activities for the 2017 period was primarily due to
the purchase of scientific equipment.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Hercules Loan and Security Agreement</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
February&nbsp;17, 2016, we entered into a loan and security
agreement with Hercules. The loan agreement provided for funding in
an aggregate principal amount of up to $10.0&nbsp;million in two
separate tranches. The first tranche was funded on
February&nbsp;17, 2016 in the amount of $6.0&nbsp;million. A second
tranche of $4.0&nbsp;million was available provided that we met
certain milestones on or before December&nbsp;31, 2016. We did not
meet these milestones and, therefore, we did not draw the second
tranche, the availability of which expired on December&nbsp;31,
2016. The principal balance of the term loan under the Hercules
loan facility bears interest at a floating per annum interest rate
(based on a year consisting of 360 days) equal to the greater of
either (i) 9.95% or (ii)&nbsp;the sum of (a) 9.95% plus
(b)&nbsp;the prime rate (as reported in The Wall Street Journal)
minus 3.50%. We were required to make interest-only payments
through June 2017. Commencing on July&nbsp;1, 2017, the loan began
amortizing in equal monthly installments of principal and interest
in an amount sufficient to fully amortize the outstanding principal
balance of the loan over the remaining scheduled monthly payments
due prior to the maturity date on September&nbsp;1, 2019. Pursuant
to an amendment dated January 15, 2018, amortization payments due
for the thirteen (13) consecutive months commencing on December 1,
2017 through and including December 1, 2018 were deferred.&nbsp;
Commencing on January 1, 2019, and continuing on the first business
day of each month thereafter, the loan, including the deferred
payments, shall begin amortizing in equal monthly installments of
principal and interest based upon an amortization schedule equal to
eighteen (18) consecutive months. Any remaining obligations under
the loan agreement and other loan documents are due and payable on
the maturity date. On the earliest to occur of the maturity date,
the date we prepay the term loan in full or the date the loan
otherwise becomes due and payable, we must pay the lender under the
agreement an additional charge equal to 3.85% of the total amounts
funded under the loan agreement. In addition, if we prepaid the
term loan on or prior to February&nbsp;1, 2017, we would be
required to pay a prepayment charge equal to 3% of the amount being
prepaid, if we prepaid the term loan after February&nbsp;1, 2017
but on or prior to February&nbsp;1, 2018, we would be required to
pay a prepayment charge equal to 2% of the amount being prepaid,
and if we prepay the term loan after February&nbsp;1, 2018, we must
pay a prepayment charge of 1% of the amount being prepaid. As of
the date of this report, we have not prepaid the Hercules term
loan. The loan agreement was amended on October&nbsp;10, 2016 to
revise the language granting Hercules a contingent security
interest in certain of our assets.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">30</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
term loan under the Hercules loan facility is secured by
substantially all of our assets, other than intellectual property,
which is the subject of a negative pledge. Under the loan
agreement, we are subject to certain customary covenants that limit
or restrict our ability to, among other things, incur additional
indebtedness, grant any security interests, pay cash dividends,
repurchase our common stock, make loans, or enter into certain
transactions without Herculesâ prior consent.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Under
the loan agreement, Hercules or its affiliates have a right to
participate in a single subsequent unregistered financing by us in
an amount of up $1.0&nbsp;million on the same terms, conditions and
pricing afforded to others participating in such financing.
Hercules has not yet exercised this right to participate which
expires on the earliest to occur of the maturity date, the date we
prepay the term loan in full or the date the loan otherwise becomes
due and payable.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
Funding Requirements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect that our primary uses of capital will continue to be
third-party clinical research and development services,
compensation and related expenses, laboratory and related supplies,
legal and other regulatory expenses and general overhead
costs.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Based
on our current operating plans, existing working capital at March
31, 2018 is not sufficient to sustain operations beyond March 31,
2019.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">However,
we may require additional capital for the further development of
our existing therapeutic candidates and may also need to raise
additional funds sooner to pursue other development activities
related to additional therapeutic candidates. We believe that we
will be able to obtain additional working capital through equity
financings, partnerships and licensing, or other arrangements to
fund our current operating plans, which we believe will allow us to
execute on the strategy and pipeline development as described in
this Quarterly Report on Form 10-Q. To the extent that we raise
additional capital through future equity financings, the ownership
interest of our stockholders will be diluted, and the terms of
these securities may include liquidation or other preferences that
adversely affect the rights of our existing common stockholders. If
we raise additional funds through the issuance of debt securities,
these securities could contain covenants that would restrict our
operations. We cannot assure you that such additional financing, if
available, can be obtained on terms acceptable to us. If we are
unable to obtain such additional financing, we would need to
reevaluate our future operating plans.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
forecast of the period of time through which our financial
resources will be adequate to support our operations is a
forward-looking statement that involves risks and uncertainties,
and actual results could vary materially as a result of a number of
factors. We have based this estimate on assumptions that may prove
to be wrong, and we could utilize our available capital resources
sooner than we currently expect. Our future capital requirements
are difficult to forecast and will depend on many factors,
including:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
terms and timing of any other collaboration, licensing and other
arrangements that we may establish;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
initiation, progress, timing and completion of preclinical studies
and clinical trials for our potential therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
number and characteristics of therapeutic candidates that we
pursue;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
progress, costs and results of our preclinical studies and clinical
trials;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
outcome, timing and cost of regulatory approvals;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">delays
that may be caused by changing regulatory
requirements;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
cost and timing of hiring new employees to support our continued
growth;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">unknown
legal, administrative, regulatory, accounting, and information
technology costs as well as additional costs associated with
operating as a public company;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
costs involved in filing and prosecuting patent applications and
enforcing and defending patent claims;</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">31</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
costs of filing and prosecuting intellectual property rights and
enforcing and defending any intellectual property-related
claims;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
costs and timing of procuring clinical and commercial supplies of
our therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
extent to which we acquire or in-license other therapeutic
candidates and technologies; and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
extent to which we acquire or invest in other businesses,
therapeutic candidates or technologies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Please
see the section titled âRisk Factorsâ elsewhere in this Quarterly
Report on Form 10-Q for additional risks associated with our
substantial capital requirements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Until
such time, if ever, we generate product revenue, we expect to
finance our cash needs through a combination of public or private
equity offerings, debt financings and research collaboration and
license agreements. We may be unable to raise capital or enter into
such other arrangements when needed or on favorable terms or at
all. Our failure to raise capital or enter into such other
arrangements as and when needed would have a negative impact on our
financial condition and our ability to develop our therapeutic
candidates.</font></div>
<div><a name="sB7D34AB472C25C8485992697B5B8C5A5" id=
"sB7D34AB472C25C8485992697B5B8C5A5"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Contractual Obligations and Commitments</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">There
have been no material changes outside the ordinary course of
business during the period covered by this Quarterly Report on Form
10-Q from the contractual obligations and commitments discussed in
our Annual Report on Form 10-K for the year ended December 31,
2017</font></div>
<div><a name="sC24115ECD17353BEA0ACAABBF3DD0637" id=
"sC24115ECD17353BEA0ACAABBF3DD0637"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Off-balance Sheet Arrangements</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We did
not have during the periods presented, and we do not currently
have, any off-balance sheet arrangements, as defined in the rules
and regulations of the SEC.</font></div>
<div><a name="s5786233E3032526B9AFB8308C03D1530" id=
"s5786233E3032526B9AFB8308C03D1530"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
JOBS Act</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
April 2012, the Jumpstart Our Business Startups Act of 2012 (the 
âJOBS Actâ) was enacted by the federal government. Section&nbsp;107
of the JOBS Act provides that an emerging growth company can take
advantage of the extended transition period for complying with new
or revised accounting standards. Thus, an emerging growth company
can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We have
irrevocably elected not to avail ourselves of this extended
transition period and, as a result, we will adopt new or revised
accounting standards on the relevant dates on which adoption of
such standards is required for other public companies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, as an emerging growth company, we will not be required to
provide an auditorâs attestation report on our internal control
over financial reporting in future annual reports on Form 10-K as
otherwise required by Section&nbsp;404(b) of the Sarbanes-Oxley
Act.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">32</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s213B96CD2A81533894D39E7337ED3F63" id=
"s213B96CD2A81533894D39E7337ED3F63"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item&nbsp;3. Quantitative and Qualitative Disclosures about Market
Risk.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
primary objectives of our investment activities are to ensure
liquidity and to preserve principal while at the same time
maximizing the income we receive from our marketable securities
without significantly increasing risk. Some of the securities that
we invest in may have market risk related to changes in interest
rates. As of March 31, 2018 and December&nbsp;31, 2017, we had cash
equivalents of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively, consisting of interest-bearing money market accounts.
Our primary exposure to market risk is interest rate sensitivity,
which is affected by changes in the general level of U.S. interest
rates. Due to the short-term maturities of our cash equivalents and
the low risk profile of our investments, an immediate
100&nbsp;basis point change in interest rates would not have a
material effect on the fair market value of our cash equivalents.
To minimize the risk in the future, we intend to maintain our
portfolio of cash equivalents and short-term investments in a
variety of securities, including commercial paper, money market
funds, government and non-government debt securities and corporate
obligations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
subject to interest rate risk in connection with our borrowings
under the $6.0 million term loan with Hercules. The principal
balance of the term loan under the Hercules loan facility bears
interest at a floating per annum interest rate (based on a year
consisting of 360 days) equal to the greater of either (i) 9.95% or
(ii)&nbsp;the sum of (a) 9.95% plus (b)&nbsp;the prime rate (as
reported in The Wall Street Journal) minus 3.50% which bears
interest at a variable per annum rate calculated for any day as the
greater of either (i) the prime rate plus 6.80%, and (ii) 10.55%.
We currently do not engage in any interest rate hedging activity
and we have no intention to do so in the foreseeable future. Based
on the current interest rate of the term loan with Hercules and the
scheduled payments thereunder, we believe a 100 basis point
increase in interest rates would not have a material impact on our
financial condition or results of operations.</font></div>
<div><a name="s97E51EC7E22652158C3791BEBE7744C7" id=
"s97E51EC7E22652158C3791BEBE7744C7"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
Item&nbsp;4. Controls and Procedures.</font></div>
<div style=
"line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Evaluation of Disclosure Controls and Procedures</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As we
are an emerging growth company and a newly public company, we have
not prepared a formal managementâs report on internal control over
financial reporting, as would otherwise be required by Section 404
of the Sarbanes-Oxley Act of 2002, nor have we engaged an
independent registered public accounting firm to perform an audit
of our internal control over financial reporting as of any balance
sheet date in our condensed consolidated interim financial
statements. Our compliance with Section 404 of the Sarbanes-Oxley
Act will first be subject to managementâs assessment regarding
internal control over financial reporting in connection with the
filing of our Annual Report on Form 10-K for the fiscal year ending
December 31, 2018, and we will not be required to have an
independent registered public accounting firm attest to the
effectiveness of our internal control over financial reporting
until the filing of our first Annual Report on Form 10-K after we
lose emerging growth company status, which may not be until the
2022 Annual Report on Form 10-K.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
management, with the participation of our principal executive
officer and principal financial officer, evaluated the
effectiveness of our disclosure controls and procedures as of March
31, 2018. The term âdisclosure controls and procedures,â as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means
controls and other procedures of a company that are designed to
ensure that information required to be disclosed by a company in
the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time
periods specified in the SECâs rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by a
company in the reports that it files or submits under the Exchange
Act is accumulated and communicated to its management, including
its principal executive and principal financial officers, as
appropriate to allow timely decisions regarding required
disclosure. Management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only
reasonable assurance of achieving their objectives and management
necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Based
on the evaluation of our disclosure controls and procedures as of
March 31, 2018, our principal executive officer and principal
financial officer concluded that our disclosure controls and
procedures were not effective to provide reasonable assurance that
all information required to be disclosed in reports filed or
submitted under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the SECâs
rules</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">33</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and
forms, due to a material weakness in internal control over
financial reporting. The material weakness related to a deficiency
in the Companyâs information and communication controls, which led
to ineffectively designed controls over managementâs review of
certain research and development contracts to ensure expenses were
recognized as incurred by third-party contract research
organizations. Specifically these ineffectively designed controls,
which arose in a prior period and were identified in the quarter
ended March 31, 2018, resulted in an immaterial error, which was
corrected in this Quarterly Report on Form 10-Q in previously
issued financial statements as disclosed in Note 1 to the unaudited
condensed consolidated interim financial statements for the period
ended March 31, 2018.</font></div>
<div style=
"line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Remediation Plan for Material Weakness in Internal Control over
Financial Reporting</font></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
working towards remediating the deficiencies that led to the
material weakness by enhancing the information used for periodic
assessment of contract progress and increasing the frequency of
communication in the process for accounting for certain research
and development contracts with contract research
organization</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">s</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
ensure expenses are recognized as incurred.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
material weakness will not be considered remediated until the
applicable remedial controls operate for a sufficient period of
time and management has concluded, through testing, that these
controls are operating effectively. We are working to remediate the
material weakness as quickly and efficiently as possible and expect
that the material weakness will be remediated by the end of fiscal
2018.</font></div>
<div style=
"line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Changes in Internal Control over Financial Reporting</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Other
than the remediation efforts related to the material weakness
discussed above, no changes occurred in our internal control over
financial reporting identified in connection with the evaluation
required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during
the fiscal quarter ended March 31, 2018 that have materially
affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">34</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s7613DD62978555E8AEC018304441B665" id=
"s7613DD62978555E8AEC018304441B665"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;font-weight:bold;">PART II â
OTHER INFORMATION</font></div>
<div><a name="s512CA2DAA9CA58EBA11D26873A81E943" id=
"s512CA2DAA9CA58EBA11D26873A81E943"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item&nbsp;1. Legal Proceedings.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">From
time to time, we may be subject to legal proceedings. We are not
currently a party to or aware of any proceedings that we believe
will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or results of
operations.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><a name="sB7688808B3FE51B0A60E302430411435" id=
"sB7688808B3FE51B0A60E302430411435"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 1A. Risk Factors.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
We are providing the following cautionary discussion of risk
factors, uncertainties and assumptions that we believe are relevant
to our business. These are factors that, individually or in the
aggregate, we think could cause our actual results to differ
materially from expected and historical results and our
forward-looking statements. We note these factors for investors as
permitted by Section 21E of the Exchange Act and Section 27A of the
Securities Act. You should understand that it is not possible to
predict or identify all such factors. Consequently, you should not
consider this section to be a complete discussion of all potential
risks or uncertainties that may substantially impact our business.
Moreover, we operate in a competitive and rapidly changing
environment. New factors emerge from time to time and it is not
possible to predict the impact of all of these factors on our
business, financial condition or results of
operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Risks Related to Our Business</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We are a clinical-stage biotechnology company with a history of
losses. We expect to continue to incur significant losses for the
foreseeable future and may never achieve or maintain profitability,
which could result in a decline in the market value of our common
stock.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
a biotechnology company developing gene regulatory and
immuno-oncology therapeutics based on our proprietary SNA
technology. We have a limited operating history. Since our
inception in June 2011, we have devoted our resources to the
development of SNA technology. We have had significant operating
losses since our inception. As of March 31, 2018, we have generated
an accumulated deficit of</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">. For
the three months ended March 31, 2018 and 2017, our net loss
was</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$5.5
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7
million</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
respectively. Substantially all of our losses have resulted from
expenses incurred in connection with our research programs and from
general and administrative costs associated with our operations.
Our technology and therapeutic candidates are in early stages of
development, and we are subject to the risks of failure inherent in
the development of therapeutic candidates based on novel
technologies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
not generated, and do not expect to generate, any product revenue
for the foreseeable future, and we expect to continue to incur
significant operating losses for the foreseeable future due to the
cost of research and development, preclinical studies, clinical
trials, and the regulatory approval process for therapeutic
candidates. The amount of future losses is uncertain. Our ability
to achieve profitability, if ever, will depend on, among other
things, us, or any current or future collaborators, successfully
developing therapeutic candidates, obtaining regulatory approvals
to market and commercialize therapeutic candidates, manufacturing
any approved products on commercially reasonable terms,
establishing a sales and marketing organization or suitable third
party alternatives for any approved product and raising sufficient
funds to finance business activities. If we, or any current or
future collaborators, are unable to develop and commercialize one
or more of our therapeutic candidates or if sales revenue from any
therapeutic candidate that receives approval is insufficient, we
will not achieve profitability, which could have a material adverse
effect on our business, financial condition, results of operations
and prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our approach to the discovery and development of innovative
therapeutic treatments based on our technology is unproven and may
not result in marketable products.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We plan
to develop a pipeline of therapeutic candidates using our
proprietary SNAs as therapeutic agents. We believe that therapeutic
candidates identified with our therapeutic discovery technology may
offer an improved therapeutic approach to small molecules and
antibodies, as well as several advantages over linear
oligonucleotide-based therapeutics. However, the scientific
research that forms the basis of our efforts to develop therapeutic
candidates based on our SNAs and the identification and
optimization of SNAs is relatively new. Further, the</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">35</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">scientific
evidence to support the feasibility of developing therapeutic
treatments based on SNAs is both preliminary and
limited.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Therapeutic
candidates based on SNA technology have not been extensively tested
in humans, and a number of clinical trials conducted by other
companies using oligonucleotide technologies have not been
successful. We may discover that the SNAs do not possess certain
properties required for therapeutic treatment to be effective, such
as the ability to remain stable in the human body for the period of
time required for the therapeutic candidate to reach the target
tissue or the ability to cross the cell membrane and enter into
cells within the target tissue for effective delivery. We currently
have only limited data, and no conclusive evidence, to suggest that
we can introduce these necessary drug-like properties into SNAs. We
may spend substantial funds attempting to introduce these
properties and may never succeed in doing so. In addition,
therapeutic candidates based on SNAs may demonstrate different
chemical and pharmacological properties in patients than they do in
laboratory studies. Even if therapeutic candidates have successful
results in animal studies, they may not demonstrate the same
chemical and pharmacological properties in humans and may interact
with human biological systems in unforeseen, ineffective or harmful
ways. As a result, we may never succeed in developing a marketable
therapeutic, we may not become profitable and the value of our
common stock will decline.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Further,
the U.S. Food and Drug Administration (the âFDAâ) has limited
experience with SNA-based therapeutics. No regulatory authority has
granted approval to any person or entity, including us, to market
and commercialize therapeutics using SNAs, which may increase the
complexity, uncertainty and length of the regulatory approval
process for our therapeutic candidates. We and any current or
future collaborators may never receive approval to market and
commercialize any therapeutic candidate. Even if we or a future
collaborator obtain regulatory approval, the approval may be for
disease indications or patient populations that are not as broad as
we intended or desired or may require labeling that includes
significant use or distribution restrictions or safety warnings. We
or a future collaborator may be required to perform additional or
unanticipated clinical trials to obtain approval or be subject to
post-marketing testing requirements to maintain regulatory
approval. If our SNA technology proves to be ineffective, unsafe or
commercially unviable, our technology and pipeline would have
little, if any, value, which could have a material adverse effect
on our business, financial condition, results of operations and
prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our therapeutic candidates are in early stages of development and
may fail in development or suffer delays that materially and
adversely affect their commercial viability.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
no therapeutics on the market and all of our therapeutic candidates
are in early stages of development. Our ability to achieve and
sustain profitability depends on obtaining regulatory approvals,
including an institutional review board (âIRBâ), approval to
conduct clinical trials at particular sites for, and successfully
commercializing, our therapeutic candidates, either alone or with
third parties. Before obtaining regulatory approval for the
commercial distribution of our therapeutic candidates, we or an
existing or a future collaborator must conduct extensive
preclinical studies and clinical trials to demonstrate the safety
and efficacy in humans of our therapeutic candidates. Preclinical
studies and clinical trials are expensive, difficult to design and
implement, can take many years to complete and are uncertain as to
outcome. The start or end of a clinical trial is often delayed or
halted due to changing regulatory requirements, manufacturing
challenges, required clinical trial administrative actions, slower
than anticipated patient enrollment, changing standards of care,
availability or prevalence of use of a comparative therapeutic or
required prior therapy, clinical outcomes or financial constraints.
For instance, delays or difficulties in patient enrollment or
difficulties in retaining trial participants can result in
increased costs, longer development times or termination of a
clinical trial. Clinical trials of a new therapeutic candidate
require the enrollment of a sufficient number of patients,
including patients who are suffering from the disease the
therapeutic candidate is intended to treat and who meet other
eligibility criteria. Rates of patient enrollment are affected by
many factors, including the size of the patient population, the
eligibility criteria for the clinical trial, the age and condition
of the patients, the stage and severity of disease, the nature of
the protocol, the proximity of patients to clinical sites and the
availability of effective treatments for the relevant
disease.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">A
therapeutic candidate can unexpectedly fail at any stage of
preclinical and clinical development. In our completed Phase 1
trial, AST-005 did not show an antipsoriatic effect. Although we
believe this result was due to the short length of this clinical
trial, there is no guarantee that AST-005 will show an
antipsoriatic effect in future</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">36</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">clinical
trials of longer duration. The historical failure rate for
therapeutic candidates is high due to scientific feasibility,
safety, efficacy, changing standards of medical care and other
variables. The results from preclinical studies or early clinical
trials of a therapeutic candidate may not predict the results that
will be obtained in later phase clinical trials of the therapeutic
candidate. We, the FDA, an IRB, an independent ethics committee, or
other applicable regulatory authorities may suspend clinical trials
of a therapeutic candidate at any time for various reasons,
including a finding that subjects participating in such trials are
being exposed to unreasonable and significant risk of illness or
injury. Similarly, an IRB or ethics committee may suspend a
clinical trial at a particular trial site. We may not have the
financial resources to continue development of, or to enter into
collaborations for, a therapeutic candidate if we experience any
problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize,
therapeutic candidates, including:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">negative
or inconclusive results from our clinical trials or the clinical
trials of others for therapeutic candidates similar to ours,
leading to a decision or requirement to conduct additional
preclinical testing or clinical trials or abandon a
program;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic-related
side effects experienced by participants in our clinical trials or
by individuals using therapeutics similar to our therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">delays
in submitting INDs or CTAs, or comparable foreign applications or
delays or failure in obtaining the necessary approvals from
regulators or IRBs to commence a clinical trial, or a suspension or
termination of a clinical trial once commenced;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">conditions
imposed by the FDA or comparable foreign authorities, such as the
European Medicines Agency (âEMAâ) or European Union national
competent authorities, regarding the scope or design of our
clinical trials;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">delays
in enrolling research subjects in clinical trials;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">high
drop-out rates of research subjects;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">inadequate
supply or quality of therapeutic candidate components or materials
or other supplies necessary for the conduct of our clinical
trials;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">greater
than anticipated clinical trial costs;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">poor
effectiveness of our therapeutic candidates during clinical
trials;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">unfavorable
FDA or other regulatory agency inspection and review of a clinical
trial site;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">failure
of our third party contractors or investigators to comply with
regulatory requirements or otherwise meet their contractual
obligations in a timely manner, or at all;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">delays
and changes in regulatory requirements, policy and guidelines,
including the imposition of additional regulatory oversight around
clinical testing generally or with respect to our technology in
particular, especially in light of the novelty of our therapeutic
candidates; or</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">varying
interpretations of data by the FDA and similar foreign regulatory
agencies; or</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">refusal
of the FDA to accept data from clinical trials conducted outside
the United States, or acceptance of these data subject to certain
conditions by the FDA.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Product development involves a lengthy and expensive process with
an uncertain outcome, and results of earlier preclinical studies
and clinical trials may not be predictive of future clinical trial
results.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical
testing is expensive and generally takes many years to complete,
and the outcome is inherently uncertain. Failure can occur at any
time and at any stage during the clinical trial process. The
results of preclinical studies and early clinical trials of our
therapeutic candidates may not be predictive of the result of any
subsequent clinical trials. Therapeutic candidates that have shown
promising results in early stage clinical trials may still
suffer</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">37</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">significant
setbacks in subsequent clinical trials. We will have to conduct
trials in our proposed indications to verify the results obtained
to date and to support any regulatory submissions for further
clinical development. A number of companies in the
biopharmaceutical industry have suffered significant setbacks in
clinical trials due to&nbsp;lack of efficacy or adverse safety
profiles despite promising results in earlier clinical trials.
Moreover, clinical data is often susceptible to varying
interpretations and analyses. We do not know whether Phase 1, Phase
2, Phase 3, or other clinical trials we may conduct will
demonstrate consistent or adequate efficacy and safety with respect
to the proposed indication for use sufficient to receive regulatory
approval or market our therapeutic candidates. &nbsp;If we
experience delays in the completion of, or termination of, any
clinical trial of our therapeutic candidates, the commercial
prospects of our therapeutic candidates may be harmed, and our
ability to generate product revenues from any of these therapeutic
candidates will be delayed.&nbsp; In addition, any delays in
completing clinical trials will increase our costs, slow down our
therapeutic candidate development and approval process and
jeopardize our ability to commence product sales and generate
revenues.&nbsp; Any of these occurrences could materially and
adversely affect our business, financial condition, results of
operations or prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We will need substantial additional funds to advance the
development of our therapeutic candidates, and we cannot guarantee
that we will have sufficient funds available in the future to
develop and commercialize our current or future therapeutic
candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If our
existing therapeutic candidates or our future therapeutic
candidates enter and advance through preclinical studies and
clinical trials, we will need substantial additional funds to
expand our development, regulatory, manufacturing, marketing, and
sales capabilities or contract with other organizations to provide
these capabilities for us. We have used substantial funds to
develop our therapeutic candidates and will require significant
funds to conduct further research and development and preclinical
studies and clinical trials of our therapeutic candidates, to seek
regulatory approvals for our therapeutic candidates and to
manufacture and market products, if any, that are approved for
commercial sale. As of March 31, 2018 and December&nbsp;31, 2017,
we had</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in cash
and cash equivalents, respectively.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Based
on our current operating plans, existing working capital at March
31, 2018 is not sufficient to sustain operations beyond March 31,
2019.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
future capital requirements and the period for which we expect our
existing resources to support our operations may vary significantly
from what we expect. Our monthly spending levels vary based on new
and ongoing development and corporate activities. Since the length
of time and activities associated with successful development of
our therapeutic candidates is highly uncertain, we are unable to
estimate the actual funds we will require for development and any
approved marketing and commercialization activities. To execute our
business plan, we will need, among other things:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
obtain the human and financial resources necessary to develop,
test, obtain regulatory approval for, manufacture and market our
therapeutic candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
build and maintain a strong intellectual property portfolio and
avoid infringing the intellectual property of third
parties;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
establish and maintain successful licenses, collaborations and
alliances;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
satisfy the requirements of clinical trial protocols, including
patient enrollment;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
establish and demonstrate the clinical efficacy and safety of our
therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
obtain regulatory approvals;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
manage our spending as costs and expenses increase due to
preclinical studies and clinical trials, regulatory approvals, and
commercialization;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
obtain additional capital to support and expand our operations;
and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
market our products to achieve acceptance and use by the medical
community in general.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
are unable to obtain funding on a timely basis or on acceptable
terms, we may have to delay, reduce or terminate our research and
development programs and preclinical studies or clinical trials, if
any, limit strategic opportunities or undergo reductions in our
workforce or other corporate restructuring activities. We also
could be</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">38</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">required
to seek funds through arrangements with collaborators or others
that may require us to relinquish rights to some of our technology
or therapeutic candidates that we would otherwise pursue on our
own. We do not expect to realize revenue from product sales,
milestone payments or royalties in the foreseeable future, if at
all. Our revenue sources are, and will remain, extremely limited
unless and until our therapeutic candidates are clinically tested,
approved for commercialization and successfully marketed. To date,
we have primarily financed our operations through the sale of
equity securities, payments received in connection with our
research collaboration, license, and option agreement with Purdue
or as a primary contractor or as a subcontractor on government
grants, and proceeds from our loan agreement with Hercules. We will
be required to seek additional funding in the future and intend to
do so through either collaborations, public or private equity
offerings or debt financings, credit or loan facilities or a
combination of one or more of these funding sources. Our ability to
raise additional funds will depend on financial, economic and other
factors, many of which are beyond our control. Additional funds may
not be available to us on acceptable terms or at all. If we raise
additional funds by issuing equity securities, our stockholders
will suffer dilution and the terms of any financing may adversely
affect the rights of our stockholders. In addition, as a condition
to providing additional funds to us, future investors may demand,
and may be granted, rights superior to those of existing
stockholders. Debt financing, if available, may involve restrictive
covenants limiting our flexibility in conducting future business
activities, and, in the event of insolvency, debt holders would be
repaid before holders of equity securities received any
distribution of corporate assets.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our quarterly operating results may fluctuate significantly or may
fall below the expectations of investors or securities analysts,
each of which may cause our stock price to fluctuate or
decline.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect our operating results to be subject to quarterly
fluctuations. Our net loss and other operating results will be
affected by numerous factors, including:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">variations
in the level of expense related to our therapeutic candidates or
future development programs;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">results
of clinical trials, or the addition or termination of clinical
trials or funding support by us, or a future collaborator or
licensing partner;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
execution of any collaboration, licensing or similar arrangement,
and the timing of payments we may make or receive under such
existing or future arrangements or the termination or modification
of any such existing or future arrangements;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">any
intellectual property infringement lawsuit or opposition,
interference or cancellation proceeding in which we may become
involved;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">additions
and departures of key personnel;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">strategic
decisions by us or our competitors, such as acquisitions,
divestitures, spin-offs, joint ventures, strategic investments or
changes in business strategy;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">whether
or not any of our therapeutic candidates receives regulatory
approval, market acceptance and demand for such therapeutic
candidates;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory
developments affecting our therapeutic candidates or those of our
competitors; and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">changes
in general market and economic conditions.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If our
quarterly operating results fall below the expectations of
investors or securities analysts, the price of our common stock
could decline substantially. Furthermore, any quarterly
fluctuations in our operating results may, in turn, cause the price
of our stock to fluctuate substantially.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We are dependent on Purdue for the successful development of
therapeutic candidates in our collaboration arrangement with
Purdue.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
December&nbsp;2, 2016, we entered into a research collaboration,
option and license agreement with Purdue. As part of the agreement,
Purdue has the option to obtain from us the full worldwide
development and commercial</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">39</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">rights
to AST-005, an option to obtain three additional collaboration
targets and a further option to obtain from us the full worldwide
development and commercial rights to any therapeutic candidates
developed targeting the three additional collaboration targets. In
April 2018, Purdue notified the Company it has declined to exercise
its option to develop AST-005 at this time, but that it also
intends to retain rights relating to the TNF target, and Purdue
reserves its right to continue joint development with Exicure of
new anti-TNF drug candidates and to retain its exclusivity and
other rights to AST-005. Additionally, Purdue has rights of first
offer to some potential collaboration targets. These rights of
first offer are subject to limitations in time and scope. In
connection with the Purdue Collaboration, we received a
non-refundable development fee of $10.0&nbsp;million. In addition,
we are eligible to receive up to $776.5 million upon successful
completion of certain research, regulatory and commercial sales
milestones. There can be no assurance these milestones will be
achieved as they are subject to highly significant risks and
uncertainties, many of which are outside of our control. In the
event a therapeutic candidate subject to the collaboration results
in commercial sales, we are eligible to receive royalties ranging
from the low single digits to a maximum of 10% on future net sales
of such commercialized therapeutic candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
success of our collaboration programs with Purdue depends largely
upon the efforts of Purdue. Purdue has sole discretion in
determining and directing the efforts and resources, including the
ability to discontinue all efforts and resources, it applies to the
development and, if approval is obtained, commercialization and
marketing of the therapeutic candidates covered by the
collaboration. Purdue may not be effective in obtaining approvals
for the therapeutic candidates developed under the collaboration
arrangement or marketing or arranging for necessary supply,
manufacturing or distribution relationships for any approved
products. Purdue may change its strategic focus or pursue
alternative technologies in a manner that results in reduced,
delayed or no revenue to us. Purdue has a variety of marketed
products, and its own corporate objectives may not be consistent
with our best interests. If Purdue fails to develop, obtain
regulatory approval for or ultimately commercialize any therapeutic
candidate under our collaboration or if Purdue terminates our
collaboration, our business, financial condition, results of
operations and prospects could be materially and adversely
affected. In addition, any dispute or litigation proceedings we may
have with Purdue in the future could delay development programs,
create uncertainty as to ownership of intellectual property rights,
distract management from other business activities and generate
substantial expense.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If third parties on which we depend to conduct our preclinical
studies and clinical trials do not perform as contractually
required, fail to satisfy regulatory or legal requirements, or miss
expected deadlines, our development program could be delayed with
materially adverse effects on our business, financial condition,
results of operations and prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We rely
on third party clinical investigators, contract research
organizations (âCROsâ), clinical data management organizations and
consultants to design, conduct, supervise and monitor preclinical
studies and clinical trials for our therapeutic candidates. Because
we rely on third parties and do not have the ability to conduct
preclinical studies or clinical trials independently, we have less
control over the timing, quality and other aspects of preclinical
studies and clinical trials than we would if we conducted them on
our own. These investigators, CROs and consultants are not our
employees and we have limited control over the amount of time and
resources that they dedicate to our programs. These third parties
may have contractual relationships with other entities, some of
which may be our competitors, which may draw time and resources
away from our programs. The third parties with which we contract
might not be diligent, careful or timely in conducting our
preclinical studies or clinical trials, resulting in the
preclinical studies or clinical trials being delayed or
unsuccessful.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
cannot contract with acceptable third parties on commercially
reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory
requirements for the conduct of preclinical studies or clinical
trials or meet expected deadlines, our clinical development
programs could be delayed and otherwise adversely affected. In all
events, we are responsible for ensuring that each of our
preclinical studies and clinical trials is conducted in accordance
with the general investigational plan and protocols for the trial.
The FDA requires preclinical studies to be conducted in accordance
with applicable Good Laboratory Practices (âGLPsâ) and clinical
trials to be conducted in accordance with applicable FDA
regulations and Good Clinical Practices (âGCPsâ), including
requirements for conducting, recording and reporting the results of
preclinical studies and clinical trials to assure that data and
reported results are credible and accurate and that the rights,
integrity and confidentiality of clinical trial participants are
protected. Our reliance on third parties that we do not control
does not relieve us of these responsibilities and requirements. Any
adverse development or delay in our preclinical studies
or</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">40</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">clinical
trials could have a material adverse effect on our business,
financial condition, results of operations and
prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Because we rely on third party manufacturing and supply partners,
our supply of research and development, preclinical studies and
clinical trial materials may become limited or interrupted or may
not be of satisfactory quantity or quality.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We rely
on third party partners to manufacture and supply the materials and
components for our research and development, preclinical study and
clinical trial supplies. We do not own manufacturing facilities or
supply sources for such components and materials. Our manufacturing
requirements include oligonucleotides and lipids. We procure our
nonclinical toxicology and clinical development materials from a
single source supplier on a purchase order basis. There can be no
assurance that our supply of research and development, preclinical
study and clinical trial therapeutic candidates and other materials
will not be limited, interrupted, restricted in certain geographic
regions or of satisfactory quality or continue to be available at
acceptable prices. In particular, any replacement of our drug
product manufacturers could require significant effort and
expertise because there may be a limited number of qualified
replacements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
manufacturing process for a therapeutic candidate is subject to
oversight by the FDA and foreign regulatory authorities. Suppliers
and manufacturers must meet applicable manufacturing requirements
and undergo rigorous facility and process validation tests required
by regulatory authorities in order to comply with regulatory
requirements, such as current Good Manufacturing Practices (âcGMPsâ
). In the event that any of our suppliers or manufacturers fails to
comply with such requirements or to perform its obligations to us
in relation to quality, timing or otherwise, or if our supply of
components or other materials becomes limited or interrupted for
other reasons, we may be forced to manufacture the materials
ourselves, for which we currently do not have the capabilities or
resources, or enter into an agreement with another third party,
which we may not be able to do on reasonable terms, if at all. In
some cases, the technical skills or technology required to
manufacture our therapeutic candidates may be unique or proprietary
to the original manufacturer and we may have difficulty, or there
may be contractual restrictions prohibiting us from, transferring
such skills or technology to another third party and a feasible
alternative may not exist. These factors would increase our
reliance on such manufacturer or require us to obtain a license
from such manufacturer in order to have another third party
manufacture our therapeutic candidates. If we are required to
change manufacturers for any reason, we will be required to verify
that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations.
The delays associated with the verification of a new manufacturer
could negatively affect our ability to develop therapeutic
candidates in a timely manner or within budget.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
expect to continue to rely on third party manufacturers if we
receive regulatory approval for any therapeutic candidate. To the
extent that we have existing, or enter into future, manufacturing
arrangements with third parties, we will depend on these third
parties to perform their obligations in a timely manner consistent
with contractual and regulatory requirements, including those
related to quality control and assurance. If we are unable to
obtain or maintain third party manufacturing for therapeutic
candidates, or to do so on commercially reasonable terms, we may
not be able to develop and commercialize our therapeutic candidates
successfully. Our or a third partyâs failure to execute on our
manufacturing requirements and comply with cGMP could adversely
affect our business in a number of ways, including:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">an
inability to initiate or continue preclinical studies or clinical
trials of our therapeutic candidates under
development;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">delay
in submitting regulatory applications, or receiving regulatory
approvals, for therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">loss of
the cooperation of a future collaborator;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">subjecting
manufacturing facilities of our therapeutic candidates to
additional inspections by regulatory authorities;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">requirements
to cease distribution or to recall batches of our therapeutic
candidates; and</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">41</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in the
event of approval to market and commercialize a therapeutic
candidate, an inability to meet commercial demands for our
therapeutics.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We may not successfully engage in strategic transactions, including
any collaborations we seek, which could adversely affect our
ability to develop and commercialize therapeutic candidates, impact
our cash position, increase our expense, and present significant
distractions to our management.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">From
time to time, we may consider strategic transactions, such as
collaborations, acquisitions of companies, asset purchases and out-
or in-licensing of therapeutic candidates or technologies. In
particular, we will evaluate and, if strategically attractive, seek
to enter into collaborations, including with major biotechnology or
pharmaceutical companies. The competition for collaborators is
intense, and the negotiation process is time-consuming and complex.
Any new collaboration may be on terms that are not optimal for us,
and we may be unable to maintain any new collaboration if, for
example, development or approval of a therapeutic candidate is
delayed, sales of an approved therapeutic candidate do not meet
expectations or the collaborator terminates the collaboration. Any
such collaboration, or other strategic transaction, may require us
to incur non-recurring or other charges, increase our near- and
long-term expenditures and pose significant integration or
implementation challenges or disrupt our management or business.
These transactions would entail numerous operational and financial
risks, including exposure to unknown liabilities, disruption of our
business and diversion of our managementâs time and attention in
order to manage a collaboration or develop acquired therapeutics,
therapeutic candidates or technologies, incurrence of substantial
debt or dilutive issuances of equity securities to pay transaction
consideration or costs, higher than expected collaboration,
acquisition or integration costs, write-downs of assets or goodwill
or impairment charges, increased amortization expenses, difficulty
and cost in facilitating the collaboration or combining the
operations and personnel of any acquired business, impairment of
relationships with key suppliers, manufacturers or customers of any
acquired business due to changes in management and ownership and
the inability to retain key employees of any acquired business.
Accordingly, although there can be no assurance that we will
undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be
subject to the foregoing or other risks and may have a material
adverse effect on our business, results of operations, financial
condition and prospects. Conversely, any failure to enter into any
collaboration or other strategic transaction that would be
beneficial to us could delay the development and potential
commercialization of our therapeutic candidates and have a negative
impact on the competitiveness of any therapeutic candidate that
reaches market.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We face competition from entities that have developed or may
develop therapeutic candidates for our target disease indications,
including companies developing novel treatments and technology
platforms based on modalities and technology similar to ours. If
these companies develop technologies, including delivery
technologies, or therapeutic candidates more rapidly than we do or
their technologies are more effective, our ability to develop and
successfully commercialize therapeutic candidates may be adversely
affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
development and commercialization of therapeutic candidates is
highly competitive. We compete with a number of multinational
pharmaceutical companies and specialized biotechnology companies,
as well as technology being developed at universities and other
research institutions. Our competitors have developed, are
developing or will develop therapeutic candidates and processes
competitive with our therapeutic candidates. Competitive
therapeutic treatments include those that have already been
approved and accepted by the medical community and any new
treatments that enter the market. We believe that a significant
number of therapeutics are currently under development, and may
become commercially available in the future, for the treatment of
conditions for which we may try to develop therapeutic candidates.
There is intense and rapidly evolving competition in the
biotechnology, pharmaceutical and oligonucleotide therapeutics
fields. While we believe that our SNA technology, its associated
intellectual property and our scientific and technical know-how
give us a competitive advantage in this space, competition from
many sources remains. Our competitors include larger and better
funded pharmaceutical, biotechnology and oligonucleotide
therapeutics companies. Moreover, we also compete with current and
future therapeutics developed at universities and other research
institutions.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
aware of several companies that are developing oligonucleotide
delivery platforms and oligonucleotide-based therapeutics. These
competitors include Ionis Pharmaceuticals, Inc., Alnylam
Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus
Biopharma Corp., Wave Life Sciences Ltd., Dynavax Technologies
Corp., Idera</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">42</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Pharmaceuticals,
Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and
other competitors compete with us in recruiting scientific and
managerial talent, and for funding from pharmaceutical
companies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
success will partially depend on our ability to develop and protect
therapeutics that are safer and more effective than competing
therapeutics. Our commercial opportunity and success will be
reduced or eliminated if competing therapeutics are safer, more
effective, or less expensive than the therapeutics we
develop.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If our
lead therapeutic candidates are approved for the indications we are
currently pursuing, they will compete with a range of therapeutic
treatments that are either in development or currently marketed. A
number of therapeutics for treating psoriasis and cancers are on
the market or in clinical development. For the treatment of
psoriasis, marketed therapies range from small molecules like
topical steroids to biologics, such as AbbVie Inc.âs adalimumab. In
addition, numerous compounds are in clinical development for
psoriasis treatment. With respect to immunogenic cancers such as
melanoma, the most common treatments are chemotherapeutic
compounds, radiation therapy and now immunotherapeutic antibodies
such as ipilimumab, atezolizumab and pembrolizumab.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Many of
our competitors have significantly greater financial, technical,
manufacturing, marketing, sales and supply resources or experience
than we do. If we successfully obtain approval for any therapeutic
candidate, we will face competition based on many different
factors, including the safety and effectiveness of our
therapeutics, the ease with which our therapeutics can be
administered and the extent to which patients accept relatively new
routes of administration, the timing and scope of regulatory
approvals for these therapeutics, the availability and cost of
manufacturing, marketing and sales capabilities, price,
reimbursement coverage and patent position. Competing therapeutics
could present superior treatment alternatives, including by being
more effective, safer, less expensive or marketed and sold more
effectively than any therapeutics we may develop. Competitive
therapeutics may make any therapeutics we develop obsolete or
noncompetitive before we recover the expense of developing and
commercializing our therapeutic candidates. Such competitors could
also recruit our employees, which could negatively impact our level
of expertise and our ability to execute our business
plan.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The market may not be receptive to our therapeutic candidates based
on a novel therapeutic modality, and we may not generate any future
revenue from the sale or licensing of therapeutic
candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Even if
approval is obtained for a therapeutic candidate, we may not
generate or sustain revenue from sales of the product due to
factors such as whether the product can be sold at a competitive
cost and otherwise accepted in the market. The therapeutic
candidates that we are developing are based on our SNA technology.
Market participants with significant influence over acceptance of
new treatments, such as physicians and third party payors, may not
adopt a treatment based on SNA technology, and we may not be able
to convince the medical community and third party payors to accept
and use, or to provide favorable reimbursement for, any therapeutic
candidates developed by us or any current or future collaborators.
Market acceptance of our therapeutic candidates will depend on,
among other factors:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
timing of our receipt of any marketing and commercialization
approvals;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
terms of any approvals and the countries in which approvals are
obtained;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
safety and efficacy of our therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
prevalence and severity of any adverse side effects associated with
our therapeutic candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">limitations
or warnings contained in any labeling approved by the FDA or other
regulatory authority;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">relative
convenience and ease of administration of our therapeutic
candidates;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
willingness of patients to accept any new methods of
administration;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
success of our physician education programs;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
availability of adequate government and third party payor
reimbursement;</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">43</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
pricing of our products, particularly as compared to alternative
treatments; and</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">availability
of alternative effective treatments for indications our therapeutic
candidates are intended to treat and the relative risks, benefits
and costs of those treatments.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">With
our focus on SNAs, these risks may increase to the extent the space
becomes more competitive or less favored in the commercial
marketplace. Additional risks apply in relation to any disease
indications we may pursue which are classified as rare diseases and
allow for orphan drug designation by regulatory agencies in major
commercial markets, such as the U.S., Europe and Japan. Because of
the small patient population for a rare disease, if pricing is not
approved or accepted in the market at an appropriate level for an
approved product with orphan drug designation, such therapeutic may
not generate enough revenue to offset costs of development,
manufacturing, marketing and commercialization despite any benefits
received from the orphan drug designation, such as market
exclusivity, assistance in clinical trial design or a reduction in
user fees or tax credits related to development expense. Market
size is also a variable in disease indications not classified as
rare. Our estimates regarding potential market size for any
indication may be materially different from what we discover to
exist at the time we commence commercialization, if any, for a
therapeutic, which could result in significant changes in our
business plan and have a material adverse effect on our business,
financial condition, results of operations and
prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If a
therapeutic candidate that has orphan drug designation subsequently
receives the first FDA approval for the indication for which it has
such designation, the therapeutic candidate is entitled to orphan
product exclusivity, which means that the FDA may not approve any
other applications to market the same therapeutic candidate for the
same indication, except in very limited circumstances, for seven
years. Orphan drug exclusivity, however, could also block the
approval of one of our therapeutic candidates for seven years if a
competitor obtains approval of the same therapeutic candidate as
defined by the FDA or if our therapeutic candidate is determined to
be contained within the competitorâs therapeutic candidate for the
same indication or disease.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As in
the U.S., we may apply for designation of a therapeutic candidate
as an orphan drug for the treatment of a specific indication in the
European Union before the application for marketing authorization
is made. Sponsors of orphan drugs in the European Union can enjoy
economic and marketing benefits, including up to ten years of
market exclusivity for the approved indication. During such period,
marketing applications for similar medicinal products will not be
accepted, unless certain exceptions apply. In the EU, a âsimilar
medicinal productâ is a medicinal product containing a similar
active substance or substances as contained in a currently
authorized orphan medicinal product, and which is intended for the
same therapeutic indication.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Any inability to attract and retain qualified key management and
technical personnel would impair our ability to implement our
business plan.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
success largely depends on the continued service of key management
and other specialized personnel, including David A. Giljohann,
Ph.D., our Chief Executive Officer, David S. Snyder, our Chief
Financial Officer, Ekambar Kandimalla, Ph.D., our Chief Scientific
Officer, and Matthias G. Schroff, our Chief Operating Officer. The
loss of one or more members of our management team or other key
employees or advisors could delay our research and development
programs and materially harm our business, financial condition,
results of operations and prospects. The relationships that our key
managers have cultivated within our industry make us particularly
dependent upon their continued employment with us. We are dependent
on the continued service of our technical personnel because of the
highly technical nature of our therapeutic candidates and our
technology and the specialized nature of the regulatory approval
process. Because our management team and key employees are not
obligated to provide us with continued service, they could
terminate their employment with us at any time without penalty. We
do not maintain key person life insurance policies on any of our
management team members or key employees. Our future success will
depend in large part on our continued ability to attract and retain
highly qualified scientific, technical and management personnel, as
well as personnel with expertise in clinical testing,
manufacturing, governmental regulation and commercialization. We
face competition for personnel from other companies, universities,
public and private research institutions, government entities and
other organizations.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">44</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If our therapeutic candidates advance into clinical trials, we may
experience difficulties in managing our growth and expanding our
operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
limited experience in therapeutic development and limited
experience with clinical trials of therapeutic candidates. As our
therapeutic candidates enter and advance through preclinical
studies and clinical trials, we will need to expand our
development, regulatory and manufacturing capabilities or contract
with other organizations to provide these capabilities for us. In
the future, we expect to have to manage additional relationships
with collaborators or partners, suppliers and other organizations.
Our ability to manage our operations and future growth will require
us to continue to improve our operational, financial and management
controls, reporting systems and procedures. We may not be able to
implement improvements to our management information and control
systems in an efficient or timely manner and may discover
deficiencies in existing systems and controls.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If any of our therapeutic candidates are approved for marketing and
commercialization and we are unable to develop sales, marketing and
distribution capabilities on our own or enter into agreements with
third parties to perform these functions on acceptable terms, we
will be unable to successfully commercialize any such future
therapeutics.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
currently have no sales, marketing or distribution capabilities or
experience. If any of our therapeutic candidates is approved, we
will need to develop internal sales, marketing and distribution
capabilities to commercialize such therapeutics, which would be
expensive and time-consuming, or enter into collaborations with
third parties to perform these services. If we decide to market our
approved therapeutics directly, we will need to commit significant
financial and managerial resources to develop a marketing and sales
force with technical expertise and supporting distribution,
administration and compliance capabilities. If we rely on third
parties with such capabilities to market our approved therapeutics
or decide to co-promote therapeutics with collaborators, we will
need to establish and maintain marketing and distribution
arrangements with third parties, and there can be no assurance that
we will be able to enter into such arrangements on acceptable terms
or at all. In entering into third party marketing or distribution
arrangements, any revenue we receive will depend upon the efforts
of the third parties and there can be no assurance that such third
parties will establish adequate sales and distribution capabilities
or be successful in gaining market acceptance of any approved
therapeutic. If we are not successful in commercializing any
therapeutic approved in the future, either on our own or through
third parties, our business, financial condition, results of
operations and prospects could be materially and adversely
affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If we fail to comply with U.S. or foreign regulatory requirements,
regulatory authorities could withhold marketing or
commercialization approvals, limit or withdraw any marketing or
commercialization approvals we may receive and subject us to other
penalties that could materially harm our business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We and
our therapeutic candidates, as well as our suppliers, contract
manufacturers, distributors, and contract testing laboratories are
subject to extensive regulation by governmental authorities in the
European Union, the U.S., and other countries, with the regulations
differing from country to country.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
or current or future collaborators, manufacturers or service
providers fail to comply with applicable requirements, these
regulatory authorities could refuse to issue necessary approvals
for marketing and commercialization. Even if we receive marketing
and commercialization approval of a therapeutic candidate, we and
our third party service providers will be subject to continuing
regulatory requirements, including a broad array of regulations
related to establishment, registration and product listing,
manufacturing processes, risk management measures, quality and
pharmacovigilance systems, pre- and post-approval clinical data,
labeling, advertising and promotional activities for such
therapeutic, record keeping, distribution, and import and export of
therapeutics for any therapeutic for which we obtain marketing
approval. We are required to submit safety and other post market
information and reports and are subject to continuing regulatory
review, including in relation to adverse patient experiences with
the therapeutic and clinical results that are reported after a
therapeutic is made commercially available, both in the U.S. and
any foreign jurisdiction in which we seek regulatory approval. The
FDA and certain foreign regulatory authorities, such as the EMA,
have significant post-market authority, including the authority to
require labeling changes based on new safety information and to
require post-market studies or clinical trials to evaluate safety
risks related to the use of a therapeutic or to require withdrawal
of the therapeutic from the market. The FDA also has the authority
to require a Risk Evaluation and Mitigation Strategies, or REMS,
plan either before</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">45</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">or
after approval, which may impose further requirements or
restrictions on the distribution or use of an approved therapeutic.
The EMA now routinely requires risk management plans, or RMPs, as
part of the marketing authorization application process, and such
plans must be continually modified and updated throughout the
lifetime of the product as new information becomes available. In
addition, for nationally authorized medicinal products, the
relevant governmental authority of any European Union member state
can request an RMP whenever there is a concern about the
risk/benefit balance of the product.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
manufacturer and manufacturing facilities we use to make a future
therapeutic, if any, will also be subject to periodic review and
inspection by the FDA and other regulatory agencies, including for
continued compliance with cGMP requirements. The discovery of any
new or previously unknown problems with our third party
manufacturers, manufacturing processes or facilities may result in
restrictions on the therapeutic, manufacturer or facility,
including withdrawal of the therapeutic from the market. If we rely
on third party manufacturers, we will not have control over
compliance with applicable rules and regulations by such
manufacturers. Any product promotion and advertising will also be
subject to regulatory requirements and continuing regulatory
review. If we or our future collaborators, manufacturers or service
providers fail to comply with applicable continuing regulatory
requirements in the U.S. or foreign jurisdictions in which we seek
to market our therapeutics, we or they may be subject to, among
other things, fines, warning and untitled letters, clinical holds,
delay or refusal by the FDA or foreign regulatory authorities to
approve pending applications or supplements to approved
applications, suspension, refusal to renew or withdrawal of
regulatory approval, recalls, seizures or administrative detention
of products, refusal to permit the import or export of
therapeutics, operating restrictions, inability to participate in
government programs including Medicare and Medicaid, and total or
partial suspension of production or distribution, injunction,
restitution, disgorgement, debarment, civil and criminal penalties
and criminal prosecution.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Price controls imposed in foreign markets may adversely affect our
future profitability.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In some
countries, particularly member states of the European Union, the
pricing of prescription drugs is subject to governmental control at
the national level, and in some cases also at the regional level.
In these countries, pricing negotiations with governmental
authorities can take considerable time after receipt of marketing
approval for a therapeutic. In addition, there can be considerable
pressure by governments and other stakeholders on prices and
reimbursement levels, including as part of cost containment
measures. Political, economic and regulatory developments may
further complicate pricing and reimbursement negotiations, and
pricing negotiations may continue after reimbursement has been
obtained. Reference pricing used by various European Union member
states and parallel distribution, or arbitrage between low-priced
and high-priced member states, can further reduce prices. In some
countries, we or current or future collaborators may be required to
conduct a clinical trial or other studies that compare the
cost-effectiveness of our SNA therapeutic candidates to other
available therapies in order to obtain or maintain reimbursement or
pricing approval. Publication of discounts by third party payors or
authorities may lead to further pressure on the prices or
reimbursement levels within the country of publication and other
countries. If reimbursement of any therapeutic candidate approved
for marketing is unavailable or limited in scope or amount, or if
pricing is set at unsatisfactory levels, our business, financial
condition, results of operations or prospects could be adversely
affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our business entails a significant risk of product liability and
our inability to obtain sufficient insurance coverage could have a
material adverse effect on our business, financial condition,
results of operations or prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
business exposes us to significant product liability risks inherent
in the development, testing, manufacturing and marketing of
therapeutic treatments. Product liability claims could delay or
prevent completion of our development programs. If we succeed in
marketing therapeutics, such claims could result in an
investigation by certain regulatory authorities, such as the FDA or
foreign regulatory authorities, of the safety and effectiveness of
our therapeutics, our manufacturing processes and facilities or our
marketing programs and potentially a recall of our therapeutics or
more serious enforcement action, limitations on the approved
indications for which they may be used or suspension or withdrawal
of approvals. Regardless of the merits or eventual outcome,
liability claims may also result in decreased demand for our
therapeutics, injury to our reputation, costs to defend the related
litigation, a diversion of managementâs time and our resources,
substantial monetary awards to trial participants or patients and a
decline in our stock price. We currently have product liability
insurance that we believe is appropriate for our stage</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">46</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">of
development and may need to obtain higher levels of product
liability insurance prior to marketing any of our therapeutic
candidates. Any insurance we have or may obtain may not provide
sufficient coverage against potential liabilities. Furthermore,
clinical trial and product liability insurance is becoming
increasingly expensive. As a result, we may be unable to obtain
sufficient insurance at a reasonable cost to protect us against
losses caused by product liability claims that could have a
material adverse effect on our business.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and
requirements which could have an adverse effect on our
business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
exposed to the risk of employee fraud or other misconduct.
Misconduct by employees could include, but is not limited to,
intentional failures to comply with FDA regulations, applicable
laws, regulations, guidance or codes of conduct set by foreign
governmental authorities or self-regulatory industry organizations,
or provide accurate information to any governmental authorities,
such as the FDA, comply with manufacturing standards we may
establish, comply with federal and state healthcare fraud and abuse
laws and regulations, report financial information or data
accurately or disclose unauthorized activities to us.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws, regulations,
guidance and codes of conduct intended to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws, regulations,
guidance and codes of conduct may restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business
arrangements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Employee
misconduct could also involve the improper use of information
obtained in the course of clinical trials, which could result in
regulatory sanctions, including debarment or disqualification of
those employees from participation in FDA-regulated activities, and
serious harm to our reputation. This could include violations of
the U.S. federal Health Insurance Portability and Accountability
Act of 1996, or HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act, or HITECH, other
U.S. federal and state law, and requirements of non-U.S.
jurisdictions, including the European Union Data Protection
Directive.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">It is
not always possible to identify and deter employee misconduct, and
the precautions we take to detect and prevent this activity may not
be effective in controlling unknown or unmanaged risks or losses or
in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with such
laws, regulations, guidance or codes of conduct. If any such
actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could
have a significant impact on our business, including the imposition
of significant fines or other sanctions.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Compliance with governmental regulations regarding the treatment of
animals used in research could increase our operating costs, which
would adversely affect the commercialization of our
technology.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Animal Welfare Act, or AWA, is the federal law that covers the
treatment of certain animals used in research. Currently, the AWA
imposes a wide variety of specific regulations that govern the
humane handling, care, treatment and transportation of certain
animals by producers and users of research animals, most notably
relating to personnel, facilities, sanitation, cage size, and
feeding, watering and shipping conditions. Third parties with whom
we contract are subject to registration, inspections and reporting
requirements under the AWA. Furthermore, some states have their own
regulations, including general anti-cruelty legislation, which
establish certain standards in handling animals. Comparable rules,
regulations, and or obligations exist in many foreign
jurisdictions. If we or our contractors fail to comply with
regulations concerning the treatment of animals used in research,
we may be subject to fines and penalties and adverse publicity, and
our operations could be adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our internal computer systems, or those of our CROs or other
contractors or consultants, may fail or suffer security breaches,
which could result in a material disruption of our therapeutic
development programs.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Despite
the implementation of security measures, our internal computer
systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and
electrical failures. Such events could cause interruptions of
our</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">47</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">operations.
For instance, the loss of preclinical study or clinical trial data
involving our therapeutic candidates could result in delays in our
development and regulatory filing efforts and significantly
increase our costs. In addition, theft or other exposure of data
may interfere with our ability to protect our intellectual
property, trade secrets, and other information critical to our
operations. We can provide no assurances that certain sensitive and
proprietary information relating to one or more of our therapeutic
candidates has not been, or will not in the future be, compromised.
Although we have invested resources to enhance the security of our
computer systems, there can be no assurances we will not experience
additional unauthorized intrusions into our computer systems, or
those of our CROs and other contractors and consultants, that we
will successfully detect future unauthorized intrusions in a timely
manner, or that future unauthorized intrusions will not result in
material adverse effects on our financial condition, reputation, or
business prospects. Payments related to the elimination of
ransomware may materially affect our financial condition and
results of operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Certain
data breaches must also be reported to affected individuals and the
government, and in some cases to the media, under provisions of
HIPAA, as amended by HITECH, other U.S. federal and state law, and
requirements of non-U.S. jurisdictions, including the European
Union Data Protection Directive, and financial penalties may also
apply.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">To the
extent that any disruption or security breach were to result in a
loss of, or damage to, our data, or inappropriate disclosure of
confidential or proprietary information, we could incur liability
and the development of our therapeutic candidates could be
delayed.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If we do not comply with laws regulating the protection of the
environment and health and human safety, our business could be
adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
research, development and manufacturing involve the use of
hazardous materials and various chemicals. We maintain quantities
of various flammable and toxic chemicals in our facilities in
Skokie, Illinois that are required for our research, development
and manufacturing activities. We are subject to federal, state and
local laws and regulations governing the use, manufacture, storage,
handling and disposal of these hazardous materials. We believe our
procedures for storing, handling and disposing these materials in
our Skokie facilities comply with the relevant guidelines of
Skokie, the state of Illinois, and the Occupational Safety and
Health Administration of the U.S. Department of Labor. Although we
believe that our safety procedures for handling and disposing of
these materials comply with the standards mandated by applicable
regulations, the risk of accidental contamination or injury from
these materials cannot be eliminated. If an accident occurs, we
could be held liable for resulting damages, which could be
substantial. We are also subject to numerous environmental, health
and workplace safety laws and regulations, including those
governing laboratory procedures, exposure to blood-borne pathogens
and the handling of animals and biohazardous materials. Although we
maintain workersâ compensation insurance to cover us for costs and
expenses we may incur due to injuries to our employees resulting
from the use of these materials, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may
be asserted against us in connection with our storage or disposal
of biological or hazardous materials. Additional federal, state and
local laws and regulations affecting our operations may be adopted
in the future. We may incur substantial costs to comply with, and
substantial fines or penalties if we violate, any of these laws or
regulations.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our information technology systems could face serious disruptions
that could adversely affect our business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
information technology and other internal infrastructure systems,
including corporate firewalls, servers, leased lines and connection
to the Internet, face the risk of systemic failure that could
disrupt our operations. A significant disruption in the
availability of our information technology and other internal
infrastructure systems could cause interruptions and delays in our
research and development work.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our current operations are concentrated in one location and any
events affecting this location may have material adverse
consequences.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
current operations are located in our facilities situated in
Skokie, Illinois. Any unplanned event, such as flood, fire,
explosion, earthquake, extreme weather condition, medical
epidemics, power shortage,</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">48</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">telecommunication
failure or other natural or man-made accidents or incidents that
result in us being unable to fully utilize the facilities, may have
a material adverse effect on our ability to operate our business,
particularly on a daily basis, and have significant negative
consequences on our financial and operating conditions. Loss of
access to these facilities may result in increased costs, delays in
the development of our therapeutic candidates or interruption of
our business operations. As part of our risk management policy, we
maintain insurance coverage at levels that we believe are
appropriate for our business. However, in the event of an accident
or incident at these facilities, we cannot assure you that the
amounts of insurance will be sufficient to satisfy any damages and
losses. If our facilities are unable to operate because of an
accident or incident or for any other reason, even for a short
period of time, any or all of our research and development programs
may be harmed. Any business interruption may have a material
adverse effect on our business, financial position, results of
operations and prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The investment of our cash, cash equivalents and fixed income
marketable securities is subject to risks which may cause losses
and affect the liquidity of these investments.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As of
March 31, 2018 and as of December&nbsp;31, 2017, we had</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8
million</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">in cash
and cash equivalents, respectively. We historically have invested
excess cash in certificates of deposit or money market mutual funds
that invest in U.S. government or U.S. government agency
securities, floating rate and variable rate demand notes of U.S.
and foreign corporations, and commercial paper. These investments
are subject to general credit, liquidity, market and interest rate
risks, including potential future impacts similar to the impact of
U.S. sub-prime mortgage defaults that have affected various sectors
of the financial markets and caused credit and liquidity issues. We
may realize losses in the fair value of these investments, an
inability to access cash in these investments for a potentially
meaningful period, or a complete loss of these investments, which
would have a negative effect on our financial
statements.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, should our investments cease paying or reduce the amount
of interest paid to us, our interest income would suffer. The
market risks associated with our investment portfolio may have an
adverse effect on our results of operations, liquidity and
financial condition.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Changes in accounting rules and regulations, or interpretations
thereof, could result in unfavorable accounting charges or require
us to change our compensation policies.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Accounting
methods and policies for biotechnology companies, including
policies governing revenue recognition, research and development
and related expenses, and accounting for stock-based compensation,
are subject to review, interpretation and guidance from our
auditors and relevant accounting authorities, including the SEC.
Changes to accounting methods or policies, or interpretations
thereof, may require us to reclassify, restate or otherwise change
or revise our historical financial statements, including those
contained in this report.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We have identified a&nbsp;material weakness&nbsp;in our internal
control over financial reporting, and if we are unable to implement
and maintain effective internal control over financial reporting in
the future, investors may lose confidence in the accuracy and
completeness of our financial reports, the market price of our
common stock may be adversely effected, and we may become subject
to litigation and regulatory investigation.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
identified one&nbsp;material weakness&nbsp;in our internal control
over financial reporting related to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">a
deficiency in our information and communication controls, which led
to ineffectively designed controls over managementâs review of
certain research and development contracts to ensure expenses were
recognized as incurred by third-party contract research
organizations</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">.
A&nbsp;material weakness&nbsp;is a deficiency, or a combination of
deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement
of the registrantâs annual or interim condensed consolidated
financial statements will not be prevented or detected in a timely
basis. This deficiency resulted in the overstatement of accumulated
deficit by $1.0 million, the understatement of prepaid expense and
other current assets by $0.9 million, and the overstatement of
accrued expenses by $0.1 million as of December 31,
2017.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As
further described above and in Part I, Item 4 âControls and
Procedures,â of this Form 10-Q, management is implementing a
remediation plan to implement controls in the near term</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">by
enhancing the information used for</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">49</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">periodic
assessment of contract progress and increasing the frequency of
communication in the process for accounting for certain research
and development contracts with contract research organizations to
ensure expenses are recognized as incurred.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, if we identify new material weaknesses in the future in
our internal controls over financial reporting, we may not detect
errors in a timely manner and our condensed consolidated financial
statements may be materially misstated. We or our independent
registered public accounting firm may not be able to conclude on an
ongoing basis that we have effective internal control over
financial reporting, which could harm our operating results, cause
investors to lose confidence in our reported financial information
and cause the trading price of our stock to fall. We may also fail
to report our financial results on a timely and accurate basis,
which could result in sanctions, lawsuits, or other adverse
consequences that would materially harm our business. In addition,
we could become subject to investigations by the stock exchange on
which our securities are eventually listed, the SEC, or other
regulatory authorities, and become subject to litigation from
investors and stockholders, which could harm our reputation and our
financial condition, or divert financial and management resources
from our core business.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;padding-top:24px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We have incurred significant losses since our inception and expect
to incur continued losses in the future. We must obtain additional
funds to finance our operations and to remain a going
concern.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
recurring losses from operations raise substantial doubt about our
ability to continue as a going concern. As a result, we included an
explanatory paragraph in our consolidated financial statements for
the period ended March&nbsp;31, 2018 with respect to this
uncertainty. Our ability to continue as a going concern will
require us to obtain additional funding. We believe that our
existing working capital will be sufficient to fund our current
operating plans through at least the end of March 2019. We have
based these estimates, however, on assumptions that may prove to be
wrong, and we could spend our available financial resources much
faster than we currently expect and need to raise additional funds
sooner than we anticipate.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
perception&nbsp;of our ability&nbsp;to continue&nbsp;as
a&nbsp;going
concern&nbsp;may&nbsp;make&nbsp;it&nbsp;more&nbsp;difficult&nbsp;for&nbsp;us
to obtain&nbsp;financing for&nbsp;the&nbsp;continuation&nbsp;of our
operations&nbsp;and could&nbsp;result&nbsp;in the&nbsp;loss&nbsp;of
confidence&nbsp;by investors,&nbsp;suppliers&nbsp;and
employees.</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
are unable to raise capital when needed or on acceptable terms, we
would be forced to delay, reduce or eliminate our research and
development programs and commercialization efforts.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our business may be affected by litigation and government
investigations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We may
from time to time receive inquiries and subpoenas and other types
of information requests from government authorities and others and
we may become subject to claims and other actions related to our
business activities. While the ultimate outcome of investigations,
inquiries, information requests and legal proceedings is difficult
to predict, defense of litigation claims can be expensive,
time-consuming and distracting, and adverse resolutions or
settlements of those matters may result in, among other things,
modification of our business practices, costs and significant
payments, any of which could have a material adverse effect on our
business, financial condition, results of operations and
prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Risks Related to Intellectual Property</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If we are not able to obtain and enforce patent protection for our
technology or therapeutic candidates, development and
commercialization of our therapeutic candidates may be adversely
affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
success depends in part on our ability to obtain and maintain
patents and other forms of intellectual property rights, including
in-licenses of intellectual property rights of others, for our
therapeutic candidates, methods used to manufacture our therapeutic
candidates and methods for treating patients using our therapeutic
candidates, as well as our ability to preserve our trade secrets,
to prevent third parties from infringing upon our proprietary
rights and to operate without infringing upon the proprietary
rights of others. As of March 31, 2018, our patent portfolio
consists of over 55 issued patents and allowed patent applications
and over 140 pending patent applications. We may not be able to
apply for patents on certain aspects of our therapeutic candidates
in a timely fashion or at all. Our existing issued and granted
patents and any future patents we obtain may not be sufficiently
broad to prevent others from using our technology or from
developing competing therapeutics and technology. There is no
guarantee that</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">50</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">any of
our pending patent applications will result in issued or granted
patents, that any of our issued or granted patents will not later
be found to be invalid or unenforceable or that any issued or
granted patents will include claims that are sufficiently broad to
cover our therapeutic candidates or to provide meaningful
protection from our competitors. Moreover, the patent position of
pharmaceutical and biotechnology companies can be highly uncertain
because it involves complex legal and factual questions. We will be
able to protect our proprietary rights from unauthorized use by
third parties only to the extent that our current and future
proprietary technology and therapeutic candidates are covered by
valid and enforceable patents or are effectively maintained as
trade secrets. If third parties disclose or misappropriate our
proprietary rights, it may materially and adversely impact our
position in the market.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
U.S. Patent and Trademark Office, or USPTO, and various foreign
governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions during
the patent process. There are situations in which noncompliance can
result in abandonment or lapse of a patent or patent application,
resulting in partial or complete loss of patent rights in the
relevant jurisdiction. In such an event, competitors might be able
to enter the market earlier than would otherwise have been the
case. The standards applied by the USPTO and foreign patent offices
in granting patents are not always applied uniformly or
predictably. For example, there is no uniform worldwide policy
regarding patentable subject matter or the scope of claims
allowable in biotechnology and pharmaceutical patents. As such, we
do not know the degree of future protection that we will have on
our proprietary therapeutics and technology. While we will endeavor
to try to protect our therapeutic candidates with intellectual
property rights such as patents, as appropriate, the process of
obtaining patents is time-consuming, expensive and sometimes
unpredictable.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, there are numerous recent changes to the patent laws and
proposed changes to the rules of the USPTO, which may have a
significant impact on our ability to protect our technology and
enforce our intellectual property rights. For example, the
Leahy-Smith America Invents Act enacted in 2011, involves
significant changes in patent legislation. The U.S. Supreme Court
has ruled on several patent cases in recent years, some of which
cases either narrow the scope of patent protection available in
certain circumstances or weaken the rights of patent owners in
certain situations. The 2013 decision by the Supreme Court
in</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
Association for Molecular Pathology v. Myriad Genetics, Inc.</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">precludes
a claim to a nucleic acid having a stated nucleotide sequence that
is identical to a sequence found in nature and unmodified. We
currently are not aware of an immediate impact of this decision on
our patents or patent applications because we are developing
oligonucleotide therapeutics which contain modifications that we
believe are not found in nature. However, this decision has yet to
be clearly interpreted by courts and by the USPTO. We cannot assure
you that the interpretations of this decision or subsequent rulings
will not adversely impact our patents or patent applications. In
addition to increasing uncertainty with regard to our ability to
obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once
obtained. Depending on decisions by the U.S. Congress, the federal
courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that may weaken our ability to
obtain new patents or to enforce our existing patents and patents
that we might obtain in the future.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Once
granted, patents may remain open to opposition, interference,
re-examination, post-grant review, inter partes review,
nullification or derivation action in court or before patent
offices or similar proceedings for a given period after allowance
or grant, during which time third parties can raise objections
against such initial grant. In the course of such proceedings,
which may continue for a protracted period of time, the patent
owner may be compelled to limit the scope of the allowed or granted
claims thus attacked, or may lose the allowed or granted claims
altogether. In addition, there can be no assurance
that:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:47px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:-6px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Others
will not or may not be able to make, use or sell compounds that are
the same as or similar to our therapeutic candidates but that are
not covered by the claims of the patents that we own or
license.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We or
our licensors, or any current or future collaborators, are the
first to make the inventions covered by each of our issued patents
and pending patent applications that we own or
license.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We or
our licensors, or any current or future collaborators, are the
first to file patent applications covering certain aspects of our
inventions.</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">51</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Others
will not independently develop similar or alternative technologies
or duplicate any of our technology without infringing our
intellectual property rights.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">A third
party will not challenge our patents and, if challenged, a court
may not hold that our patents are valid, enforceable and
infringed.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Any
issued patents that we own or have licensed will provide us with
any competitive advantages, or will not be challenged by third
parties.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We will
develop additional proprietary technologies that are
patentable.</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
patents of others will not have an adverse effect on our
business.</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
competitors will not conduct research and development activities in
countries where we lack enforceable patent rights and then use the
information learned from such activities to develop competitive
therapeutics for sale in our major commercial markets.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We currently license patent rights from Northwestern University and
may in the future license patent rights from third party owners or
licensees. If Northwestern University or such other owners or
licensees do not properly or successfully obtain, maintain or
enforce the patents underlying such licenses, or if they retain or
license to others any competing rights, our competitive position
and business prospects may be adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We do,
and will continue to, rely on intellectual property rights licensed
from third parties to protect our technology. We are a party to a
number of licenses that give us rights to third party intellectual
property that is necessary or useful for our business. In
particular, we have a license from Northwestern University, which
provides us the exclusive worldwide right under certain patents and
patent applications owned by Northwestern University to exploit
therapeutics and processes using nanoparticles, nanotechnology,
microtechnology and nanomaterial-based constructs as therapeutics
or accompanying therapeutics as a means of administration. We may
also license additional third party intellectual property in the
future. Our success will depend in part on the ability of our
licensors to obtain, maintain and enforce patent protection for our
licensed intellectual property, and in particular, for those
patents to which we have secured exclusive rights. Our licensors
may not successfully prosecute the patent applications licensed to
us. Even if patents issue or are granted, our licensors may fail to
maintain these patents, may determine not to pursue litigation
against other companies that are infringing these patents, or may
pursue litigation less aggressively than we would. Further, we may
not obtain exclusive rights, which would allow for third parties to
develop competing therapeutics. Without protection for, or
exclusive rights to, the intellectual property we license, other
companies might be able to offer substantially identical
therapeutics for sale, which could adversely affect our competitive
business position and harm our business prospects. In addition, the
U.S. government has certain rights to the inventions covered by the
patent rights licensed to us by third parties and Northwestern
University, as an academic research and medical center, has
reserved the right to practice the patent rights it has licensed to
us (i)&nbsp;for research, teaching and/or other educationally
related purposes (including the right to distribute materials for
such purposes) and (ii)&nbsp;for use in the field of diagnostics
(including theradiagnostics) and in any field other than the field
of use licensed to us.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Other companies or organizations may challenge our or our licensorsâ
 patent rights or may assert patent rights that prevent us from
developing and commercializing our therapeutics.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Oligonucleotide
and SNA-based therapeutics are a relatively new scientific field.
We have obtained grants and issuances of SNA therapeutic patents
and have licensed many of these patents from a third party on an
exclusive basis for therapeutics applications. The issued patents
and pending patent applications in the U.S. and in key markets
around the world that we own or license claim many different
methods, compositions and processes relating to the discovery,
development, manufacture and commercialization of SNA therapeutics.
Specifically, we own and have licensed a portfolio of patents,
patent applications and other intellectual property covering SNA
compositions of matter as well as their methods of
use.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As the
field of SNA therapeutics matures, patent applications are being
processed by national patent offices around the world. There is
uncertainty about which patents will issue, and, if they do, as to
when, to whom, and with</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">52</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">what
claims. In addition, third parties may attempt to invalidate our
intellectual property rights. Even if our rights are not directly
challenged, disputes could lead to the weakening of our
intellectual property rights. Our defense against any attempt by
third parties to circumvent or invalidate our intellectual property
rights could be costly to us, could require significant time and
attention of our management and could have a material adverse
effect on our business and our ability to successfully
compete.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">There
are many issued and pending patents that claim aspects of
oligonucleotide chemistry and modifications that we may need to
apply to our SNA therapeutic candidates. There are also many issued
patents that claim targeting genes or portions of genes that may be
relevant for SNA therapeutics we wish to develop. Thus, it is
possible that one or more organizations will hold patent rights to
which we will need a license. If those organizations refuse to
grant us a license to such patent rights on reasonable terms, we
may not be able to market therapeutics or perform research and
development or other activities covered by these
patents.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We may be unable to protect our intellectual property rights
throughout the world.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Obtaining
a valid and enforceable issued or granted patent covering our
technology in the U.S. and worldwide can be extremely costly. In
jurisdictions where we have not obtained patent protection,
competitors may use our technology to develop their own
therapeutics and, further, may export otherwise infringing
therapeutics to territories where we have patent protection, but
where it is more difficult to enforce a patent as compared to the
U.S. Competitor therapeutics may compete with our future
therapeutics in jurisdictions where we do not have issued or
granted patents or where our issued or granted patent claims or
other intellectual property rights are not sufficient to prevent
competitor activities in these jurisdictions. The legal systems of
certain countries, particularly certain developing countries, make
it difficult to enforce patents and such countries may not
recognize other types of intellectual property protection,
particularly that relating to biotechnology and pharmaceuticals.
This could make it difficult for us to prevent the infringement of
our patents or marketing of competing therapeutics in violation of
our proprietary rights generally in certain jurisdictions.
Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial cost and divert our efforts and
attention from other aspects of our business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
generally file a provisional patent application first, also known
as a priority filing, at the USPTO. An international application
under the Patent Cooperation Treaty, or PCT, is usually filed
within twelve months after the priority filing. Based on the PCT
filing, national and regional patent applications may be filed in
the U.S., European Union, Japan, Australia and Canada and,
depending on the individual case, also in any or all of,</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
inter alia</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">,
China, India, South Korea, and Mexico. We have so far not filed for
patent protection in all national and regional jurisdictions where
such protection may be available. In addition, we may decide to
abandon national and regional patent applications before grant.
Finally, the grant proceeding of each national or regional patent
is an independent proceeding which may lead to situations in which
applications might in some jurisdictions be refused by the relevant
registration authorities, while granted by others. It is also quite
common that depending on the country, various scopes of patent
protection may be granted on the same therapeutic candidate or
technology.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
laws of some jurisdictions do not protect intellectual property
rights to the same extent as the laws in the U.S., and many
companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. If we or our
licensors encounter difficulties in protecting, or are otherwise
precluded from effectively protecting, the intellectual property
rights important for our business in such jurisdictions, the value
of these rights may be diminished and we may face additional
competition from others in those jurisdictions. Many countries have
compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties. In addition, many
countries limit the enforceability of patents against government
agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish
the value of such patent. If we or any of our licensors are forced
to grant a license to third parties with respect to any patents
relevant to our business, our competitive position in the relevant
jurisdiction may be impaired and our business and results of
operations may be adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We or our licensors, or any current or future strategic partners,
may become subject to third party claims or litigation alleging
infringement of patents or other proprietary rights or seeking to
invalidate patents or other proprietary rights, and we may need to
resort to litigation to protect or enforce our patents or other
proprietary</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">53</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
rights, all of which could be costly, time consuming, delay or
prevent the development and commercialization of our therapeutic
candidates, or put our patents and other proprietary rights at
risk.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We or
our licensors, or any current or future strategic partners, may be
subject to third party claims for infringement or misappropriation
of patent or other proprietary rights. We are generally obligated
under our license agreements to indemnify and hold harmless our
licensors for damages arising from intellectual property
infringement by us. If we or our licensors, or any current or
future strategic partners, are found to infringe a third party
patent or other intellectual property rights, we could be required
to pay damages, potentially including treble damages, if we are
found to have willfully infringed. In addition, we or our
licensors, or any current or future strategic partners, may choose
to seek, or be required to seek, a license from a third party,
which may not be available on acceptable terms, if at all. Even if
a license can be obtained on acceptable terms, the rights may be
non-exclusive, which could give our competitors access to the same
technology or intellectual property rights licensed to us. If we
fail to obtain a required license, we or any current or future
collaborator may be unable to effectively market therapeutic
candidates based on our technology, which could limit our ability
to generate revenue or achieve profitability and possibly prevent
us from generating revenue sufficient to sustain our operations. In
addition, we may find it necessary to pursue claims or initiate
lawsuits to protect or enforce our patent or other intellectual
property rights. The cost to us in defending or initiating any
litigation or other proceeding relating to patent or other
proprietary rights, even if resolved in our favor, could be
substantial, and litigation would divert our managementâs
attention. Some of our competitors may be able to sustain the costs
of complex patent litigation more effectively than we can because
they have substantially greater resources. Uncertainties resulting
from the initiation and continuation of patent litigation or other
proceedings could delay our research and development efforts and
limit our ability to continue our operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
were to initiate legal proceedings against a third party to enforce
a patent covering one of our therapeutics or our technology, the
defendant could counterclaim that our patent is invalid or
unenforceable. In patent litigation in the U.S., defendant
counterclaims alleging invalidity or unenforceability are
commonplace. Grounds for a validity challenge could be an alleged
failure to meet any of several statutory requirements, for example,
lack of novelty, obviousness or non-enablement. Grounds for an
unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity
and unenforceability during patent litigation is unpredictable.
With respect to the validity question, for example, we cannot be
certain that there is no invalidating prior art, of which we and
the patent examiner were unaware during prosecution. If a defendant
were to prevail on a legal assertion of invalidity or
unenforceability, we would lose at least part, and perhaps all, of
the patent protection on one or more of our therapeutics or certain
aspects of our technology. Such a loss of patent protection could
have a material adverse impact on our business. Patents and other
intellectual property rights also will not protect our technology
if competitors design around our protected technology without
legally infringing our patents or other intellectual property
rights.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">It is
also possible that we have failed to identify relevant third party
patents or applications. For example, U.S. applications filed
before November&nbsp;29, 2000 and certain U.S. applications filed
after that date that will not be filed outside the U.S. remain
confidential until patents issue. Patent applications in the U.S.
and elsewhere are published approximately 18 months after the
earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date.
Therefore, patent applications covering our therapeutics or
technology could have been filed by others without our knowledge.
Additionally, pending patent applications which have been published
can, subject to certain limitations, be later amended in a manner
that could cover our SNA technology, our therapeutics or the use of
our therapeutics. Third party intellectual property right holders
may also actively bring infringement claims against us. We cannot
guarantee that we will be able to successfully settle or otherwise
resolve such infringement claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required
to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial
delays in marketing our therapeutics. If we fail in any such
dispute, in addition to being forced to pay damages, we may be
temporarily or permanently prohibited from commercializing any of
our therapeutic candidates that are held to be infringing. We
might, if possible, also be forced to redesign therapeutic
candidates so that we no longer infringe the third party
intellectual property rights. Any of these events, even if
we</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">54</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">were
ultimately to prevail, could require us to divert substantial
financial and management resources that we would otherwise be able
to devote to our business.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If we fail to comply with our obligations under any license,
collaboration or other agreements, we may be required to pay
damages and could lose intellectual property rights that are
necessary for developing and protecting our therapeutic candidates
or we could lose certain rights to grant sublicenses.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
current licenses impose, and any future licenses we enter into are
likely to impose, various development, commercialization, funding,
milestone, royalty, diligence, sublicensing, insurance, patent
prosecution and enforcement, and other obligations on us. If we
breach any of these obligations, or use the intellectual property
licensed to us in an unauthorized manner, we may be required to pay
damages and the licensor may have the right to terminate the
license, which could result in us being unable to develop,
manufacture and sell therapeutics that are covered by the licensed
technology or could enable a competitor to gain access to the
licensed technology. Moreover, our licensors may own or control
intellectual property that has not been licensed to us and, as a
result, we may be subject to claims, regardless of their merit,
that we are infringing or otherwise violating the licensorâs rights
in such unlicensed intellectual property. In addition, while we
cannot currently determine the amount of the royalty obligations we
would be required to pay on sales of future therapeutics, if any,
the amounts may be significant. The amount of our future royalty
obligations will depend on the technology and intellectual property
we use in therapeutics that we successfully develop and
commercialize, if any. Therefore, even if we successfully develop
and commercialize therapeutics, we may be unable to achieve or
maintain profitability.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
If we are unable to pr</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">otect
the con</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">fidentiality
of our trade secrets, our business and competitive position would
be harmed.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition to seeking patent protection for certain aspects of our
therapeutic candidates, we also consider trade secrets, including
confidential and unpatented know-how important to the maintenance
of our competitive position. We protect trade secrets and
confidential and unpatented know-how, in part, by entering into
non-disclosure and confidentiality agreements with parties who have
access to such knowledge, such as our employees, corporate
collaborators, outside scientific collaborators, CROs, contract
manufacturers, consultants, advisors and other third parties. We
also enter into confidentiality and invention or patent assignment
agreements with our employees and consultants that obligate them to
maintain confidentiality and assign their inventions to us. Despite
these efforts, any of these parties may breach the agreements and
disclose our proprietary information, including our trade secrets,
and we may not be able to obtain adequate remedies for such
breaches. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some
courts in the U.S. and certain foreign jurisdictions are less
willing or unwilling to protect trade secrets. If any of our trade
secrets were to be lawfully obtained or independently developed by
a competitor, we would have no right to prevent them from using
that technology or information to compete with us. If any of our
trade secrets were to be disclosed to or independently developed by
a competitor, our competitive position would be
harmed.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Under
the terms of the Northwestern University license agreements,
Northwestern University could publish research findings relating to
the patent rights licensed to us by Northwestern University, which
could have a material adverse effect on our business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
also subject both in the U.S. and outside the U.S. to various
regulatory schemes regarding requests for the information we
provide to regulatory authorities, which may include, in whole or
in part, trade secrets or confidential commercial information.
While we are likely to be notified in advance of any disclosure of
such information and would likely object to such disclosure, there
can be no assurance that our challenge to the request would be
successful.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">55</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We may be subject to claims that we or our employees or consultants
have wrongfully used or disclosed alleged trade secrets of our
employeesâ or consultantsâ former employers or their clients. These
claims may be costly to defend and if we do not successfully do so,
we may be required to pay monetary damages and may lose valuable
intellectual property rights or personnel.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Many of
our employees were previously employed at universities or
pharmaceutical or biotechnology companies, including our
competitors or potential competitors. Although no claims against us
are currently pending, we may be subject to claims that these
employees or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former
employers. Litigation may be necessary to defend against these
claims. If we fail in defending such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights
or personnel. A loss of key research personnel or their work
product could hamper our ability to commercialize, or prevent us
from commercializing, our therapeutic candidates, which could
severely harm our business. Even if we are successful in defending
against these claims, litigation could result in substantial costs
and be a distraction to management.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If our trademarks and trade names are not adequately protected,
then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
trademarks or trade names may be challenged, infringed,
circumvented or declared generic or determined to be infringing on
other marks. We may not be able to protect our rights to these
trademarks and trade names or may be forced to stop using these
names, which we need for name recognition by potential partners or
customers in our markets of interest. If we are unable to establish
name recognition based on our trademarks and trade names, we may
not be able to compete effectively and our business may be
adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Third parties may independently develop similar or superior
technology.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">There
can be no assurance that others will not independently develop, or
have not already developed, similar or more advanced technologies
than our technology; or that others will not design around, or have
not already designed around, aspects of our technology and/or our
trade secrets developed therefrom. If third parties develop
technology similar or superior to our technology, or they
successfully design around our current or future technology, our
competitive position, business prospects, and results of operations
could be materially and adversely affected.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The intellectual property which we have licensed from Northwestern
University was discovered through government funded programs and
thus may be subject to federal regulations such as âmarch-inâ
rights, certain reporting requirements, and a preference for U.S.
industry. Compliance with such regulations may limit our exclusive
rights, subject us to expenditure of resources with respect to
reporting requirements, and limit our ability to contract with
non-U.S. manufacturers.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
licensed certain intellectual property from Northwestern University
pursuant to the Northwestern University license agreements. The
Northwestern University license agreements indicate that the rights
licensed to us by Northwestern University are subject to the
obligations to and the rights of the U.S. government, including
those set&nbsp;forth in the Bayh-Dole Act of 1980, or the Bayh-Dole
Act. As a result, the U.S. government may have certain rights to
intellectual property embodied in our current or future
therapeutics based on the licensed Northwestern University
intellectual property. These U.S. government rights&nbsp;in certain
inventions developed under a government-funded program include a
non-exclusive, non-transferable, irrevocable worldwide&nbsp;license
to use inventions for any governmental purpose. In addition, the
U.S. government has the right to require us to grant exclusive,
partially exclusive, or nonexclusive licenses to any of these
inventions to a third party if it determines that:
(i)&nbsp;adequate steps have not been taken to commercialize the
invention; (ii)&nbsp;government action is necessary to meet public
health or safety needs; or (iii) government action is necessary to
meet requirements for public use under federal regulations, also
referred to as&nbsp;âmarch-in rights.â While the U.S. government
has sparingly used, and to the Companyâs knowledge never
successfully exercised, such march-in rights, any exercise of the
march-in rights by the U.S. government could harm our competitive
position, business, financial condition, results of operations, and
prospects. If the U.S. government exercises such march-in rights,
we may receive compensation that is deemed reasonable by the U.S.
government in its sole discretion, which may be less than what we
might be able to obtain in</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">56</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
open market. Intellectual property generated under a government
funded program is also subject to certain reporting requirements,
compliance with which may require us to expend substantial
resources.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, the U.S. government requires that any therapeutics
embodying any invention generated through the use of U.S.
government funding be manufactured substantially in the U.S. The
manufacturing preference requirement can be waived if the owner of
the intellectual property can show that reasonable but unsuccessful
efforts have been made to grant licenses on similar terms to
potential licensees that would be likely to manufacture
substantially in the United States or that under the circumstances
domestic manufacture is not commercially feasible. This preference
for U.S. manufacturers may limit our ability to contract with
non-U.S. therapeutic manufacturers for therapeutics covered by such
intellectual property.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Risks Related to Government Regulation</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We may be unable to obtain U.S. or foreign regulatory approval and,
as a result, unable to commercialize our therapeutic
candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
therapeutic candidates are subject to extensive governmental
regulations relating to, among other things, research, testing,
development, manufacturing, safety, efficacy, approval,
recordkeeping, reporting, labeling, storage, packaging, advertising
and promotion, pricing, marketing, sampling, and distribution of
therapeutics. Rigorous preclinical testing and clinical trials and
an extensive regulatory approval process are required to be
successfully completed in the U.S. and in many foreign
jurisdictions before a new therapeutic can be marketed.
Satisfaction of these and other regulatory requirements is costly,
time consuming, uncertain and subject to unanticipated delays. It
is possible that none of the therapeutic candidates we may develop
will obtain the regulatory approvals necessary for us or any
current or future collaborators to begin selling them.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
very limited experience in conducting and managing the clinical
trials necessary to obtain regulatory approvals, including approval
by the FDA as well as foreign regulatory authorities, such as the
EMA and European Union national competent authorities. The time
required to obtain FDA and foreign regulatory approvals is
unpredictable but typically takes many years following the
commencement of clinical trials, depending upon the type,
complexity and novelty of the therapeutic candidate. The standards
that the FDA and its foreign counterparts use when regulating us
are not always applied predictably or uniformly and can change. Any
analysis we perform of data from preclinical and clinical
activities is subject to confirmation and interpretation by
regulatory authorities, which could delay, limit or prevent
regulatory approval. We may also encounter unexpected delays or
increased costs due to new government regulations, for example,
from future legislation or administrative action, or from changes
in the policy of the FDA or foreign regulatory authorities during
the period of therapeutic development, clinical trials and
regulatory review by the FDA or foreign regulatory authorities. It
is impossible to predict whether legislative changes will be
enacted, or whether FDA or foreign laws, regulations, guidance or
interpretations will be changed, or what the impact of such
changes, if any, may be.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Because
the therapeutics we are developing may represent a new class of
therapeutic, the FDA and its foreign counterparts have not yet
established any definitive policies, practices or guidelines in
relation to these therapeutics. While we believe the therapeutic
candidates that we are currently developing are regulated as new
drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA,
the FDA could decide to regulate them or other therapeutics we may
develop as biologics under the Public Health Service Act. The lack
of policies, practices or guidelines may hinder or slow review by
the FDA or foreign regulatory authorities of any regulatory filings
that we may submit. Moreover, the FDA may respond to these
submissions by defining requirements we may not have anticipated.
Such responses could lead to significant delays in the clinical
development of our therapeutic candidates. In addition, because
there may be therapeutic candidates approved for some of the
diseases for which we may seek approval, in order to receive
regulatory approval, we may need to demonstrate through clinical
trials that the therapeutic candidates we develop to treat these
diseases, if any, are not only safe and effective, but safer or
more effective than existing products.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Any
delay or failure in obtaining required approvals could have a
material adverse effect on our ability to generate revenues from
the particular therapeutic candidate for which we are seeking
approval. Furthermore, any regulatory approval to market a
therapeutic may be subject to limitations on the approved uses for
which we may</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">57</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">market
the therapeutic or the labeling or other restrictions. Regulatory
authorities also may impose requirements for costly post-marketing
studies or clinical trials and surveillance to monitor the safety
or efficacy of the therapeutic. In addition, the FDA has the
authority to require a REMS plan as part of a NDA or a Biologics
License Application, or BLA, or after approval, which may impose
further requirements or restrictions on the distribution or use of
an approved drug or biologic, such as limiting prescribing to
certain physicians or medical centers that have undergone
specialized training, limiting treatment to patients who meet
certain safe-use criteria and requiring treated patients to enroll
in a registry. These limitations and restrictions may limit the
size of the market for the therapeutic and affect coverage and
reimbursement by third party payors.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
also subject to numerous foreign regulatory requirements governing,
among other things, the conduct of clinical trials, manufacturing
and marketing authorization, pricing and third party reimbursement.
The foreign regulatory approval process varies among countries and
may include all of the risks associated with FDA approval described
above as well as risks attributable to the satisfaction of local
regulations in foreign jurisdictions. Moreover, the time required
to obtain approval may differ from that required to obtain FDA
approval. Approval by the FDA does not ensure approval by
regulatory authorities outside the U.S. and vice
versa.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Certain of our product candidates may require companion diagnostics
in certain indications. Failure to successfully develop, validate
and obtain regulatory clearance or approval for such tests could
harm our product development strategy or prevent us from realizing
the full commercial potential of our product
candidates.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Certain
of our product candidates may require companion diagnostics to
identify appropriate patients for those product candidates in
certain indications. Companion diagnostics are subject to
regulation by the FDA and comparable foreign regulatory authorities
as a medical device and may require separate regulatory
authorization prior to commercialization. We may rely on third
parties for the design, development, testing and manufacturing of
these companion diagnostics, the application for and receipt of any
required regulatory authorization, and the commercial supply of
these companion diagnostics. If these parties are unable to
successfully develop companion diagnostics for these product
candidates, or experience delays in doing so, the development of
our product candidates may be adversely affected and we may not be
able to obtain marketing authorization for these product
candidates. Furthermore, our ability to market and sell, as well as
the commercial success, of any of our product candidates that
require a companion diagnostic will be tied to, and dependent upon,
the receipt of required regulatory authorization and the continued
ability of such third parties to make the companion diagnostic
commercially available on reasonable terms in the relevant
geographies. Any failure to develop, validate, obtain and maintain
marketing authorization for a companion diagnostic and supply such
companion diagnostic will harm our business, results of operations
and financial condition.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If we or current or future collaborators, manufacturers or service
providers fail to comply with healthcare laws and regulations, we
or they could be subject to enforcement actions, which could affect
our ability to develop, market and sell our therapeutics and may
harm our reputation.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Although
we do not currently have any products on the market, once we begin
commercializing our therapeutic candidates, we will be subject to
additional healthcare statutory and regulatory requirements and
enforcement by the federal, state and foreign governments of the
jurisdictions in which we conduct our business. Healthcare
providers, physicians and third-party payors play a primary role in
the recommendation and prescription of any therapeutic candidates
for which we obtain marketing approval. Our future arrangements
with third-party payors and customers may expose us to broadly
applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial
arrangements and relationships through which we market, sell and
distribute our therapeutic candidates for which we obtain marketing
approval. Restrictions under applicable federal and state
healthcare laws and regulations, include the
following:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
U.S. federal Anti-Kickback Statute, which prohibits, among other
things, persons from soliciting, receiving, offering or providing
remuneration, directly or indirectly, to induce either the referral
of an individual for a healthcare item or service, or the
purchasing or ordering of an item or service, for which payment may
be made, in whole or in part, under a federal healthcare program
such as Medicare or Medicaid;</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">58</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
U.S.&nbsp;federal False Claims Act, which imposes criminal and
civil penalties, including through civil whistleblower or qui tam
actions, against individuals or entities for knowingly presenting,
or causing to be presented, to the federal government, claims for
payment that are false or fraudulent or making a false statement to
avoid, decrease or conceal an obligation to pay money to the
federal government. In addition, the government may assert that a
claim including items and services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the False Claims Act;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA
includes a fraud and abuse provision referred to as the HIPAA
All-Payor Fraud Law, which imposes criminal and civil liability for
executing a scheme to defraud any healthcare benefit program, or
knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement in
connection with the delivery of or payment for healthcare benefits,
items or services; similar to the federal Anti-Kickback Statute, a
person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed
a violation;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA,
as amended by HITECH, and its implementing regulations, which
impose obligations on certain covered entity healthcare providers,
health plans, and healthcare clearinghouses as well as their
business associates that perform certain services involving the use
or disclosure of individually identifiable health information,
including mandatory contractual terms, with respect to safeguarding
the privacy, security, and transmission of individually
identifiable health information, and require notification to
affected individuals and regulatory authorities of certain breaches
of security of individually identifiable health
information;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
federal Physician Payment Sunshine Act and the implementing
regulations, also referred to as âOpen Payments,â issued under the
Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act, collectively, the
ACA, which require that manufacturers of pharmaceutical and
biological drugs reimbursable under Medicare, Medicaid, and
Childrenâs Health Insurance Programs report to the Department of
Health and Human Services all consulting fees, travel
reimbursements, research grants, and other payments, transfers of
value or gifts made to physicians and teaching hospitals with
limited exceptions; and</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">analogous
state laws and regulations, such as, state anti-kickback and false
claims laws potentially applicable to sales or marketing
arrangements and claims involving healthcare items or services
reimbursed by non-governmental third-party payors, including
private insurers; and some state laws require pharmaceutical
companies to comply with the pharmaceutical industryâs voluntary
compliance guidelines and the relevant compliance guidance
promulgated by the federal government in addition to requiring drug
manufacturers to report information related to payments to
physicians and other healthcare providers or marketing
expenditures, and state laws governing the privacy and security of
health information in certain circumstances, many of which differ
from each other in significant ways and often are not preempted by
HIPAA, thus complicating compliance efforts.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Ensuring
that our future business arrangements with third-parties comply
with applicable healthcare laws and regulations could involve
substantial costs. If our operations are found to be in violation
of any such requirements, we may be subject to penalties, including
civil or criminal penalties, monetary damages, the curtailment or
restructuring of our operations, or exclusion from participation in
government contracting, healthcare reimbursement or other
government programs, including Medicare and Medicaid, any of which
could adversely affect our financial results. Although effective
compliance programs can mitigate the risk of investigation and
prosecution for violations of these laws, these risks cannot be
entirely eliminated. Any action against us for an alleged or
suspected violation could cause us to incur significant legal
expenses and could divert our managementâs attention from the
operation of our business, even if our defense is successful. In
addition, achieving and sustaining compliance with applicable laws
and regulations may be costly to us in terms of money, time and
resources.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If we
or current or future collaborators, manufacturers or service
providers fail to comply with applicable federal, state or foreign
laws or regulations, we could be subject to enforcement actions,
which could affect our ability to develop, market and sell our
therapeutics successfully and could harm our reputation and lead to
reduced acceptance of our therapeutics by the market. These
enforcement actions include, among others:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">adverse
regulatory inspection findings;</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">59</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">warning
or untitled letters;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">voluntary
product recalls or public notification or medical product safety
alerts to healthcare professionals;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions
on, or prohibitions against, marketing our
therapeutics;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions
on, or prohibitions against, importation or exportation of our
therapeutics;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">suspension
of review or refusal to approve pending applications or supplements
to approved applications;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion
from participation in government-funded healthcare
programs;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion
from eligibility for the award of government contracts for our
therapeutics;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">FDA
debarment;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">suspension
or withdrawal of therapeutic approvals;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">seizures
or administrative detention of therapeutics;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions;
and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">civil
and criminal penalties and fines.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Any therapeutics we develop may become subject to unfavorable
pricing regulations, third party coverage and reimbursement
practices or healthcare reform initiatives, thereby harming our
business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
regulations that govern marketing approvals, pricing and
reimbursement for new therapeutics vary widely from country to
country. Some countries require approval of the sale price of a
therapeutic before it can be marketed. In many countries, the
pricing review period begins after marketing or therapeutic
licensing approval is granted. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted.
Although we intend to monitor these regulations, our programs are
currently in the early stages of development and we will not be
able to assess the impact of price regulations for a number of
years. As a result, we might obtain regulatory approval for a
therapeutic in a particular country, but then be subject to price
regulations that delay our commercial launch of the therapeutic and
negatively impact the revenues we are able to generate from the
sale of the therapeutic in that country.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
ability to commercialize any therapeutics successfully also will
depend in part on the extent to which coverage and reimbursement
for these therapeutics and related treatments will be available
from government health administration authorities, private health
insurers and other organizations. However, there may be significant
delays in obtaining coverage for newly-approved therapeutics.
Moreover, eligibility for coverage does not necessarily signify
that a therapeutic will be reimbursed in all cases or at a rate
that covers our costs, including research, development,
manufacture, sale and distribution costs. Also, interim payments
for new therapeutics, if applicable, may be insufficient to cover
our costs and may not be made permanent. Thus, even if we succeed
in bringing one or more therapeutics to the market, these
therapeutics may not be considered cost-effective, and the amount
reimbursed for any therapeutics may be insufficient to allow us to
sell our therapeutics on a competitive basis. Because our programs
are in the early stages of development, we are unable at this time
to determine their cost effectiveness or the likely level or method
of reimbursement. Increasingly, the third party payors who
reimburse patients or healthcare providers, such as government and
private insurance plans, are seeking greater upfront discounts,
additional rebates and other concessions to reduce the prices for
therapeutics. If the price we are able to charge for any
therapeutics we develop, or the reimbursement provided for such
therapeutics, is inadequate in light of our development and other
costs, our return on investment could be adversely
affected.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
currently expect that some therapeutics we develop may need to be
administered under the supervision of a physician on an outpatient
basis. Under currently applicable U.S. law, certain therapeutics
that are not usually self-administered (including injectable
therapeutics) may be eligible for coverage under Medicare through
Medicare Part B. Medicare Part B is part of original Medicare, the
federal health care program that provides health care benefits
to</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">60</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
aged and disabled, and covers outpatient services and supplies,
including certain pharmaceutical products that are medically
necessary to treat a beneficiaryâs health condition. Specifically,
Medicare Part B coverage may be available for eligible
beneficiaries when the following, among other requirements, have
been satisfied:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
product is reasonable and necessary for the diagnosis or treatment
of the illness or injury for which the product is administered
according to accepted standards of medical practice;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
product is typically furnished incident to a physicianâs
services;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
indication for which the product will be used is included or
approved for inclusion in certain Medicare-designated
pharmaceutical compendia (when used for an off-label use);
and</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
product has been approved by the FDA.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Under
current law, as a condition of receiving Medicare Part B
reimbursement (the Medicare program that generally covers
physician-administered, outpatient drugs) for a manufacturerâs
eligible drugs or biologicals, the manufacturer is required to
participate in other government healthcare programs, including the
Medicaid Drug Rebate Program, the Veterans Health Administration
program, and the 340B Drug Pricing Program. The Medicaid Drug
Rebate Program requires pharmaceutical manufacturers to enter into
and have in effect a national rebate agreement with the Secretary
of the Department of Health and Human Services as a condition for
states to receive federal matching funds for the manufacturerâs
outpatient drugs furnished to Medicaid patients. Under the 340B
Drug Pricing Program, the manufacturer must extend discounts to
entities eligible to participate in the program. Average prices for
drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of therapeutics
from countries where they may be sold at lower prices than in the
U.S. Reimbursement rates under Medicare Part B would depend in part
on whether the newly approved therapeutic would be eligible for a
unique billing code. Self-administered therapeutics are typically
reimbursed under Medicare Part D, and therapeutics that are
administered in an inpatient hospital setting are typically
reimbursed under Medicare Part A under a bundled payment. It is
difficult for us to predict how Medicare coverage and reimbursement
policies will be applied to our therapeutics in the future and
coverage and reimbursement under different federal healthcare
programs are not always consistent. Medicare reimbursement rates
may also reflect budgetary constraints placed on the Medicare
program.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Third-party
payors often rely upon Medicare coverage policies and payment
limitations in setting their own reimbursement rates. These
coverage policies and limitations may rely, in part, on compendia
listings for approved therapeutics. Our inability to promptly
obtain relevant compendia listings, coverage, and adequate
reimbursement from both government-funded and private payors for
new therapeutics we develop and for which we obtain regulatory
approval could have a material adverse effect on our operating
results, our ability to raise capital needed to commercialize
products and our financial condition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We
believe that the efforts of governments and third party payors to
contain or reduce the cost of healthcare and legislative and
regulatory proposals to broaden the availability of healthcare will
continue to affect the business and financial condition of
pharmaceutical and biotechnology companies. A number of legislative
and regulatory changes in the healthcare system in the U.S. and
other major healthcare markets have been proposed, and such efforts
have expanded substantially in recent years. These developments
could, directly or indirectly, affect our ability to sell our
therapeutics, if approved, at a favorable price.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">For
example, in the U.S., in 2010, the U.S. Congress passed the ACA, a
sweeping law intended to broaden access to health insurance, reduce
or constrain the growth of health spending, enhance remedies
against fraud and abuse, add new transparency requirements for the
healthcare and health insurance industries, impose new taxes and
fees on the health industry and impose additional policy
reforms.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">61</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Among
the provisions of the ACA addressing coverage and reimbursement of
pharmaceutical products, of importance to our potential therapeutic
candidates are the following:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Increases
to pharmaceutical manufacturer rebate liability under the Medicaid
Drug Rebate Program due to an increase in the minimum basic
Medicaid rebate on most branded prescription drugs and the
application of Medicaid rebate liability to drugs used in
risk-based Medicaid managed care plans.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
expansion of the 340B Drug Pricing Program to require discounts for
âcovered outpatient drugsâ sold to certain childrenâs hospitals,
critical access hospitals, freestanding cancer hospitals, rural
referral centers, and sole community hospitals.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements
imposed on pharmaceutical companies to offer discounts on
brand-name drugs to patients who fall within the Medicare Part D
coverage gap, commonly referred to as the âDonut Hole.â In February
2018, Congress passed the Bipartisan Budget Act of 2018, which,
beginning in 2019, increased the discount to be paid by
pharmaceutical companies from 50% to 70% of a brand-name drugâs
negotiated price and added biosimilars to the coverage gap discount
program.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements
imposed on pharmaceutical companies to pay an annual
non-tax-deductible fee to the federal government based on each
companyâs market share of prior year total sales of branded drugs
to certain federal healthcare programs, such as Medicare, Medicaid,
Department of Veterans Affairs, and Department of Defense. Since we
currently expect our branded pharmaceutical sales to constitute a
small portion of the total federal healthcare program
pharmaceutical market, we do not currently expect this annual
assessment to have a material impact on our financial
condition.</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">For
therapeutic candidates classified as biologics, marketing approval
for a follow-on biologic therapeutic may not become effective until
12 years after the date on which the reference innovator biologic
therapeutic was first licensed by the FDA, with a possible
six-month extension for pediatric therapeutics. After this
exclusivity ends, it may be possible for biosimilar manufacturers
to enter the market, which is likely to reduce the pricing for such
therapeutics and could affect our profitability if our therapeutics
are classified as biologics.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Separately,
pursuant to the health reform legislation and related initiatives,
the Centers for Medicare and Medicaid Services, or CMS, is working
with various healthcare providers to develop, refine, and implement
Accountable Care Organizations, or ACOs, and other innovative
models of care for Medicare and Medicaid beneficiaries, including
the Bundled Payments for Care Improvement Initiative, the
Comprehensive Primary Care Initiative, the Duals Demonstration, and
other models. The continued development and expansion of ACOs and
other innovative models of care will have an uncertain impact on
any future reimbursement we may receive for approved therapeutics
administered by such organizations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, in recent years, the U.S. Congress has enacted various
laws seeking to reduce the federal debt level and contain
healthcare expenditures. For example, as a result of the Budget
Control Act of 2011 and the Bipartisan Budget Act of 2015, an
annual 2% reduction to Medicare payments took effect on
April&nbsp;1, 2013 and has been extended through 2027. These
across-the-board spending cuts could adversely affect our future
revenues, earnings, and cash flows.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
financial impact of U.S. healthcare reform legislation over the
next few years will depend on a number of factors, including the
policies reflected in implementing regulations and guidance and
changes in sales volumes for therapeutics affected by the
legislation.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">From
time to time, legislation is drafted, introduced and passed in the
U.S. Congress that could significantly change the statutory
provisions governing coverage, reimbursement, and marketing of
products regulated by CMS or other government agencies. In addition
to new legislation, CMS coverage and reimbursement policies are
often revised or interpreted in ways that may significantly affect
our business and our products. In particular, we expect that the
new administration and the U.S. Congress will seek to modify,
repeal, or otherwise invalidate all, or certain provisions of, the
U.S. healthcare reform legislation. Since taking office, President
Trump has continued to support the repeal of all or portions of the
ACA. President Trump has also issued an executive order in which he
stated that it</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">62</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">is his
administrationâs policy to seek the prompt repeal of the ACA and in
which he directed executive departments and federal agencies to
waive, defer, grant exemptions from, or delay the implementation of
the provisions of the ACA to the maximum extent permitted by law.
Congress has also enacted legislation that repeals certain portions
of the ACA, including the Tax Cuts and Jobs Act, passed in December
2017, which included a provision that eliminates the penalty under
the ACAâs individual mandate, effective January 1, 2019, as well as
the Bipartisan Budget Act of 2018, passed in February 2018, which,
among other things, repealed the Independent Payment Advisory Board
that was established by the ACA and was intended to reduce the rate
of growth in Medicare spending. There is still uncertainty with
respect to the impact President Trumpâs Administration and the U.S.
Congress may have, if any, and any changes will likely take time to
unfold. Such reforms could have an adverse effect on anticipated
revenues from therapeutic candidates that we may successfully
develop and for which we may obtain regulatory approval and may
affect our overall financial condition and ability to develop
therapeutic candidates. However, we cannot predict the ultimate
content, timing or effect of any healthcare reform legislation or
the impact of potential legislation on us.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The healthcare industry is heavily regulated in</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
the</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
U.S. at the federal, state, and local levels, and our failure to
comply with applicable requirements may subject us to penalties and
negatively affect our financial condition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As a
healthcare company, our operations, clinical trial activities and
interactions with healthcare providers may be subject to extensive
regulation in the U.S., particularly if the company receives FDA
approval for any of its therapeutics in the future. For example, if
we receive FDA approval for a therapeutic for which reimbursement
is available under a federal healthcare program (e.g., Medicare,
Medicaid), it would be subject to a variety of federal laws and
regulations, including those that prohibit the filing of false or
improper claims for payment by federal healthcare programs (e.g.,
the False Claims Act), prohibit unlawful inducements for the
referral of business reimbursable by federal healthcare programs
(e.g., the federal Anti-Kickback Statute), and require disclosure
of certain payments or other transfers of value made to
U.S.-licensed physicians and teaching hospitals, or Open Payments.
We are not able to predict how third parties will interpret these
laws and apply applicable governmental guidance and may challenge
our practices and activities under one or more of these laws. If
our past or present operations are found to be in violation of any
of these laws, we could be subject to civil and criminal penalties,
which could hurt our business, our operations and financial
condition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Similarly,
HIPAA prohibits, among other offenses, knowingly and willfully
executing a scheme to defraud any health care benefit program,
including private payors, or falsifying, concealing or covering up
a material fact or making any materially false, fictitious or
fraudulent statement in connection with the delivery of or payment
for items or services under a health care benefit program. To the
extent that we act as a business associate to a healthcare provider
engaging in electronic transactions, we may also be subject to the
privacy and security provisions of HIPAA, as amended by HITECH,
which restricts the use and disclosure of patient-identifiable
health information, mandates the adoption of standards relating to
the privacy and security of patient-identifiable health
information, and requires the reporting of certain security
breaches to healthcare provider customers with respect to such
information. Additionally, many states have enacted similar laws
that may impose more stringent requirements on entities like ours.
Failure to comply with applicable laws and regulations could result
in substantial penalties and adversely affect our financial
condition and results of operations.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our ability to</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">
obtain</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
services, reimbursement or funding from the federal government may
be impacted by possible reductions in federal
spending.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">U.S.
federal government agencies currently face potentially significant
spending reductions. The Budget Control Act of 2011, or the BCA,
established a Joint Select Committee on Deficit Reduction, which
was tasked with achieving a reduction in the federal debt level of
at least $1.2 trillion. That committee did not draft a proposal by
the BCAâs deadline. As a result, automatic cuts, referred to as
sequestration, in various federal programs were scheduled to take
place, beginning in January 2013, although the American Taxpayer
Relief Act of 2012 delayed the BCAâs automatic cuts until
March&nbsp;1, 2013. While the Medicare programâs eligibility and
scope of benefits are generally exempt from these cuts, Medicare
payments to providers and Part D health plans are not exempt. The
BCA did, however, provide that the Medicare cuts to providers and
Part D health plans would not exceed two percent. President Obama
issued the sequestration order on March&nbsp;1, 2013, and cuts went
into effect on April&nbsp;1, 2013. Additionally, the Bipartisan
Budget Act of 2015 extended sequestration for Medicare through
fiscal year 2027.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">63</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
U.S. federal budget remains in flux, which could, among other
things, cut Medicare payments to providers. Although the BBA passed
in February 2018 enacts a two-year federal spending agreement and
raises the federal spending cap on non-defense spending for fiscal
years 2018 and 2019, the Medicare program is frequently identified
as a target for spending cuts. The full impact on our business of
any future cuts in Medicare or other programs is uncertain. In
addition, we cannot predict any impact President Trumpâs
administration and the U.S. Congress may have on the federal
budget. If federal spending is reduced, anticipated budgetary
shortfalls may also impact the ability of relevant agencies, such
as the FDA or the National Institutes of Health, to continue to
function at current levels. Amounts allocated to federal grants and
contracts may be reduced or eliminated. These reductions may also
impact the ability of relevant agencies to timely review and
approve therapeutic research and development, manufacturing, and
marketing activities, which may delay our ability to develop,
market, and sell any therapeutics we may develop.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If any of our therapeutic candidates receives marketing approval
and we or others later identify undesirable side effects caused by
the therapeutic candidate, our ability to market and derive revenue
from the therapeutic candidates could be compromised.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In the
event that any of our therapeutic candidates receive regulatory
approval and we or others identify undesirable side effects,
adverse events or other problems caused by one of our therapeutics,
any of the following adverse events could occur, which could result
in the loss of significant revenue to us and materially and
adversely affect our results of operations and
business:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">regulatory
authorities may withdraw their approval of the therapeutic or seize
the therapeutic;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">we may need to
recall the therapeutic or change the way the therapeutic is
administered to patients;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">additional
restrictions may be imposed on the marketing of the particular
therapeutic or the manufacturing processes for the therapeutic or
any component thereof;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">we may be subject
to fines, restitution or disgorgement of profits or revenues,
injunctions, or the imposition of civil penalties or criminal
prosecution;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">regulatory
authorities may require the addition of labeling statements, such
as a âblack boxâ warning or a contraindication;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">regulatory
authorities may require us to implement a REMS, or to conduct
post-marketing studies or clinical trials and surveillance to
monitor the safety or efficacy of the therapeutic;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">we may be
required to create a Medication Guide outlining the risks of such
side effects for distribution to patients;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">we could be sued
and held liable for harm caused to patients;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">the therapeutic
may become less competitive; and</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:24px;">
<font style="font-family:inherit;font-size:10pt;">â¢</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">our reputation
may suffer.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Significant developments stemming from the United Kingdomâs recent
referendum on membership in the European Union could have a
material adverse effect on our business.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">On
June&nbsp;23, 2016, the United Kingdom held a referendum and voted
in favor of leaving the European Union. This referendum has created
political and economic uncertainty, particularly in the United
Kingdom and the European Union, and this uncertainty may last for
years. Any business we conduct, now and in the future, in the
United Kingdom, the European Union, and worldwide could be affected
during this period of uncertainty, and perhaps longer, by the
impact of the United Kingdomâs referendum. The referendum, and the
likely withdrawal of the United Kingdom from the European Union it
triggers, has caused and, along with events potentially occurring
in the future as a consequence of the United Kingdomâs withdrawal,
including the possible breakup of the United Kingdom, may continue
to cause significant volatility in global financial markets,
including in global currency and</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">64</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">debt
markets. This volatility could cause a slowdown in economic
activity in the United Kingdom, Europe, or globally, which could
adversely affect our operating results and growth prospects. In
addition, our business could be negatively affected by new trade
agreements between the United Kingdom and other countries,
including the U.S., and by the possible imposition of trade or
other regulatory barriers in the United Kingdom.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">It is
currently unclear how regulations affecting clinical trials, the
approval of our future therapeutic candidates, and the sale of
these therapeutic candidates will be affected by this referendum
either in the United Kingdom or elsewhere in Europe. These possible
negative impacts, and others resulting from the United Kingdomâs
actual or threatened withdrawal from the European Union, may
adversely affect our operating results and growth
prospects.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Risks Related to Our Common Stock</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We are an âemerging growth companyâ and we cannot be certain if the
reduced reporting requirements applicable to emerging growth
companies will make our common stock less attractive to
investors.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We are
an âemerging growth companyâ as defined in the JOBS Act. For as
long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that
are applicable to other public companies that are not emerging
growth companies, including (1)&nbsp;not being required to comply
with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act,
(2)&nbsp;reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements and
(3)&nbsp;exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of
any golden parachute payments not previously approved. In addition,
as an emerging growth company, we are only required to provide two
years of audited financial statements and two years of selected
financial data. We could be an emerging growth company for up to
five years, although circumstances could cause us to lose that
status earlier, including if the market value of our common stock
held by&nbsp;non-affiliates&nbsp;exceeds $700.0&nbsp;million as of
any June&nbsp;30 before that time or if we have total annual gross
revenue of $1.07&nbsp;billion or more during any fiscal year before
that time, in which cases we would no longer be an emerging growth
company as of the following December&nbsp;31, or if we issue more
than $1.0&nbsp;billion in&nbsp;non-convertible&nbsp;debt during any
three-year period before that time, in which case we would no
longer be an emerging growth company immediately. Even after we no
longer qualify as an emerging growth company, we may still qualify
as a âsmaller reporting companyâ which would allow us to take
advantage of many of the same exemptions from disclosure
requirements including not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act and reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy
statements. We cannot predict if investors will find our common
stock less attractive because we may rely on these exemptions. If
some investors find our common stock less attractive as a result,
there may be a less active trading market for our common stock and
our share price may be more volatile.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Under
the JOBS Act, emerging growth companies can also delay adopting new
or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to
avail ourselves of this exemption from new or revised accounting
standards and, therefore, will be subject to the same new or
revised accounting standards as other public companies that are not
emerging growth companies.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our stock price may be volatile and purchasers of our common stock
could incur substantial losses.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">If a
market for our common stock develops, its market price could
fluctuate substantially due to a variety of factors, including the
other risks described in this section titled âRisk Factorsâ in this
report and the following:</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
success of competitive therapeutics or technologies;</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">results
of our preclinical studies and clinical trials of our therapeutic
candidates, or those of our competitors, or any current or future
collaborators;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory
or legal developments in the U.S. and other countries, especially
changes in laws or regulations applicable to our
therapeutics;</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">65</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">introductions
and announcements of new therapeutics by us, our future
commercialization partners, or our competitors, and the timing of
these introductions or announcements;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">actions
taken by regulatory agencies with respect to our therapeutics,
clinical studies, manufacturing process or sales and marketing
terms;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">actual
or anticipated variations in our financial results or those of
companies that are perceived to be similar to us;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
success of our efforts to acquire or in-license additional
technologies, therapeutics or therapeutic candidates;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">developments
concerning any current or future collaborations, including but not
limited to those with our sources of manufacturing supply and our
commercialization partners;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">announcements
by us or our competitors of significant acquisitions, strategic
partnerships, joint ventures or capital commitments;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">developments
or disputes concerning patents or other proprietary rights,
including patents, litigation matters and our ability to obtain
patent protection for our therapeutics;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
ability or inability to raise additional capital and the terms on
which we raise it;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
recruitment or departure of key personnel;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">changes
in the structure of healthcare payment systems;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">market
conditions in the pharmaceutical and biotechnology
sectors;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">actual
or anticipated changes in earnings estimates or changes in stock
market analyst recommendations regarding our common stock, other
comparable companies or our industry generally;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
failure or the failure of our competitors to meet analystsâ
projections or guidance that we or our competitors may give to the
market;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">fluctuations
in the valuation of companies perceived by investors to be
comparable to us;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">announcement
and expectation of additional financing efforts;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">speculation
in the press or investment community;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">trading
volume of our common stock;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">sales
of our common stock by us or our stockholders;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
concentrated ownership of our common stock;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">changes
in accounting principles;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">terrorist
acts, acts of war or periods of widespread civil
unrest;</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">natural
disasters and other calamities; and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">general
economic, industry and market conditions.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
addition, the stock markets in general, and the markets for
pharmaceutical and biotechnology stocks in particular, have
experienced extreme volatility that has been often unrelated to the
operating performance of the issuer. These broad market and
industry factors may seriously harm the market price of our common
stock, regardless of our operating performance.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">66</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The future issuance of equity or of debt securities that are
convertible into equity may dilute your investment and reduce your
equity interest.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We may
choose to raise additional capital in the future, depending on
market conditions, strategic considerations and operational
requirements. To the extent that we raise additional capital
through the issuance of shares or other securities convertible into
shares, our stockholders will be diluted. Future issuances of our
common stock or other equity securities, or the perception that
such sales may occur, could adversely affect the prevailing market
price of our common stock and impair our ability to raise capital
through future offerings of equity or equity-linked securities. For
example, we have filed, and the SEC has declared effective, a
registration statement to register the resale of up to 39,714,143
shares of our common stock issued in connection with the Merger and
the Private Placement or held by pre-Merger stockholders of us.
This registration statement will permit the resale of these shares
at any time for up to five years from the effective date of the
registration statement. The resale of a substantial number of
shares of our common stock in the public market could adversely
affect the market price for our common stock and make it more
difficult for you to sell shares of our common stock at times and
prices that you feel are appropriate. Furthermore, we expect that,
because there will be a large number of shares registered pursuant
to this registration statement, selling stockholders will continue
to offer shares covered by this registration statement for a
significant period of time, the precise duration of which cannot be
predicted. Accordingly, the adverse market and price pressures
resulting from an offering pursuant to this registration statement
may continue for an extended period of time and continued negative
pressure on the market price of our common stock could have a
material adverse effect on our ability to raise additional equity
capital.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our&nbsp;debt obligations expose us to risks that could adversely
affect our business, operating results and&nbsp;financial condition
and may result in further dilution to our
stockholders.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
entered into a loan and security agreement with Hercules pursuant
to which we may borrow in an aggregate principal amount of up to
$10.0&nbsp;million from Hercules at a floating per annum interest
rate (based on a year consisting of 360 days) equal to the greater
of either (i) 9.95% or (ii)&nbsp;the sum of (a) 9.95% plus
(b)&nbsp;the prime rate (as reported in</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">
The Wall Street Journal</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">) minus
3.50%. We were required to make interest only payments on the
amounts borrowed until June 2017. Commencing on July&nbsp;1, 2017,
the loan began amortizing in equal monthly installments of
principal and interest in an amount sufficient to fully amortize
the outstanding principal balance of the loan over the remaining
scheduled monthly payments due prior to the maturity date on
September&nbsp;1, 2019. Pursuant to an amendment dated January 15,
2018, amortization payments due for the thirteen (13) consecutive
months commencing on December 1, 2017 through and including
December 1, 2018 were deferred.&nbsp; Commencing on January 1,
2019, and continuing on the first business day of each month
thereafter, the loan, including the deferred payments, shall begin
amortizing in equal monthly installments of principal and interest
based upon an amortization schedule equal to eighteen (18)
consecutive months. Any remaining obligations under the loan
agreement and other loan documents (other than the warrant) are due
and payable on the maturity date. On the earliest to occur of the
maturity date, the date we prepay the term loan in full or the date
the loan otherwise becomes due and payable, we must pay the lender
under the agreement an additional charge equal to 3.85% of the
total amounts funded under the loan agreement. To the extent we
desire to prepay the indebtedness prior to maturity, we will be
obligated to pay a prepayment penalty to Hercules ranging from 1%
to 3% of the amounts being prepaid, depending on when such
prepayment occurs. The loan agreement was amended on
October&nbsp;10, 2016 to revise the language granting Hercules a
contingent security interest in certain of our assets. Under the
loan agreement, Hercules or its affiliates have a right to
participate in a single subsequent unregistered financing by us in
an amount of up $1.0&nbsp;million on the same terms, conditions and
pricing afforded to others participating in such financing.
Hercules has not yet exercised this right to
participate.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
ability to make payments on this indebtedness depends on our
ability to generate cash in the future. We expect to experience
negative cash flow for the foreseeable future as we fund our
operations and capital expenditures. There can be no assurance that
we will be in a position to repay this indebtedness when due or
obtain extensions of the maturity date. We anticipate that we will
need to secure additional funding in order for us to be able to
satisfy our obligations when due. We cannot guarantee that future
financing will be available in sufficient amounts or on terms
acceptable to us, if at all. If that additional funding involves
the sale of equity securities or convertible securities, it would
result in the issuance of additional shares of our capital stock,
which would result in</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">67</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">dilution
to our stockholders. The indebtedness is secured by substantially
all of our assets other than intellectual property, on which we
have given Hercules a negative pledge. In addition, under the loan
agreement, we are subject to certain customary covenants that limit
or restrict our ability to, among other things, incur additional
indebtedness, grant any security interests, pay cash dividends,
repurchase our common stock, make loans, or enter into certain
transactions without the prior consent of Hercules.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">This
level of debt could have important consequences to you as an
investor in our securities. For example, it could:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">limit
our flexibility in planning for the development, clinical testing,
approval and marketing of our products;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">place
us at a competitive disadvantage compared to any of our competitors
that are less leveraged than we are;</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">increase
our vulnerability to both general and industry-specific adverse
economic conditions; and</font></div>
<div style=
"line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;">
<font style=
"padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">
â¢</font><font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">limit
our ability to obtain additional funds.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The employment agreements with our executive officers may require
us to pay severance benefits to officers in connection with
termination of employment or upon a change of control of us, which
could harm our financial condition.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Each of
David A. Giljohann, our Chief Executive Officer, Ekambar
Kandimalla, our Chief Scientific Officer, David S. Snyder, our
Chief Financial Officer, and Matthias G. Schroff, our Chief
Operating Officer, is entitled to receive cash severance equal to
twelve months, six months, six months, and six months,
respectively, of his base salary if his employment is terminated by
us without cause (as such term is defined in his employment offer
letter). In addition, our 2015 Plan, which was assumed by us in the
Merger, generally provides for accelerated vesting of equity awards
upon the involuntary termination of an employee within the twelve
month period following a change in control (as defined under the
plan) and accelerated vesting of equity awards upon a change of
control (as defined under the plan) for each of our executive
officers. This vesting acceleration is intended to provide each of
our executive officers with the full benefit of their equity awards
and reward them for a successful outcome for our stockholders. The
accelerated vesting of equity awards could result in dilution to
our existing stockholders and harm the market price of our common
stock. The payment of these severance benefits could harm our
financial condition. In addition, these potential severance
payments may discourage or prevent third parties from seeking a
business combination with us.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
There is currently no market for our common stock and we cannot
assure you that any market will ever develop. You may therefore be
unable to re-sell shares of our common stock at times and prices
that you believe are appropriate.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
common stock is not listed on a national securities exchange or any
other exchange, or quoted on an over-the-counter market. Therefore,
there is no trading market, active or otherwise, for our common
stock and our common stock may never be included for trading on any
stock exchange, automated quotation system or any over-the-counter
market. Accordingly, our common stock is highly illiquid and you
will likely experience difficulty in re-selling such shares at
times and prices that you may desire and without depressing the
market price for the shares or at all.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our common stock may not be eligible for listing or quotation on
any securities exchange.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We do
not currently meet the initial quantitative listing standards of
any national securities exchange. We</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">cannot
assure you that we will be able to meet the initial listing
standards of any national securities exchange, or, if we do meet
such initial listing</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">standards,
that we will be able to maintain any such listing. Further, the
national securities exchanges are adopting so-called âseasoningâ
rules that</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">will
require that we meet certain requirements, including prescribed
periods of time trading over-the-counter and minimum filings of
periodic reports</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">with
the SEC, before we are eligible to apply for listing on such
national securities exchanges. We have contacted an authorized
market</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">68</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">maker
for</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">an
over-the-counter quotation system for sponsorship of our common
stock, but we cannot guarantee that such sponsorship will be
approved and</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">our
common stock listed and quoted for sale. Even if our common stock
is quoted for sale on an over-the-counter quotation system, buyers
may</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">be
insufficient in numbers to allow for a robust market and it may
prove impossible to sell your shares. In addition, an investor may
find it difficult</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">to
obtain accurate quotations as to the market value of our common
stock. In addition, if we fail to meet the criteria set forth in
SEC regulations,</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">various
requirements would be imposed by law on broker-dealers who sell our
securities to persons other than established customers and</font>
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">accredited
investors. Consequently, such regulations may deter broker-dealers
from recommending or selling our common stock, which may
further</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">affect
its liquidity. This would also make it more difficult for us to
raise additional capital.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The designation of our common stock as a âpenny stockâ would limit
the liquidity of our common stock.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
common stock may be deemed a âpenny stockâ (as that term is defined
under Rule 3a51-1 of the Exchange Act) in any market that may
develop in the future. Generally, a âpenny stockâ is a common stock
that is not listed on a securities exchange and trades for less
than $5.00 a share. Prices often are not available to buyers and
sellers and the market may be very limited. Penny stocks in
start-up companies are among the riskiest equity investments.
Broker-dealers who sell penny stocks must provide purchasers of
these stocks with a standardized risk-disclosure</font>
<font style="font-family:Times New Roman;font-size:10pt;color:#000000;">
document prepared by the SEC. The document provides information
about penny stocks and the nature and level of risks involved in
investing in</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
penny stock market. A broker must also provide purchasers with bid
and offer quotations and information regarding broker and
salesperson</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">compensation
and make a written determination that the penny stock is a suitable
investment for the purchaser and obtain the purchaserâs
written</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">agreement
to the purchase. Many brokers choose not to participate in penny
stock transactions. Because of the penny stock rules, there may
be</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">less
trading activity in penny stocks in any market that develops for
our common stock in the future and stockholders are likely to have
difficulty</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">selling
their shares.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
FINRA sales practice requirements may limit a stockholderâs ability
to buy and sell our stock.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
Financial Industry Regulatory Authority, or FINRA, has adopted
rules requiring that, in recommending an investment to a customer,
a broker-dealer must have reasonable grounds for believing that the
investment is suitable for that customer. Prior to recommending
speculative or low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain
information about the customerâs financial status, tax status,
investment objectives and other information. Under interpretations
of these rules, FINRA has indicated its belief that there is a high
probability that speculative or low-priced securities will not be
suitable for at least some customers. If these FINRA requirements
are applicable to us or our securities, they may make it more
difficult for broker-dealers to recommend that at least some of
their customers buy our common stock, which may limit the ability
of our stockholders to buy and sell our common stock and could have
an adverse effect on the market for and price of our common
stock.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
If securities or industry analysts do not publish research or
reports about our business, or if they issue an adverse or
misleading opinion regarding our stock, our stock price and trading
volume could decline.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">The
trading market for our common stock will be influenced by the
research and reports that industry or securities analysts publish
about us or our business. We do not currently have and may never
obtain research coverage by securities and industry analysts. In
addition, because we did not become a reporting company by
conducting an underwritten initial public offering of our common
stock, and because we will not be listed on a national securities
exchange, security analysts of brokerage firms may not provide
coverage of our Company. In addition, investment banks may be less
likely to agree to underwrite secondary offerings on our behalf
than they might if we became a public reporting company by means of
an underwritten initial public offering, because they may be less
familiar with our Company as a result of more limited coverage by
analysts and the media, and because we became public at an early
stage in our development. The failure to receive research coverage
or support in the market for our shares will have an adverse effect
on our ability to develop a liquid market for our common stock and
the trading price for our stock would be negatively
impacted.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In the
event we obtain securities or industry analyst coverage, if any of
the analysts who cover us issue an adverse or misleading opinion
regarding us, our business model, our intellectual property or our
stock performance,</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">69</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">or if
our target studies and operating results fail to meet the
expectations of analysts, our stock price would likely decline. If
one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the
financial markets, which in turn could cause our stock price or
trading volume to decline.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our principal stockholders and management own a significant
percentage of our stock and will be able to exert significant
control over matters subject to stockholder approval.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Based
on the beneficial ownership of our common stock as of March 31,
2018, our executive officers and directors, together with holders
of five percent or more of our outstanding common stock and their
respective affiliates, will beneficially own
approximately&nbsp;47.7 percent of our outstanding common stock. As
a result, these stockholders, if acting together, will continue to
have significant influence over the outcome of corporate actions
requiring stockholder approval, including the election of
directors, any merger, consolidation or sale of all or
substantially all of our assets and any other significant corporate
transaction. The interests of these stockholders may not be the
same as or may even conflict with your interests. For example,
these stockholders could delay or prevent a change of control of
our Company, even if such a change of control would benefit our
other stockholders, which could deprive our stockholders of an
opportunity to receive a premium for their common stock as part of
a sale of our company or our assets and might affect the prevailing
market price of our common stock. The significant concentration of
stock ownership may adversely affect the trading price of our
common stock due to investorsâ perception that conflicts of
interest may exist or arise.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Anti-takeover provisions in our charter documents and under the
General Corporation Law of the State of Delaware could make an
acquisition of us more difficult and may prevent attempts by our
stockholders to replace or remove our management.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Provisions
in our amended and restated certificate of incorporation and our
bylaws may delay or prevent an acquisition of us or a change in our
management. These provisions include a classified board of
directors, a prohibition on actions by written consent of our
stockholders, and the ability of the board of directors to issue
preferred stock without stockholder approval. In addition, because
we are incorporated in Delaware, we are governed by the provisions
of Section&nbsp;203 of the Delaware General Corporation Law, or the
DGCL, which prohibits stockholders owning in excess of 15% of the
outstanding combined organization voting stock from merging or
combining with the combined organization. Although we believe these
provisions collectively will provide for an opportunity to receive
higher bids by requiring potential acquirers to negotiate with our
board of directors, they would apply even if the offer may be
considered beneficial by some stockholders. In addition, these
provisions may frustrate or prevent any attempts by our
stockholders to replace or remove then-current management by making
it more difficult for stockholders to replace members of the board
of directors, which is responsible for appointing the members of
management.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Anti-takeover provisions in our charter documents could discourage,
delay or prevent a change in control of us and may affect the
trading price of our common stock.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
corporate documents and the DGCL contain provisions that may enable
our board of directors to resist a change in control of us even if
a change in control were to be considered favorable by our
stockholders. These provisions:</font></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">stagger
the terms of our board of directors and require 66 and 2/3%
stockholder voting to remove directors, who may only be removed for
cause;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">authorize
our board of directors to issue âblank checkâ preferred stock and
to determine the rights and preferences of those shares, which may
be senior to our common stock, without prior stockholder
approval;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">establish
advance notice requirements for nominating directors and proposing
matters to be voted on by stockholders at stockholdersâ
meetings;</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit
our stockholders from calling a special meeting and prohibit
stockholders from acting by written consent;</font></div>
</td>
</tr>
</table>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">70</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">require
66 and 2/3% stockholder voting to effect certain amendments to our
certificate of incorporation and bylaws; and</font></div>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style=
"padding-bottom:12px;font-family:Times New Roman; font-size:10pt;">
<tr>
<td style="width:48px;"></td>
<td></td>
</tr>
<tr>
<td style="vertical-align:top">
<div style="line-height:120%;font-size:10pt;padding-left:0px;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">â¢
</font></div>
</td>
<td style="vertical-align:top;">
<div style="line-height:120%;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit
cumulative voting in the election of directors, which limits the
ability of minority stockholders to elect director
candidates.</font></div>
</td>
</tr>
</table>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">These
provisions could discourage, delay or prevent a transaction
involving a change in control of us. These provisions could also
discourage proxy contests and make it more difficult for
stockholders to elect directors of their choosing and cause us to
take other corporate actions our stockholders desire.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
The requirements of being a public company may strain our resources
and divert managementâs attention.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As a
public company, we are subject to the reporting requirements of the
Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other
applicable securities rules and regulations. In the future, we may
also be subject to the listing requirements of the NASDAQ Stock
Market. Despite recent reforms made possible by the JOBS Act,
compliance with these rules and regulations nonetheless increases
our legal and financial compliance costs, makes some activities
more difficult, time-consuming or costly, and increases demand on
our systems and resources, particularly after we will no longer be
an âemerging growth company.â The Exchange Act requires, among
other things, that we file annual, quarterly, and current reports
with respect to our business and operating results.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">As a
result of disclosure of information in this report and in other
filings required of a public company, our business and financial
condition are more visible, which we believe may result in
threatened or actual litigation, including by competitors and other
third parties. If such claims are successful, our business and
operating results could be harmed, and even if the claims do not
result in litigation or are resolved in our favor, these claims,
and the time and resources necessary to resolve them, could divert
the resources of our management and adversely affect our business,
brand and reputation and results of operations.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We also
expect that being a public company and these new rules and
regulations will make it more expensive for us to obtain director
and officer liability insurance, and we may be required to accept
reduced coverage or incur substantially higher costs to obtain
coverage. These factors could also make it more difficult for us to
attract and retain qualified members of our board of directors,
particularly to serve on our audit committee and compensation
committee, and qualified executive officers.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Because we do not anticipate paying any cash dividends on our
capital stock in the foreseeable future, capital appreciation, if
any, will be your sole source of gain.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
never declared or paid cash dividends on our capital stock. We
currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. As a result,
capital appreciation, if any, of our common stock will be your sole
source of gain for the foreseeable future.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
We may incur significant costs from class action litigation due to
our expected stock volatility.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
stock price may fluctuate for many reasons, including as a result
of public announcements regarding the progress of our development
efforts or the development efforts of current or future
collaborators or competitors, the addition or departure of our key
personnel, variations in our quarterly operating results and
changes in market valuations of pharmaceutical and biotechnology
companies. This risk is especially relevant to us because
pharmaceutical and biotechnology companies have experienced
significant stock price volatility in recent years. When the market
price of a stock has been volatile as our stock price may be,
holders of that stock have occasionally brought securities class
action litigation against the company that issued the stock. If any
of our stockholders were to bring a lawsuit of this type against
us, even if the lawsuit is without merit, we could incur
substantial costs defending the lawsuit. The lawsuit could also
divert the time and attention of our management.</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">71</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our amended and restated certificate of incorporation designates
the Court of Chancery of the State of Delaware as the sole and
exclusive forum for certain types of actions and proceedings that
may be initiated by our stockholders, which could limit our
stockholdersâ ability to obtain a favorable judicial forum for
disputes with us or our directors, officers, employees or
agents.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Our
amended and restated certificate of incorporation provides that,
unless we consent in writing to an alternative forum, the Court of
Chancery of the State of Delaware will be the sole and exclusive
forum for any derivative action or proceeding brought on our
behalf, any action asserting a claim of breach of a fiduciary duty
owed by any of our directors, officers, employees or agents to us
or our stockholders, any action asserting a claim arising pursuant
to any provision of the DGCL, our amended and restated certificate
of incorporation or our amended and restated bylaws or any action
asserting a claim that is governed by the internal affairs
doctrine, in each case subject to the Court of Chancery having
personal jurisdiction over the indispensable parties named as
defendants therein and the claim not being one which is vested in
the exclusive jurisdiction of a court or forum other than the Court
of Chancery or for which the Court of Chancery does not have
subject matter jurisdiction. Any person purchasing or otherwise
acquiring any interest in any shares of our common stock shall be
deemed to have notice of and to have consented to this provision of
our amended and restated certificate of incorporation. This choice
of forum provision may limit our stockholdersâ ability to bring a
claim in a judicial forum that it finds favorable for disputes with
us or our directors, officers, employees or agents, which may
discourage such lawsuits against us and our directors, officers,
employees and agents even though an action, if successful, might
benefit our stockholders. Stockholders who do bring a claim in the
Court of Chancery could face additional litigation costs in
pursuing any such claim, particularly if they do not reside in or
near Delaware. The Court of Chancery may also reach different
judgments or results than would other courts, including courts
where a stockholder considering an action may be located or would
otherwise choose to bring the action, and such judgments or results
may be more favorable to us than to our stockholders.
Alternatively, if a court were to find this provision of our
amended and restated certificate of incorporation inapplicable to,
or unenforceable in respect of, one or more of the specified types
of actions or proceedings, we may incur additional costs associated
with resolving such matters in other jurisdictions, which could
have a material adverse effect on our business, financial condition
or results of operations.</font></div>
<div style=
"line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">
Our ability to use our net operating loss carryforwards and certain
other tax attributes may be limited.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">We have
incurred substantial losses during our history and do not expect to
become profitable in the near future and we may never achieve
profitability. To the extent that we continue to generate taxable
losses, unused losses will carry forward to offset future taxable
income, if any, until such unused losses expire. Under Sections 382
and 383 of the Internal Revenue Code of 1986, as amended, if a
corporation undergoes an âownership change,â generally defined as a
greater than 50% change (by value) in its equity ownership over a
three-year period, the corporationâs ability to use its pre-change
net operating loss carryforwards, or NOLs, and other pre-change tax
attributes (such as research tax credits) to offset its post-change
income or taxes may be limited. The Merger, our prior equity
offerings and other changes in our stock ownership may have
resulted in ownership changes. In addition, we may experience
ownership changes in the future as a result of subsequent shifts in
our stock ownership, some of which are outside of our control. As a
result, if we earn net taxable income, our ability to use our
pre-change net operating loss carryforwards to offset U.S. federal
taxable income may be subject to limitations, which could
potentially result in increased future tax liability to us. In
addition, at the state level, there may be periods during which the
use of NOLs is suspended or otherwise limited, which could
accelerate or permanently increase state taxes owed.</font></div>
<div><a name="s325AD1559EB95ACD84031E94E3A6CF57" id=
"s325AD1559EB95ACD84031E94E3A6CF57"></a></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.</font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">
Sales of Unregistered Securities of Exicure</font></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">In
February 2018, Exicure issued 98,800 shares and 46,666 shares of
common stock at $3.00 per share, restricted in accordance with Rule
144 of the Securities Act, to two consultants for a value of
$296,400.00 and $139,998.00, respectively, pursuant to a restricted
stock purchase agreement in connection with a consulting agreement
entered into by us and each consultant. We deemed these issuances
of common stock to be exempt from registration under the Securities
Act pursuant to Section 4(a)(2) of the Securities Act and/or Rule
506(b) of Regulation D promulgated by the SEC under the Securities
Act. Each of the consultants represented that (a) it was an 
âaccredited investorâ as defined in Rule 501 of Regulation D
promulgated by</font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">72</font></div>
</div>
<hr style="page-break-after:always" />
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the SEC
under the Securities Act and (b)</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">the
shares of common stock were being acquired&nbsp;solely for
investment&nbsp;for its own account and not with a view to, or for
resale in connection with, any distribution thereof in violation of
the Securities Act.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">None of
the securities described in this Item 2 were sold through an
underwriter and, accordingly, there were no underwriting discounts
or commissions involved.</font></div>
<div><a name="sD587154A20295929A0A619991FE2F340" id=
"sD587154A20295929A0A619991FE2F340"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 3. Defaults Upon Senior Securities.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">None</font></div>
<div><a name="s4628008496A85BA1B834B077A738D450" id=
"s4628008496A85BA1B834B077A738D450"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 4. Mine Safety Disclosures.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Not
applicable.</font></div>
<div><a name="sAEA079C5FB045A439533AB8168552A81" id=
"sAEA079C5FB045A439533AB8168552A81"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 5. Other Information.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">None</font></div>
<div><a name="s230230A0E4C75A6F88B7605392AB2F2F" id=
"s230230A0E4C75A6F88B7605392AB2F2F"></a></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;-sec-extract:summary;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
Item 6. Exhibits.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Except
as so indicated in Exhibit 32.1, the following exhibits are filed
as part of, or incorporated by reference into, this Quarterly
Report on Form 10-Q.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;">
<tr>
<td colspan="3"></td>
</tr>
<tr>
<td style="width:13%;"></td>
<td style="width:1%;"></td>
<td style="width:86%;"></td>
</tr>
<tr>
<td style=
"vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit
Number</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:8pt;"><font style=
"font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit
Description</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">10.1(1)+</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"text-decoration:underline;color:#0000FF;-sec-extract:exhibit;"
href="exicureexhibit101-33118.htm"><font style=
"font-family:Times New Roman;font-size:10pt;">Offer Letter dated as
of January 18, 2018 by and between Exicure, Inc. and Matthias G.
Schroff, Ph.D.</font></a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">31.1(1)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"text-decoration:underline;color:#0000FF;-sec-extract:exhibit;"
href="exicureexhibit311-33118.htm"><font style=
"font-family:Times New Roman;font-size:10pt;">Rule
13a-14(a)/15d-14(a) Certification of Principal Executive
Officer</font></a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">31.2(1)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"text-decoration:underline;color:#0000FF;-sec-extract:exhibit;"
href="exicureexhibit312-33118.htm"><font style=
"font-family:Times New Roman;font-size:10pt;">Rule
13a-14(a)/15d-14(a) Certification of Principal Financial
Officer</font></a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">32.1*</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><a style=
"text-decoration:underline;color:#0000FF;-sec-extract:exhibit;"
href="exicureexhibit321-33118.htm"><font style=
"font-family:Times New Roman;font-size:10pt;">Section 1350
Certifications of Principal Executive Officer and Principal
Financial Officer</font></a></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.INS(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Instance
Document</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.SCH(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy
Extension Schema Document</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.CAL(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy
Extension Calculation Linkbase Document</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.DEF(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy
Extension Definition Linkbase Document</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.LAB(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy
Extension Label Linkbase Document</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:5px;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">101.PRE(4)</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy
Extension Presentation Linkbase Document</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">+
Indicates&nbsp;a&nbsp;management&nbsp;contract&nbsp;or&nbsp;compensatory&nbsp;plan.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">* The
certifications attached as Exhibit 32.1 that accompany this
Quarterly Report on Form 10-Q are not deemed filed with the SEC and
are not to be incorporated by reference into any filing of Exicure,
Inc. under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended (whether made before or
after the date of such Form 10-Q), irrespective of any general
incorporation language contained in such filing.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">(1) Filed
herewith.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">73</font></div>
</div>
<hr style="page-break-after:always" />
<div><a name="s0F73A67C62D05262A4B1B60D9014FE5E" id=
"s0F73A67C62D05262A4B1B60D9014FE5E"></a></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
</div>
<div><br /></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">
SIGNATURES</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">Date:
May</font> <font style=
"font-family:Times New Roman;font-size:10pt;color:#000000;">15</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,
2018</font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;">
<div style=
"padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;">
<table cellpadding="0" cellspacing="0" style=
"font-family:Times New Roman;font-size:10pt;width:44.44444444444444%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;">
<tr>
<td colspan="2"></td>
</tr>
<tr>
<td style="width:12%;"></td>
<td style="width:88%;"></td>
</tr>
<tr>
<td colspan="2" style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">EXICURE,
INC.</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;height:20px;font-size:10pt;">
<font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">By:</font></div>
</td>
<td style=
"vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">/s/ David S.
Snyder</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">David S.
Snyder</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">Chief Financial
Officer</font></div>
</td>
</tr>
<tr>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="overflow:hidden;font-size:10pt;"><font style=
"font-family:inherit;font-size:10pt;">&nbsp;</font></div>
</td>
<td style=
"vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;">
<div style="text-align:left;font-size:10pt;"><font style=
"font-family:Times New Roman;font-size:10pt;">(Principal Financial
Officer and Principal Accounting Officer)</font></div>
</td>
</tr>
</table>
</div>
</div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;">
<font style=
"font-family:Times New Roman;font-size:10pt;"><br /></font></div>
<div><br /></div>
<div>
<div style=
"line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;">
<font style="font-family:inherit;font-size:10pt;">74</font></div>
</div>
</body>
</html>

